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Control 
10"M E, 
K - 9 ~  E,
+ 1W6M FUL 










Patent Application Publication May 8,2008 Sheet 11 of 11 US 200810108513 A1 
FIGURE 11 
May 8,2008 
CELLULAR ARRAYS 
[0001] The present invention claims priority to U.S. Provi- 
sional Patent Application Ser. Nos. 601810,102 and 601810, 
110, filed Jun. 1,2006, each of which is hereby incorporated 
by reference in its entirety. 
[0002] This invention was made with government support 
under contracts W81XWH-05-1-0381 awarded by the United 
States Army Medical Research and Material Command (US- 
AMRMC); R01 GM066830 and CA89018-03 awarded by 
the National Institutes of Health; and BES0092701 awarded 
by the National Science Foundation. The government has 
certain rights in the invention. 
FIELD OF THE INVENTION 
[0003] The present invention relates to characterizing tran- 
scription within cells. In particular, the present invention pro- 
vides transfected cell arrays (e.g., two-dimensional andor 
three-dimensional arrays) and systems, kits and methods uti- 
lizing the same (e.g., for transcriptional activity characteriza- 
tion). Compositions and methods of the present invention find 
use in, among other things, research, drug discovery and 
clinical (e.g., diagnostic, preventative and therapeutic) appli- 
cations. 
BACKGROUND OF THE INVENTION 
[0004] The human genome project has lead to an incredible 
wealth of information regarding nucleic acid sequence. How- 
ever, an emerging challenge is to identify gene products and 
to determine the functional roles of the genes and gene prod- 
ucts. 
SUMMARY OF THE INVENTION 
[0005] The present invention relates to characterizing tran- 
scription within cells. In particular, the present invention pro- 
vides transfected cell arrays (e.g., two-dimensional andor 
three-dimensional arrays) and systems, kits and methods uti- 
lizing the same (e.g., for transcriptional activity characteriza- 
tion). Compositions and methods of the present invention find 
use in, among other things, research, drug discovery and 
clinical (e.g., diagnostic, preventative and therapeutic) appli- 
cations. 
[0006] Accordingly, in some embodiments, the present 
invention provides a composition comprising a three-dimen- 
sional transfection cell array comprising an array of spatially 
controllable immobilized gels, wherein the gels comprise a 
crosslinkable biopolymer solution comprising cells exposed 
to transfection molecules. In some embodiments, the gels are 
- 
formed by adding a solution comprising transfection mol- 
ecules and cells to a crosslinkable biopolymer (e.g., alginate) 
solution, allowing beads to form, and placing the same within 
cell growth media. In some embodiments, the crosslinkable 
biopolymer solution comprises alginate and collagen. the 
present invention is not limited to any particular crosslinkable 
biopolymer solution. Indeed, a variety of crosslinkable 
biopolymer solutions are contemplated to be useful in the 
compositions and methods of the present invention including, 
but not limited to, acrylated poly(ethy1ene glycol) (PEG- 
Acry1)hydrogels and other biopolymer solutions described 
herein. In some embodiments, the composition further com- 
prises a charge neutralizing reagent (e.g., polyethyleimine 
(PEI)). In some embodiments, the alginate is present at a final 
concentration of about 1.5%, although higher and lower per- 
centages may be used (e.g., as described herein). In some 
embodiments, the collagen is present at a final concentration 
of about 0.2%, although higher and lower percentages may be 
used (e.g., as described herein) In some embodiments, PEI is 
~ - 
present in an amount such that the nitrogen to phosphate ratio 
is 25. In some embodiments. the transfection molecules are 
nucleic acid sequences. In some embodiments, the nucleic 
acid sequences are located within expression vectors. In some 
embodiments, the transfection molecules comprise a normal- 
ization plasmid and a functional plasmid. In some embodi- 
ments, the normalization plasmid comprises a promoter 
region and a reporter molecule that allows cellular transfec- 
tion efficiency to be normalized over the array. In some 
embodiments, the functional plasmid comprises a reporter 
molecule that is different from the reporter molecule of the 
normalization plasmid. The present invention is not limited 
by the type of reporter molecules utilized. Indeed, a variety of 
reporter molecules are described herein including, but not 
limited to, various luciferase reporters and fluorescent report- 
ers (e.g., green fluorescent protein reporters). 
[0007] In some embodiments, the present invention also 
provides, a method of transfecting cells comprising provid- 
ing: a composition comprising a biopolymer comprising algi- 
nate and collagen, transfection molecules, and cells; and mix- 
- 
ing the composition comprising biopolymer, transfection 
molecules and cells, in the presence of PEI, under conditions 
such that beads form; and placing the beads in cell growth 
media. 
[0008] Embodiments of the present invention also provide 
a method of generating an array, comprising: forming holes in 
a first material to generate an array mold, attaching the array 
mold to a solid substrate to form a complex comprising a 
plurality ofwells; depositing first nucleic acid vectors into the 
plurality of wells under conditions such that the first nucleic 
acidvectors are generally immobilized on the solid substrate, 
wherein the first nucleic acid vectors comprise nucleic acid 
sequences, and removing the array mold from the solid sub- 
strate to generate an array on the solid substrate. In some 
embodiments, the nucleic acid sequences comprise a reporter 
gene; andor a promoter region configured to bind transcrip- 
tion factors. The present invention also provides arrays (e.g., 
two-dimensional transfection cell arrays) generated accord- 
ing to such a method. In some embodiments, the first material 
comprises PDMS. In some embodiments, the solid substrate 
comprises polystyrene. In some embodiments, method fur- 
ther comprises depositing second nucleic acidvectors into the 
plurality of wells, wherein the second nucleic acid vectors 
comprise nucleic acid comprising: 1) a second reporter gene; 
and 2) a promoter region that allows transfection efficiency to 
be normalized (e.g., relative to transcriptional activity) over 
the array. In some embodiments, the first nucleic acid vectors 
are immobilized on the solid substrate such that they can 
deliver the nucleic acid to a cell. 
DESCRIPTION OF THE DRAWINGS 
[0009] FIG. 1 shows a multiwell dish format reporter gene 
assay to compare surface delivery to traditional bolus deliv- 
ery. Surface delivery (B) of ERE reporter plasmid system 
(pERE(3 X)TK-ffLUC and normalization plasmid pTK- 
rLUC) resulted in E2-stimulated transcriptional responses in 
MCF-7 breast cancer cells similar to bolus delivery (A), 
reported as a ratio of firefly to renilla luciferase, with E2 
statistically inducing firefly luciferase expression 6-7 fold 
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over vehicle control or the addition of FUL. Columns labeled 
with same letter designate conditions not statistically differ- 
ent; all other comparisons, p<0.001. 
[0010] FIG. 2 shows the effect of DNA amount on E, acti- 
vation of ERE reporter plasmid system (pERE(3X)TK- 
ffLUC and normalization plasmid pTK-rLUC) delivered to 
MCF-7 breast cancer cells. Total amount of DNA added to the 
surface (B) or delivered as a bolus (A), in the presence of 1 oP9 
M E,, resulted in a similar dose-response effect. Columns 
labeled with same letter designate conditions not statistically 
different; all other comparisons, p<0.01 for (A), p<0.05 for 
(B). 
[0011] FIG. 3 shows the effect of complexing agent and E, 
dose response on the ERE reporter plasmid system (pERE 
(3 X)TK-ffLUC and normalization plasmid pTK-rLUC). 
Bolus and surface delivery of Lipofectamine 2000 complexes 
(A) resulted in induction profiles that were not statistically 
different from each other, for each concentration of E,. Bolus 
delivery of Effectene complexes (B) resulted in statistically 
higher induction (p<0.05) than surface delivery for all con- 
centrations of E,, except control, however surface delivery 
resulted in more statistically different induction responses. 
Columns labeled with same letter designate conditions not 
statistically different; all other comparisons, p<0.05. 
[0012] FIG. 4 shows array fabricationwith soft lithography 
techniques to pattern DNA-lipid complex deposition and 
transfection. A polydimethylsiloxane (PDMS) mold (A) was 
reversibly sealed to polystyrene slides (B), so that the holes in 
the mold, termed microwells, served as reservoirs for depo- 
sition of DNA complexes onto the polystyrene (C). After 
complex deposition in the microwells, the PDMS mold was 
peeled away from the polystyrene slide, which was then 
rinsed thoroughly. Rhodamine-labeled DNA complexes were 
immobilized on the slide in distinct regions, replicating the 
pattern of microwells in the PDMS mold (D-F). Transfection 
of MCF-7 cells seeded onto these arrays of patterned com- 
plexes on polystyrene slides was also confined to thepatterns, 
as determined by GFP expression (G-I). 
[0013] FIG. 5 shows bioluminescence imaging to detect 
dual-luciferase expression in an array format. Transfection of 
MCF-7 cells seeded onto arrays of complexes was assayed 
after 24 hours by sequentially adding the renilla and firefly 
luciferase substrates. The renilla substrate, VIVIREN (10 
pM), was first added into the media and the array was imaged 
to determine pTK-rLUC expression (A). D-Luciferin (1 mM) 
was subsequently added to the same array, which was then 
imaged to acquire a dual signal (B). Firefly luciferase expres- 
sion (pLUC) was determined by subtracting the VIVIREN 
signal from the signal obtained through imaging with the 
D-luciferin. When normalized, the firefly luciferase signal 
was 34? 8 fold greater than the respective renilla expression. 
[0014] FIG. 6 shows arrays used to monitor ERa induction 
of transcriptional activity. Complexes formed with different 
plasmids were immobilized in different spots of the array, as 
follows: 1. pLUC, 2. none, 3. pERE(3 X)TK-ffLUC, 4. pERE 
(3X)TK-ffLUC and pTK-rLUC (2:l ratio), and 5. pPGAL. 
Cells seeded on the arrays were treated with combinations of 
ethanol control (A-B), E, (C-D), or E, plus FUL (E-F). Dual- 
luciferase levels were analyzed 24 hours later with biolumi- 
nescence imaging, by first imaging with the renilla luciferase 
substrate, VIVIREN (A, C, E) and then imaging each array 
with D-luciferin, the firefly luciferase substrate (B, E, F). 
Induction of the ERE-regulated plasmid system was calcu- 
lated by normalizing firefly luciferase expression to renilla 
luciferase expression (G). Firefly luciferase expression was 
determined by subtracting the VIVIREN signal from the sig- 
nal obtained through imaging with the D-luciferin. For spots 
containing both the pERE(3 X)TK-ffLUC and pTK-rLUC 
plasmids (column4), E, statistically inducedfirefly luciferase 
expression 10-fold over control or FUL conditions, reported 
as a ratio of firefly to renilla luciferase (G). Columns labeled 
with same letter designate conditions not statistically differ- 
ent; all other comparisons, p<0.001. 
[0015] FIG. 7 shows concentration response of E, on the 
ERE reporter plasmid system in an array format. For spots 
containing both the pERE(3 X)TK-ffLUC and pTK-rLUC 
plasmids, increasing the concentration of E, statistically 
increased the induction of firefly luciferase expression, veri- 
fying a true concentration-response of E, in the induction of 
this plasmid system in an array format. Columns labeled with 
same letter designate conditions not statistically different; all 
other comparisons, p<0.05. 
[0016] FIG. 8 shows phase imaging of 1.5% alginate beads 
(a) before MTT staining (control), (b and c) after MT'T stain- 
ing after 24 and 48 hr., and (d and e) imaging of beads 
containing 1.5% alginate and 0.2% collagen stained after 24 
and 48 hr. 
[0017] FIG. 9 shows transfection efficiency for MCF-7 
cells as a function of (a) N:P ratio and (b) DNA concentration 
as determined by beta-galactosidase staining. 
[0018] FIG. 10 shows phase images of alginate beads con- 
taining MCF-7 cells transfected with beta-galactosidase. 
DNA Beta-gal staining of cells occurred 1,2, and 3 days after 
initial incubation (a, b, and c). Transfected cells appear darkly 
stained. 
[0019] FIG. 11 shows luciferase expression in array in 
terms of photon flux. 
DEFINITIONS 
[0020] To facilitate an understanding of the invention, a 
number of terms are defined below. 
[0021] As used herein, the term "transfection molecule" 
refers to a molecule that is transfected (e.g., via placid andor 
viral means) into a host cell (e.g., within a transfection cell 
array described herein). The molecule transfected may be a 
nucleic acid that is of interest with respect to its ability to 
confer a change in the phenotype of the host cells (e.g., alter 
transcription, translation, cell cycle, etc.). The molecule 
transfected mav refer to a nucleic acid seauence that varies 
from one portion of an array to the next. The molecule trans- 
fected may also include plasmid andor viral sequence. 
Nucleic acid sequences that are transfected may be coding 
sequences for a protein, or for an RNA molecule (e.g., which 
is transcribed into an anti-sense RNA sequence, a ribozyme or 
double-stranded RNA, etc.), or a regulatory sequence (e.g., as 
part of a reporter construct), or other type of sequence. 
[0022] As used herein, the terms "spot" and "transfection 
zone." refers to the location within an arrav that cells are 
exposed to transfection molecules. The location may be 
within a 2-D array or 3-D array. Within a 2-D array, a "spot" 
or "transfection zone" generally refers to a location where a 
transfection molecule is immobilized to a substrate surface. 
Within a 3-D arrav. a "snot" or "transfection zone" refers a ,  L 
generally to regions where polymeric-mediated delivery of 
transfection molecules to cells occurs. 
[0023] As used herein, the term "gene transfer system" 
refers to any means of delivering a composition comprising a 
nucleic acid sequence to a cell or tissue. For example, gene 
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transfer systems include, but are not limited to, vectors (e.g., 
retroviral, adenoviral, adeno-associated viral, and other 
nucleic acid-based delivery systems), microinjection of 
naked nucleic acid, polymer-based delivery systems (e.g., 
liposome-based and metallic particle-based systems), biolis- 
tic injection, and the like. As used herein, the term "viral gene 
transfer system" refers to gene transfer systems comprising 
viral elements (e.g., intact viruses, modified viruses and viral 
components such as nucleic acids or proteins) to facilitate 
delivery of a sample (e.g., a nucleic acid encoding a fusion 
protein of the present invention) to a desired cell or tissue. As 
used herein, the term "adenovirus gene transfer system" 
refers to gene transfer systems comprising intact or altered 
viruses belonging to the family Adenoviridae. 
[0024] As used herein, the term "site-specific recombina- 
tion target sequences" refers to nucleic acid sequences that 
provide recognition sequences for recombination factors and 
the location where recombination takes place. 
[0025] As used herein, the term "nucleic acid molecule" 
refers to any nucleic acid containing molecule, including but 
not limited to, DNA or RNA. The term encompasses 
sequences that include any of the known base analogs of DNA 
and RNA including, but not limited to, 4-acetylcytosine, 
8-hydroxy-N-6-methyladenosine, aziridinylcytosine, 
ethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, 
dihydrouracil, inosine, N6-isopentenyladenine, 1-methylad- 
enine, 1 -methylpseudouracil, 1 -methylguanine, 1 -methyli- 
nosine, 2,2-dimethylguanine, 2-methyladenine, 2-meth- 
ylguanine, 3-methylcytosine, 5-methylcytosine, 
N6-methyladenine, 7-methylguanine, 5-methylaminomethy- 
luracil, 5-methoxy-aminomethyl-2-thiouracil, beta-D-man- 
nosylqueosine, 5'-methoxycarbonylmethyluracil, 5-methox- 
yuracil, 2-methylthio-N6-isopentenyladenine, uracil-5- 
oxyacetic acid methylester, uracil-5-oxyacetic acid, 
oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 
5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methylu- 
racil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxy- 
acetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6- 
diaminopurine. 
[0026] The term "gene" refers to a nucleic acid (e.g., DNA) 
sequence that comprises coding sequences necessary for the 
production of a polypeptide, RNA (e.g., including but not 
limited to, mRNA, tRNA and rRNA) or precursor. The 
polypeptide, RNA, or precursor can be encoded by a full 
length coding sequence or by any portion thereof. The term 
also encompasses the coding region of a structural gene and 
the sequences located adjacent to the coding region on both 
the 5' and 3' ends for a distance of about 1 kb on either end 
such that the gene corresponds to the length of the full-length 
mRNA. The sequences that are located 5' of the coding region 
and which are present on the mRNA are referred to as 5' 
untranslated sequences. The sequences that are located 3' or 
downstream of the coding region and that are present on the 
mRNA are referred to as 3' untranslated sequences. The term 
"gene" encompasses both cDNA and genomic forms of a 
gene. A genomic form or clone of a gene contains the coding 
region interrupted with non-coding sequences termed 
"introns" or "intervening regions" or "intervening 
sequences." Introns are segments of a gene that are tran- 
scribed into nuclear RNA (hnRNA); introns may contain 
regulatory elements such as enhancers. Introns are removed 
or "spliced out" from the nuclear or primary transcript; 
introns therefore are absent in the messenger RNA (mRNA) 
transcript. The mRNA functions during translation to specify 
the sequence or order of amino acids in a nascent polypeptide. 
[0027] Where "amino acid sequence" is recited herein to 
refer to an amino acid sequence of a naturally occurring 
protein molecule, "amino acid sequence" and like terms, such 
as "polypeptide" or "protein" arenot meant to limit the amino 
acid sequence to the complete, native amino acid sequence 
associated with the recited protein molecule. 
[0028] In addition to containing introns, genomic forms of 
a gene may also include sequences located on both the 5' and 
3' end of the sequences that are present on the RNA transcript. 
These sequences are referred to as "flanking" sequences or 
regions (these flanking sequences are located 5' or 3' to the 
non-translated sequences present on the mRNA transcript). 
The 5' flanking region may contain regulatory sequences such 
as vromoters and enhancers that control or influence the tran- 
scription of the gene. The 3' flanking region may contain 
sequences that direct the termination of transcription, post- 
transcriptional cleavage and polyadenylation. 
[0029] The term "wild-type" refers to a gene or gene prod- 
uct that has the characteristics of that gene or gene product 
when isolated from a naturally occurring source. A wild-type 
gene is that which is most frequently observed in a population 
and is thus arbitrarily designed the "normal" or "wild-type" 
form of the gene. In contrast, the terms "modified," "mutant," 
"polymorphism," and "variant" refer to a gene or gene prod- 
uct that displays modifications in sequence andor functional 
properties (i.e., altered characteristics) when compared to the 
wild-type gene or gene product. It is noted that naturally- 
occurring mutants can be isolated; these are identified by the 
fact that they have altered characteristics (e.g., increased or 
decreased solubility) when compared to the wild-type gene or 
gene product. 
[0030] As used herein, the terms "nucleic acid molecule 
encoding," "DNA sequence encoding," and "DNA encoding" 
refer to the order or sequence of deoxyribonucleotides along 
a strand of deoxyribonucleic acid. The order of these deox- 
yribonucleotides determines the order of amino acids along 
the polypeptide (protein) chain. The DNA sequence thus 
codes for the amino acid sequence. 
[0031] As used herein, the term "heterologous gene" refers 
to a gene that is not in its natural environment. For example, 
a heterologous gene includes a gene from one species intro- 
duced into another species. A heterologous gene also includes 
a gene native to an organism that has been altered in some way 
(e.g., mutated, added in multiple copies, linked to non-native 
regulatory sequences, etc.). Heterologous genes are distin- 
guished from endogenous genes in that the heterologous gene 
sequences are typically joined to DNA sequences that are not 
found naturally associated with the gene sequences in the 
chromosome or are associated with portions of the chromo- 
some not found in nature (e.g., genes expressed in loci where 
the gene is not normally expressed). 
[0032] DNA molecules are said to have "5' ends" and "3' 
ends" because mononucleotides are reacted to make oligo- 
nucleotides or polynucleotides in a manner such that the 5' 
phosphate of one mononucleotide pentose ring is attached to 
the 3' oxygen of its neighbor in one direction via a phosphodi- 
ester linkage. Therefore, an end of an oligonucleotides or 
polynucleotide, referred to as the "5' end" if its 5' phosphate is 
not linked to the 3' oxygen of a mononucleotide pentose ring 
and as the "3' end" if its 3' oxygen is not linked to a 5' 
phosphate of a subsequent mononucleotide pentose ring. As 
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used herein, a nucleic acid sequence, even if internal to a 
larger oligonucleotide or polynucleotide, also may be said to 
have 5' and 3' ends. In either a linear or circular DNA mol- 
ecule, discrete elements are referred to as being "upstream" or 
5' of the "downstream" or 3' elements. This terminology 
reflects the fact that transcription proceeds in a 5' to 3' fashion 
along the DNA strand. The promoter and enhancer elements 
that direct transcription of a linked gene are generally located 
5' or upstream of the coding region. However, enhancer ele- 
ments can exert their effect even when located 3' of the pro- 
moter element and the coding region. Transcription termina- 
tionandpolyadenylation signals are located3' or downstream 
of the coding region. 
[0033] In addition to containing introns, genomic forms of 
a gene may also include sequences located on both the 5' and 
3' end of the sequences that are present on the RNA transcript. 
These sequences are referred to as "flanking" sequences or 
regions (these flanking sequences are located 5' or 3' to the 
non-translated sequences present on the mRNA transcript). 
The 5' flanking region may contain regulatory sequences such 
as promoters and enhancers that control or influence the tran- 
scription of the gene. The 3' flanking region may contain 
sequences that direct the termination of transcription, post- 
transcriptional cleavage and polyadenylation. 
[0034] As used herein, the terms "an oligonucleotide hav- 
ing a nucleotide sequence encoding a gene" and "polynucle- 
otide having a nucleotide sequence encoding a gene," means 
a nucleic acid sequence comprising the coding region of a 
gene or, in other words, the nucleic acid sequence that 
encodes a gene product. The coding region may be present in 
a cDNA, genomic DNA, or RNA form. When present in a 
DNA form, the oligonucleotide or polynucleotide may be 
single-stranded (i.e., the sense strand) or double-stranded. 
Suitable control elements such as enhancers/promoters, 
splice junctions, polyadenylation signals, etc. may be placed 
in close proximity to the coding region of the gene if needed 
to permit proper initiation of transcription andor correct pro- 
cessing of the primary RNA transcript. Alternatively, the cod- 
ing region utilized in the expression vectors of the present 
invention may contain endogenous enhancers/promoters, 
splice junctions, intervening sequences, polyadenylation sig- 
nals, etc. or a combination of both endogenous and exogenous 
control elements. 
[0035] As used herein, the term "regulatory element" refers 
to a genetic element that controls some aspect of the expres- 
sion of nucleic acid sequences. For example, a promoter is a 
regulatory element that facilitates the initiation of transcrip- 
tion of an operably linked coding region. Other regulatory 
elements include splicing signals, polyadenylation signals, 
termination signals, etc. 
[0036] As used herein, the terms "complementary" or 
"complementarity" are used in reference to polynucleotides 
(i.e., a sequence of nucleotides) related by the base-pairing 
rules. For example, the sequence 5'-A-G-T-3', is complemen- 
tary to the sequence 3'-T-C-A-5'. Complementarity may be 
"partial," in which only some of the nucleic acids' bases are 
matched according to the base pairing rules. Or, there may be 
"complete" or "total" complementarity between the nucleic 
acids. The degree of complementarity between nucleic acid 
strands has significant effects on the efficiency and strength of 
hybridization between nucleic acid strands. This is of particu- 
lar importance in amplificationreactions, as well as detection 
methods that depend upon binding between nucleic acids. 
Complementarity can include the formation of base pairs 
between any type of nucleotides, including non-natural bases, 
modified bases, synthetic bases and the like. 
[0037] The term "homology" refers to a degree of comple- 
mentarity. There may be partial homology or complete 
homology (i.e., identity). A partially complementary 
sequence is one that at least partially inhibits a completely 
complementary sequence from hybridizing to a target nucleic 
acid and is referred to using the functional term "substantially 
homologous." The term "inhibition of binding," when used in 
reference to nucleic acid binding, refers to inhibition of bind- 
ing caused by competition of homologous sequences for 
binding to a target sequence. The inhibition of hybridization 
of the completely complementary sequence to the target 
sequence may be examined using a hybridization assay 
(Southern or Northern blot, solution hybridization and the 
like) under conditions of low stringency. A substantially 
homologous sequence or probe will compete for and inhibit 
the binding (i.e., the hybridization) of a completely homolo- 
gous to a target under conditions of low stringency. This is not 
to say that conditions of low stringency are such that non- 
specific binding is permitted; low stringency conditions 
require that the binding of two sequences to one another be a 
specific (i.e., selective) interaction. The absence of non-spe- 
cific binding may be tested by the use of a second target that 
lacks even a partial degree of complementarity (e.g., less than 
about 30% identity); in the absence of non-specific binding 
the probe will not hybridize to the second non-complemen- 
tary target. 
[0038] The art knows well that numerous equivalent con- 
ditions may be employed to comprise low stringency condi- 
tions; factors such as the length and nature (DNA, RNA, base 
composition) of the probe and nature of the target (DNA, 
RNA, base composition, present in solution or immobilized, 
etc.) and the concentration of the salts and other components 
(e.g., the presence or absence of formamide, dextran sulfate, 
polyethylene glycol) are considered and the hybridization 
solution may be varied to generate conditions of low strin- 
gency hybridization different from, but equivalent to, the 
above listed conditions. In addition, the art knows conditions 
that promote hybridization under conditions of high strin- 
- 
gency (e.g., increasing the temperature of the hybridization 
andor wash steps, the use of formamide in the hybridization 
solution, etc.). 
[0039] Whenusedinreference to a double-strandednucleic 
acid sequence such as a cDNA or genomic clone, the term 
"substantially homologous" refers to any probe that can 
hybridize to either or both strands of the double-stranded 
nucleic acid sequence under conditions of low stringency as 
described above. 
[0040] A gene may produce multiple RNA species that are 
generated by differential splicing of the primary RNA tran- 
script. cDNAs that are splice variants of the same gene will 
contain regions of sequence identity or complete homology 
(representing the presence of the same exon or portion of the 
same exon on both cDNAs) and regions of complete non- 
identity (for example, representing the presence of exon "A'" 
on cDNA 1 wherein cDNA 2 contains exon "B" instead). 
Because the two cDNAs contain regions of sequence identity 
they will both hybridize to a probe derived from the entire 
gene or portions of the gene containing sequences found on 
both cDNAs; the two splice variants are therefore substan- 
tially homologous to such a probe and to each other. 
[0041] When used in reference to a single-stranded nucleic 
acid sequence, the term "substantially homologous" refers to 
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any probe that can hybridize (i.e., it is the complement of) the 
single-stranded nucleic acid sequence under conditions of 
low stringency as described above. 
[0042] As used herein, the term "hybridization" is used in 
reference to the pairing of complementary nucleic acids. 
Hybridization and the strength of hybridization (i.e., the 
strength of the association between the nucleic acids) is 
- 
impacted by such factors as the degree of complementary 
between the nucleic acids. strinaencv of the conditions 
involved, the T, of the formed h;brii, and the G:C ratio 
within the nucleic acids. 
[0043] As used herein, the term "T," is used in reference to 
the "melting temperature." The melting temperature is the 
temperature at which a population of double-stranded nucleic 
acid molecules becomes half dissociated into single strands. 
The equation for calculating the T, of nucleic acids is well 
known in the art. As indicated bv standard references. a 
simple estimate of the T, value may be calculated by the 
equation: T,=81 .5 +0.41 (% G+C), when anucleic acidis in 
aqueous solution at 1 M NaCl (See e.g., Anderson andyoung, 
Quantitative Filter Hybridization, in Nucleic Acid Hybridiza- 
tion (1985)). Other references include more sophisticated 
computations that take structural as well as sequence charac- 
teristics into account for the calculation of T,. 
[0044] As used herein the term "stringency" is used in 
reference to the conditions of temperature, ionic strength, and 
the presence of other compounds such as organic solvents, 
under which nucleic acid hybridizations are conducted. 
Those skilled in the art will recognize that "stringency" con- 
ditions may be altered by varying the parameters just 
described either individually or in concert. With "high strin- 
gency" conditions, nucleic acid base pairing will occur only 
between nucleic acid fragments that have a high frequency of 
complementary base sequences (e.g., hybridization under 
"high stringency" conditions may occur between homologs 
with about 85-100% identity, preferably about 70-100% 
identity). With medium stringency conditions, nucleic acid 
base pairing will occur between nucleic acids with an inter- 
- - 
mediate frequency of complementary base sequences (e.g., 
hybridization under "medium stringency" conditions may 
occur between homologs with about 50-70% identity). Thus, 
conditions of "weak" or "low" stringency are often required 
with nucleic acids that are derived from organisms that are 
genetically diverse, as the frequency of complementary 
sequences is usually less. "High stringency conditions" when 
used in reference to nucleic acid hybridization comprise con- 
ditions equivalent to binding or hybridization at 42' C. in a 
solution consisting of 5XSSPE (43.8 gll NaCl, 6.9 g/l 
NaH2P04H20 and 1.85 g/l EDTA, pH adjusted to 7.4 with 
NaOH), 0.5% SDS, 5 XDenhardt's reagent and 100 pg/ml 
denatured salmon sperm DNA followed by washing in a 
solution comprising 0.1 XSSPE, 1 .O% SDS at 42' C. when a 
probe of about 500 nucleotides in length is employed. 
[0045] "Medium stringency conditions" when used in ref- 
erence to nucleic acid hybridization comprise conditions 
equivalent to binding or hybridization at 42' C. in a solution 
consisting of 5XSSPE (43.8 gll NaCl, 6.9 g/l NaH2P04H20 
and 1.85 gll EDTA, pH adjusted to 7.4 with NaOH), 0.5% 
SDS, 5 XDenhardt's reagent and 100 pglml denatured salmon 
sperm DNA followed by washing in a solution comprising 
1 .OXSSPE, 1 .O% SDS at 42" C. when a probe of about 500 
nucleotides in length is employed. 
[0046] "Low stringency conditions" comprise conditions 
equivalent to binding or hybridization at 42' C. in a solution 
consisting of 5 XSSPE (43.8 gll NaCl, 6.9 gll NaH2P04H20 
and 1.85 gll EDTA, pH adjusted to 7.4 with NaOH), 0.1% 
SDS, 5XDenhardt's reagent (5OXDenhardt's contains per 
500 ml: 5 g Ficoll (Type 400, Pharamcia), 5 g BSA (Fraction 
V, Sigma)) and 100 pglml denatured salmon sperm DNA 
followed by washing ina solutioncomprising 5 X SSPE, 0.1% 
SDS at 42" C. whena probe of about 500nucleotides in length 
is employed. 
[0047] The art knows well that numerous equivalent con- 
ditions may be employed to comprise low stringency condi- 
tions; factors such as the length and nature (DNA, RNA, base 
composition) of the probe and nature of the target (DNA, 
RNA, base composition, present in solution or immobilized, 
etc.) and the concentration of the salts and other components 
(e.g., the presence or absence of formamide, dextran sulfate, 
polyethylene glycol) are considered and the hybridization 
solution may be varied to generate conditions of low strin- 
gency hybridization different from, but equivalent to, the 
above listed conditions. In addition, the art knows conditions 
that vromote hybridization under conditions of high strin- 
- 
gency (e.g., increasing the temperature of the hybridization 
andor wash stens. the use of formamide in the hvbridization 
L ,  
solution, etc.) (see definition above for "stringency"). 
[0048] The term "fragment" as used herein refers to a 
polypeptide that has an amino-terminal andor carboxy-ter- 
minal deletion as compared to the native protein, but where 
the remaining amino acid sequence is identical to the corre- 
sponding positions in the amino acid sequence deduced from 
a full-length cDNA sequence. Fragments typically are at least 
4 amino acids long, preferably at least 20 amino acids long, 
usually at least 50 amino acids long or longer, and span the 
portion of the polypeptide required for intermolecular bind- 
ing of the compositions (claimed in the present invention) 
with its various ligands andor substrates. 
[0049] The term "naturally-occurring" as used herein as 
applied to an object refers to the fact that an object can be 
found in nature. For example, a polypeptide or polynucleotide 
sequence that is present in an organism (including viruses) 
that can be isolated from a source in nature and which has not 
been intentionally modified by man in the laboratory is natu- 
rally-occurring. 
[0050] As used herein, the term "recombinant DNA mol- 
ecule" as used herein refers to a DNA molecule that is com- 
prised of segments of DNA joined together by means of 
molecular biological techniques. 
[0051] As used herein, the term "antisense" is used in ref- 
erence to RNA sequences that are complementary to a spe- 
cific RNA sequence (e.g., mRNA). Included within this defi- 
nition are antisense RNA ("asRNA") molecules involved in 
gene regulation by bacteria. Antisense RNA may be produced 
by any method, including synthesis by splicing the gene(s) of 
interest in a reverse orientation to a viral promoter that per- 
mits the synthesis of a coding strand. Once introduced into an 
embryo, this transcribed strand combines withnatural mRNA 
produced by the embryo to form duplexes. These duplexes 
then block either the further transcription of the mRNA or its 
translation. In this manner, mutant phenotypes may be gen- 
erated. The term "antisense strand" is used in reference to a 
nucleic acid strand that is complementary to the "sense" 
strand. The designation (-) (i.e., "negative") is sometimes 
used in reference to the antisense strand, with the designation 
(+) sometimes used in reference to the sense (i.e., "positive") 
strand. 
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[0052] As used herein the term "coding region" when used 
in reference to a structural gene refers to the nucleotide 
sequences that encode the amino acids found in the nascent 
polypeptide as a result of translation of a mRNA molecule. 
The coding region is bounded, in eukaryotes, on the 5' side by 
the nucleotide triplet "ATG" that encodes the initiator 
methionine and on the 3' side by one of the three triplets, 
which specify stop codons (i.e., TAA, TAG, TGA). 
[0053] As used herein the term "portion" when in reference 
to a nucleotide sequence (as in "a portion of a given nucle- 
otide sequence") refers to fragments of that sequence. The 
fragments may range in size from four nucleotides to the 
entire nucleotide sequence minus one nucleotide (e.g., 10 
nucleotides, 20,30,40, 50, 100, 200, etc.). 
[0054] As used herein, the terms "restriction endonu- 
cleases" and "restriction enzymes" refer to bacterial 
enzymes, each of which cut double-stranded DNA at or near 
a specific nucleotide sequence. 
[0055] The terms "in operable combination," "in operable 
order," and "operably linked" as used herein refer to the 
linkage of nucleic acid sequences in such a manner that a 
nucleic acidmolecule capable of directing the transcription of 
a given gene andor the synthesis of a desired protein mol- 
ecule is produced. The term also refers to the linkage of amino 
acid seauences in such a manner so that a functional nrotein is 
produced. The present invention is not limited to naturally 
occurring protein molecules. For example, the present inven- 
tion contemplates synthesis of fusion proteins comprising 
multiple regions of unique polypeptide sequences (e.g., a Tat 
leader sequence, a target protein sequence, and marker pro- 
tein sequence). 
[0056] The term "isolated" when used in relation to a 
nucleic acid, as in "an isolated oligonucleotide" or "isolated 
polynucleotide" refers to a nucleic acid sequence that is iden- 
tified and separated from at least one component or contami- 
nant with which it is ordinarilv associated in its natural 
source. Isolated nucleic acid is such present in a form or 
setting that is different from that in which it is found innature. 
In contrast, non-isolated nucleic acids are nucleic acids such 
as DNA and RNA found in the state they exist in nature. For 
example, a given DNA sequence (e.g., a gene) is found on the 
host cell chromosome in proximity to neighboring genes; 
RNA sequences, such as a specific mRNA sequence encoding 
a specific protein, are found in the cell as a mixture with 
numerous other mRNAs that encode a multitude of proteins. 
However, isolated nucleic acid encoding a given protein 
includes, by way of example, such nucleic acid in cells ordi- 
narily expressing the given protein where the nucleic acid is in 
a chromosomal location different from that of natural cells, or 
is otherwise flanked by a different nucleic acid sequence than 
that found in nature. The isolated nucleic acid. olinonucle- 
, u 
otide, or polynucleotide may be present in single-stranded or 
double-stranded form. When an isolated nucleic acid, oligo- 
nucleotide or polynucleotide is to be utilized to express a 
protein, the oligonucleotide or polynucleotide will contain at 
a minimum the sense or coding strand (i.e., the oligonucle- 
otide or polynucleotide may be single-stranded), but may 
contain both the sense and anti-sense strands (i.e., the oligo- 
nucleotide or polynucleotide may be double-stranded). 
[0057] As used herein, the term "purified" or "to purify" 
refers to the removal of components (e.g., contaminants) 
from a sample. For example, antibodies are purified by 
removal of contaminating non-immunoglobulin proteins; 
they are also purified by the removal of immunoglobulin that 
does not bind to the tarnet molecule. The removal of non- 
- 
immunoglobulin proteins andor the removal of immunoglo- 
bulins that do not bind to the target molecule results in an 
- 
increase in the percent of target-reactive immunoglobulins in 
the sample. In another example, recombinant polypeptides 
are expressed in bacterial host cells and the polypeptides are 
purified by the removal of host cell proteins; the percent of 
recombinant polypeptides is thereby increased in the sample. 
[0058] As used herein, the term "native protein" is used to 
indicate that a protein does not contain amino acid residues 
encoded by vector sequences; that is, the native protein con- 
tains only those amino acids found in the protein as it occurs 
in nature. A native protein may be produced by recombinant 
means or may be isolated from a naturally occurring source. 
[0059] As used herein the term "portion" when in reference 
to a protein (as in "a portion of a given protein") refers to 
fragments of that protein. The fragments may range in size 
from four amino acid residues to the entire amino acid 
sequence minus one amino acid. 
[0060] The term "Southern blot," refers to the analysis of 
DNA on agarose or acrylamide gels to fractionate the DNA 
accordinn to size followed bv transfer of the DNA from the 
u 
gel to a solid support, such as nitrocellulose or a nylon mem- 
brane. The immobilized DNA is then probed with a labeled 
probe to detect DNA species complementary to the probe 
used. The DNA may be cleaved with restriction enzymes 
prior to electrophoresis. Following electrophoresis, the DNA 
may be partially depurinated and denatured prior to or during 
transfer to the solid support. Southern blots are a standard tool 
of molecular biologists (J. Sambrook et al., Molecular Clon- 
ing: A Laboratory Manual, Cold Spring Harbor Press, NY, pp 
9.31-9.58 (1989)). 
[0061] The term "Northern blot," as used herein refers to 
the analysis of RNA by electrophoresis of RNA on agarose 
gels to fractionate the RNA according to size followed by 
transfer of the RNA from the gel to a solid support, such as 
nitrocellulose or a nylon membrane. The immobilized RNA is 
then probed with a labeled probe to detect RNA species 
complementary to the probe used. Northern blots are a stan- 
dard tool of molecular biologists (J. Sambrook, et al., supra, 
pp 7.39-7.52 (1989)). 
[0062] The term "Western blot" refers to the analysis of 
protein(s) (or polypeptides) immobilized onto a support such 
as nitrocellulose or a membrane. The proteins are run on 
acrylamide gels to separate the proteins, followed by transfer 
of the protein from the gel to a solid support, such as nitro- 
cellulose or a nvlon membrane. The immobilizednroteins are 
then exposed to antibodies with reactivity against an antigen 
of interest. The binding of the antibodies may be detected by 
various methods, including the use of radiolabeled antibod- 
ies. 
[0063] The term "transgene" as used herein refers to a 
foreign gene that is placed into an organism by, for example, 
introducing the foreign gene into newly fertilized eggs or 
early embryos. The term "foreign gene" refers to any nucleic 
acid (e.g., gene sequence) that is introduced into the genome 
of an animal by experimental manipulations and may include 
gene sequences found in that animal so long as the introduced 
gene does not reside in the same location as does the naturally 
occurring gene. 
[0064] As used herein, the term "vector" is used in refer- 
ence to nucleic acid molecules that transfer DNA segment(s) 
from one cell to another. The term "vehicle" is sometimes 
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used interchangeably with "vector." Vectors are often derived 
from plasmids, bacteriophages, or plant or animal viruses. 
[0065] The term "expression vector" as used herein refers 
to a recombinant DNA molecule containing a desired coding 
sequence and appropriate nucleic acid sequences necessary 
for the expression of the operably linked coding sequence in 
a particular host organism. Nucleic acid sequences necessary 
for expression in prokaryotes usually include a promoter, an 
operator (optional), and a ribosome binding site, often along 
with other sequences. Eukaryotic cells are known to utilize 
promoters, enhancers, and termination and polyadenylation 
signals. 
[0066] The terms "overexpression" and "overexpressing" 
and grammatical equivalents, are used in reference to levels of 
mRNA to indicate a level of expression approximately 3-fold 
higher (or greater) than that observed in a given tissue in a 
control or non-transgenic animal. Levels of mRNA are mea- 
sured using any of a number of techniques known to those 
skilled in the art including, but not limited to Northern blot 
analysis. Appropriate controls are included on the Northern 
blot to control for differences in the amount of RNA loaded 
from each tissue analyzed (e.g., the amount of 28s rRNA, an 
abundant RNA transcript present at essentially the same 
amount in all tissues, present in each sample can be used as a 
means of normalizing or standardizing the mRNA-specific 
signal observed on Northern blots). The amount of mRNA 
present in the band corresponding in size to the correctly 
spliced transgene RNA is quantified; other minor species of 
RNA which hybridize to the transgene probe are not consid- 
ered in the quantification of the expression of the transgenic 
mRNA. 
[0067] The term "transfection" as used herein refers to the 
introduction of foreign DNA into eukaryotic cells. Transfec- 
tionmay be accomplished by a variety of means known to the 
art including calcium phosphate-DNA co-precipitation, 
DEAE-dextran-mediated transfection, polybrene-mediated 
transfection, electroporation, microinjection, liposome 
fusion, lipofection, protoplast fusion, retroviral infection, and 
biolistics. 
[0068] The term "calcium phosphate co-precipitation" 
refers to a technique for the introduction of nucleic acids into 
a cell. The uptake of nucleic acids by cells is enhanced when 
the nucleic acid is presented as a calcium phosphate-nucleic 
acid co-precipitate. The original technique of Graham and 
van der Eb (Graham and van der Eb, Virol., 52:456 (1 973)), 
has been modified by several groups to optimize conditions 
for particular types of cells. The art is well aware of these 
numerous modifications. 
[0069] The term "stable transfection" or "stably trans- 
fected" refers to the introduction and integration of foreign 
DNA into the genome of the transfected cell. The term "stable 
transfectant" refers to a cell that has stably integrated foreign 
DNA into the genomic DNA. 
[0070] The term "transient transfection" or "transiently 
transfected" refers to the introduction of foreign DNA into a 
cell where the foreign DNA fails to integrate into the genome 
of the transfected cell. The foreign DNA persists in the 
nucleus of the transfected cell for several days. During this 
time the foreign DNA is subject to the regulatory controls that 
govern the expression of endogenous genes in the chromo- 
somes. The term "transient transfectant" refers to cells that 
have taken up foreign DNA but have failed to integrate this 
DNA. 
[0071] As used herein, the term "cell culture" refers to any 
in vitro culture of cells. Included within this term are continu- 
ous cell lines (e.g., with an immortal phenotype), primary cell 
cultures, transformed cell lines, finite cell lines (e.g., non- 
transformed cells), and any other cell population maintained 
in vitro. 
[0072] As used herein, the term "eukaryote" refers to 
organisms distinguishable from "prokaryotes." It is intended 
that the term encompass all organisms with cells that exhibit 
the usual characteristics of eukaryotes, such as the presence 
of a true nucleus bounded by a nuclear membrane, within 
which lie the chromosomes, the presence of membrane- 
bound organelles, and other characteristics commonly 
observed in eukaryotic organisms. Thus, the term includes, 
but is not limited to such organisms as fungi, protozoa, and 
animals (e.g., humans). 
[0073] As used herein, the term "in vitro" refers to an 
artificial environment and to processes or reactions that occur 
within an artificial environment. In vitro environments can 
consist of, but are not limited to, test tubes and cell culture. 
The term "in vivo" refers to the natural environment (e.g., an 
animal or a cell) and to processes or reaction that occur within 
a natural environment. 
[0074] The term "candidate agent" may be any substance 
that potentially inhibits or enhances protein folding andor 
solubility, including, but not limited to, any chemical entity, 
pharmaceutical, drug, and the like (e.g., a small molecule or 
compound). Candidate agents may include fragments or parts 
of naturally-occurring proteins or compounds, or may be 
found as active combinations of known proteins or com- 
pounds, which are otherwise inactive. It is to be understood 
that candidate agents comprise both known and potential 
solubility inhibiting or enhancing agents. A candidate agent 
can be determined to be capable of altering target protein 
solubility andor folding using the methods of the present 
invention. 
[0075] As used herein, the term "host cell" refers to any 
cell, whether located in vitro or in vivo, that can be, or has 
been, a recipient for or incorporates exogenous nucleic acid 
sequences (e.g., vectors comprising fusion protein sequence), 
polynucleotides andor proteins of the present invention. It is 
also meant to include progeny of a single cell, and the progeny 
may not necessarily be completely identical (e.g., inmorphol- 
ogy or in genomic or total DNA complement) to the original 
parent cell due to natural, accidental, or deliberate mutations. 
The cells may be eukaryotic or prokaryotic and include, but 
are not limited to bacterial cells (e.g., E. coli) yeast cells, 
mammalian cells, avian cells, amphibian cells, plant cells, 
fish cells, and insect cells). 
DETAILED DESCRIPTION OF THE INVENTION 
[0076] Analysis of multiple pathways or genes in a parallel 
format can be achieved using a transfected cell array, a high 
throughput technique to correlate gene expression with func- 
tional cell responses, based on gene delivery from a substrate 
that supports cell adhesion (See, e.g., Bengali et al., 2005, 
Biotechnol Bioeng 90(3):290-302; Pannier et al., 2005, Acta 
Biomaterialia 1(5):5 11 -522; Segura and Shea, 2002, Biocon- 
jug Chem 13(3):621-9; and Segura et al., 2003, J Control 
Release 93(1):69-84). While traditional microarrays can 
quantify the expression level of thousands of genes, they 
cannot accurately describe the functional activity of these 
genes in a cellular and physiological context (See, e.g., Pep- 
perkok and Ellenberg, 2006, Nat Rev Mol Cell Biol7(9):690- 
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6). Transfected cell arrays present an approach to study gene 
function in the context of a living cell, allowing proteins to be 
translated and folded correctly and to interact within the 
environment of the cell. Additionally, a large number of genes 
can potentially be screened in parallel for induction or repres- 
sionof a given function (See, e.g., Palmer and Freeman, 2005, 
Pharmacogenomics 6(5):527-34). Transfected cell arrays ini- 
tially offered the hope of compact, economical, and high- 
throughput analysis in living cells (See, e.g., Hook et al., 
2006, Trends Biotechnol24(10):471-7; Palmer and Freeman, 
2005, Pharmacogenomics 6(5):527-34). 
[0077] Since the original report on transfected cell arrays 
(See, e.g., Ziauddin and Sabatini, 2001, Nature 411(6833): 
107-lo), reverse transfection has been employed in several 
high-throughput cell based microarrays to screen for gene 
function or activity. Reverse transfection involves printing 
mixtures of different transfection molecules (e.g., viruses 
andor plasmids) with or without a carrier (e.g., gelatin) into 
specific domains onto a substrate. Next, a lipid-based trans- 
fection agent can be floated over the array, and cells subse- 
quently seeded to form a living cell microarray of locally 
transfected cells in a lawn of nontransfected cells. The first 
transfected cell array was used to analyze genes for phospho- 
tyrosine activity and identified six genes; five genes that 
encode known tyrosine kinase proteins and one that encodes 
a protein of unknown function (See, e.g., Ziauddin and Saba- 
tini. 2001. Nature 41 l(6833): 107-10). Transfected cell arravs 
, , 
have since been applied to study signaling pathways (See, 
e.g., Webb et al., 2003, J Biomol Screen 8(6):620-3; to screen 
antibody fragments (See, e.g., Delehanty et al., 2004, Anal 
Chem 76(24):7323-8); identify possible new lysophospha- 
tidic acid receptors (See, e.g., Lee et al., 2006, J Biol Chem 
281(33):23589-97; perform protein localization studies (See, 
e.g., Hu et al., 2005, Biochem Soc Trans 33(Pt 6): 1407-8; Hu 
et al., 2006, BMC Genomics 7:155), screen for proapoptotic 
genes (See, e.g., Mannherz et al., 2006, Genomics 87(5):665- 
72); Palmer et al., 2006, BMC Genomics 7(1): 145), andanno- 
tate protein function (See, e.g., Hodges et al., Mol Cell Pro- 
teomics 4(9): 1319-27). The transfected cell array has also 
been adapted to high-throughput RNAi studies (See, e.g., 
Mousses et al., Genome Res 13(10):2341-7), for example, for 
the analysis of spindle formation (See, e.g., Silva et al., 2004, 
Proc Natl Acad Sci USA 101(17):6548-52), secretory path- 
ways (Erfle et al., 2004, Biotechniques 37(3):454-8, 460, 
462), and chromosome segregation and nuclear structure in a 
time-lapse system (See, e.g., Neumannet al., 2006, Nat Meth- 
ods 3(5):385-90). 
[0078] Some technological improvements have enhanced 
the capabilities of the arrays, but have failed to yield wide- 
spread application of transfection cell arrays. Most efforts 
have focused on increasing transfection efficiency within the 
array by using preformed complexes (See, e.g., Delehanty et 
al., 2004, Biosens Bioelectron 20(4):773-9; Delehanty et al., 
2004, Anal Chem 76(24):7323-8; Erfle et al., 2004, Biotech- 
niques 37(3):454-8, 460,462; Hodges et al., 2005, Mol Cell 
Proteomics 4(9): 1319-27; Mousses et al., 2003, Genome Res 
13(10):2341-7; Pannier et al., 2005, Acta Biomaterialia l(5): 
511-522; Redmond et al., 2004, Mol Cell Proteomics 3(8): 
770-9; Silva et al., 2004, Proc Natl Acad Sci USA lOl(17): 
6548-52; andyoshikawa et al, 2004, J Control Release 96(2): 
227-32); incorporating fibronectin (See, e.g.,Yoshikawa et al, 
2004, J Control Release 96(2):227-32); atelocollagen (See, 
e.g., Honma et al., 2001, Biochem Biophys Res Commun 
289(5):1075-81); and recombinant proteins (See, e.g., Red- 
mond et al., 2004, Mol Cell Proteomics 3(8):770-9), with 
plasmid or DNA complexes, manipulating substrate hydro- 
phobicity (See, e.g., Delehanty et al., 2004, Biosens Bioelec- 
tron 20(4):773-9), or coating cationic polymer and collagen 
onto surfaces prior to transfection (See, e.g., Chang et al., 
2004, Nucleic Acids Res 32(3):e33). Micropatterning strate- 
gies have also been used to fabricate arrays, using self-as- 
sembledmonolayers to pattern DNA (See, e.g., Pannier et al., 
2005, Acta Biomaterialia 1(5):5 11 -522; Yamauchi et al., 
2004, Biochim Biophys Acta 1672(3):138-47) or siRNA 
(See, e.g., Fujimoto et al., 2006, Bioconjug Chem 17(6): 
1404-10) complex immobilization on gold slides or elec- 
trodes (See, e.g., Yamauchi et al., 2004, Nucleic Acids Res 
32(22):el87;Yamauchi et al., 2005, Langmuir 21(18):8360- 
7). Arrays have been formed with dendrimers (See, e.g., How 
et al., 2004, Comb Chem High Throughput Screen 7(5):423- 
30) andviral vectors (See, e.g., Bailey et al., 2006, Nat Meth- 
ods 3(2): 117-22; Hobson et al., 2003, BMC Biotechnol3(1): 
4; and Michiels et al., 2002, Nat Biotechnol 20(11): 11 54-7) 
for enhanced gene delivery, magnetic beads (Isalan et al., 
2005, Nat Methods 2(2): 113-8) or hydrogels (See, e.g., 
Peterbauer et al., 2006, Lab Chip 6(7):857-63) to localize 
cells and vectors, and for alternative cell types, including 
Drosophila (See, e.g., Wheeler et al., 2004, Nat Methods 
1(2):127-32) and non-adherent cells (Kato et al., 2004, Bio- 
techniques 37(3):444-8, 450, 452). 
[0079] However, multiple problems remain that have pre- 
cluded widespread application of transfection cell arrays. 
These problem include poor transfection efficiency, spot-to- 
spot variability, an inability to normalize data, complex and 
time consuming post-transfection processing, lack of sensi- 
tivity, poor image acquisition and quantification, as well as 
limitations prohibiting expansion of assessed biological end- 
points. 
[0080] Moreover, while there has beenmuch interest in two 
dimensional transfected cell arrays (e.g., see references cited 
above), three-dimensional transfected cell arrays have here- 
tofore not been described. 
[0081] Accordingly, in some embodiments, the present 
invention relates to characterizing transcription within cells. 
In particular, the present invention provides transfected cell 
arrays (e.g., two-dimensional andor three-dimensional 
arrays) and systems, kits andmethods utilizing the same (e.g., 
for transcriptional activity characterization). Compositions 
and methods of the present invention find use in, among other 
things, research, drug discovery and clinical (e.g., diagnostic, 
preventative and therapeutic) applications. 
[0082] In some embodiments, the present invention pro- 
vides compositions and methods for generating transfection 
cell arrays. In some embodiments, the present invention pro- 
vides a transfection cell array that allows for normalization of 
transfection and provides rapid and sensitive methods for 
quantification of cellular responses with minimal post-trans- 
fection processing. 
[0083] For example, in some embodiments, the present 
invention provides a plurality (e.g., two or more) plasmid 
system that provide normalization, sensitivity, and quantifi- 
cation (e.g., of transfection efficiency and cellular responses). 
Previously utilized transfection cell arrays have been 
described as suffering from spot to spot variability in trans- 
fection that compromises the ability to quantify a response 
within an array (e.g., because sub-maximal responses may 
indicate either a limited effect or simply inefficient or unequal 
delivery). Additionally, a variance in fluorescence intensity of 
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transfected cells (e.g., using GFP) has been noted between 
spots of arrays (See, e.g., Hook et al., 2006, Trends Biotech- 
no1 24(10):471-7). Accordingly, tlie present invention 
addresses these shortcoming by providing, in some embodi- 
ments, compositions and methods that enable normalization 
of transfection efficiency. For example, in some embodi- 
ments, a plurality plasmid (e.g., two or more plasmid) system 
comprising a normalization plasmid (e.g., comprising a 
reporter molecule (e.g., luciferase reporter)) that is present 
within each spot (e.g., transfection zone), and a functional 
plasmid (e.g., comprising areporter molecule (e.g., luciferese 
reporter (e.g., that is the same or different than that within a 
normalization plasmid))) that varies between spots and is 
responsible for the functional endpoint of the array, is depos- 
ited in each spotitransfection zone. The present invention is 
not limited by the number or type of plasmids utilized in a 
system. Indeed, two, three, four or more plasmids (e.g., com- 
prising similar or different components) may each be present 
in a transfection zone or spot. In some embodiments, the 
plurality of plasmids each contain the same promoter (e.g., 
TK promoter or other promoter described herein). In some 
embodiments, the presence of the same promoter permits 
normalization andor allows comparison between one or 
more cell lines on andor in an array (e.g., a 2-dimensional or 
3-dimensional array, respectively). 
[0084] In some embodiments, delivery of a plurality of 
plasmids results in a majority of cells expressing two or more 
reporter genes (e.g., one from each plasmid). In order to 
normalize data (e.g., with a second, third, fourth or more 
plasmid), efficiency of delivery should be sufficient to obtain 
a signal from each plasmid. The present invention addresses 
obstacles encountered with poor cellular transfection of mul- 
tiple plasmids in previously described transfection cell arrays 
(e.g., that utilized small transfection zone andor spot sizes 
(See, e.g., Palmer and Freeman, 2005, Pharmacogenomics 
6(5):527-34)). For example, small spotitransfection zone size 
are detrimental because each spot on the array may contain so 
few cells that an insufficient number of cells are transfected 
locally to be statistically informative (See, e.g., Hodges et al., 
2005, Mol Cell Proteomics 4(9):1319-27). Small spotsltrans- 
fection zones with low transfection efficiency make image 
acquisition and quantification difficult and less sensitive, 
leading to high false positive and false negative rates (See, 
e.g., Palmer et a]., 2006, BMC Genomics 7(1):145). Thus, in 
some embodiments, the present invention utilizes spot sizes 
that are larger relative to traditional transfection cell arrays. 
For example, in some embodiments the present invention 
provides a method of generating a 2-D transfection cell array 
comprising forming holes in a first material (e.g., polydim- 
ethylsiloxane (PDMS) or other material described herein) to 
generate an array mold, attaching the array mold to a solid 
substrate (e.g., glass, plastic, or other substrate material dis- 
closed herein) to form a complex comprising a plurality of 
wells, depositing one or more transfection molecules (e.g., 
nucleic acid (e.g., RNA, DNA, etc. (e.g., within a plasmid or 
virus)) into the plurality of wells under conditions such that 
the transfection molecules are immobilized on the solid sub- 
strate (e.g., in the hole (e.g., spot or transfection zone)) and 
removing the array mold from the solid substrate to generate 
an array (e.g., of one or more transfection molecules) on the 
substrate. In some embodiments, the transfection molecules 
colnprise a nucleic acid vector (e.g., plasmids). In some 
embodiments, the plasmid comprises a reporter gene. In some 
embodiments, the plasmid comprises a promoter region (e.g., 
configured to bind transcription factors). In some embodi- 
ments, the solid substrate is polystyrene. In some embodi- 
ments, tlie spot or transfection zone corriprises a second vec- 
tor (e.g., plasmid). In some embodiments, a second plasmid 
comprises a nucleic acid sequence comprising a reporter gene 
and a promoter region (e.g., that permits transcription effi- 
ciency to be normalized (e.g., between spotsltransfections 
zones present in the array)). Preferred sizes of the spots1 
transfection zones are described herein. In some embodi- 
ments, a transfection cell array of the present invention (e.g., 
fabricated by methods disclosed herein (e.g., to produce 
large, useful spotitransfection zone sizes) is compatible with 
viral delivery of transfection molecules (See, e.g., Bailey et 
al., 2006, Nat Methods 3(2):117-22; Hobson et al., 2003, 
BMC Biotechnol3(1):4; Michiels et al., 2002, Nat Biotech- 
no1 20(11):1154-7). In some embodiments, a transfection cell 
array of the present invention (e.g., fabricated by methods 
disclosed herein (e.g., to produce large, useful spotitransfec- 
tion zone sizes) is compatible with plasmid delivery of trans- 
fection molecules. In some embodiments, a transfection cell 
array of the present invention is compatible with delivery of 
transfection molecules andor other agents (e.g., candidate 
agents, drugs, oligonucleotides, etc.) via non-viral mediated 
and non-transfection mediated delivery (e.g., via receptor 
mediated endocytosis, phagocytosis, diffusion, etc.). 
- 
[0085] In some embodiments, the present invention pro- 
vides a method of screening transcriptional activity within 
cells comprising exposing an array (e.g., of transfection zones 
on a solid substrate comprising transfection molecules (e.g., 
wherein the transfection molecules comprise a first nucleic 
acid vector comprising a reporter gene and a promoter region 
configured to bind transcription factors and a second nucleic 
acid vector comprising a promoter configured for standard- 
ization of transfection efficiency)), wherein the array is gen- 
erated by forming holes in a first material (e.g., polydimeth- 
ylsiloxane (PDMS) or other material described herein) to 
generate an array mold, attaching the array mold to a solid 
substrate (e.g., glass, plastic, or other substrate material dis- 
closed herein) to form a complex comprising a plurality of 
wells, depositing one or more transfection molecules (e.g., 
nucleic acid (e.g., RNA, DNA, etc. (e.g., within a plasmid or 
virus)) into the plurality of wells under conditions such that 
the transfection molecules are immobilized on the solid sub- 
strate (e.g., in the hole (e.g., spot or transfection zone)) and 
removing the array mold from the solid substrate to generate 
an array (e.g., of one or more transfection molecules) on the 
substrate), to cells under conditions such that transcriptional 
activity within the cells is altered, and detecting the transcrip- 
tional activity within tlie cells. In some embodiments, detect- 
ing transcriptional activity within the cells comprises detect- 
ing expression of a reporter gene. 
[0086] In some embodiments, bioluminescence imaging 
(See, e.g., Rutter et al., 1998, Chem Biol 5(11):R285-90) is 
used with a transfection cell array (e.g., 2-dimensional (2-D) 
andor 3-dimensional (3-D) array) described herein to quan- 
tify the response of transfection molecules (e.g., two or more 
vectors canying transfection molecules) within the array 
(e.g., with minimal post-transfection processing and with 
high sensitivity). Previously utilized transfection cell arrays 
suffer from endpoint analysis that may require tagging or 
staining (See, e.g., Hook et al., 2006, Trends Biotechnol 
24(10):471-7) to report gene fwlction, which can require 
extensive post-transfection processing, such as fixation and 
immunostaining (See, e.g., Lee et al., 2006, J Biol Chem 
May 8,2008 
281(33):23589-97; Wheeler et al., 2005, Nat Methods l(2): 
127-32). In contrast, a transfection cell array fabricated and 
usedaccording to compositions andmethods disclosed herein 
permit rapid endpoint quantification (e.g., in each spotltrans- 
fection zone (e.g., via sequential addition of substrates)). For 
example, in some embodiments, two or more transfection 
molecules (e.g., normalization andor functional plasmid 
vectors) contain renilla andor firefly luciferase reporters 
(e.g., the substrates of which can be added directly to culture 
media followed by imaging of the array (e.g., of cells present 
in the array (e.g., cells that have been transfected using com- 
positions and methods of the present invention))). Luciferase 
reporters are more sensitive than GFP, without the issues of 
autofluorescence and background signals (See, e.g., Rutter et 
al., 1998, Chem Biol 5(11):R285-90). Luciferase is more 
quantitative and allows for small differences in expression to 
be determined, which, in some embodiments, permits an 
array of the present invention to determine a dose response to 
an external stimulus. In some embodiments, the short half- 
life of luciferase permits for real-time imaging (e.g., to iden- 
tify andor characterize dynamics of gene activity (See, e.g., 
Rutter et al., 1998, Chem Biol 5(11):R285-90). In some 
embodiments, the present invention utilizes imaging systems 
that use automated microscopy and image processing (See, 
e.g., Pepperkok and Ellenberg, 2006, Nat Rev Mol Cell Biol 
7(9):690-6; Wheeler et al, 2005, Nat Methods 1(2):127-32) 
(e.g., that allow for detection of changes in cellular morphol- 
ogy and cellular expression (e.g., nucleic acid, protein, etc.) 
level data (e.g., that is not possible with bioluminescence 
imaging)). The present invention is not limited by the end- 
point data analysis methods utilized. Indeed, avariety of other 
methods mav find use with the comvositions and methods of 
the present invention including those described herein. 
[0087] Compositions and methods of the present invention 
were utilized to quantify the activity of estrogen rector-alpha 
(ERu) in breast cancer cells with an estrogen-response-ele- 
ment (ERE)-regulated promoter reporter system (e.g., as an 
example of an inducible vector (e.g., plasmid) system (e.g., in 
a cancer model)). ERu, a member of the nuclear receptor 
superfamily of transcription factors, activates transcription 
through binding of its ligand, 17-P-estradiol (E,). Expression 
of ERu is used clinically as a biomarker to determine treat- 
ment for breast cancer patients (See, e.g., Ariazi et al., 2006, 
Curr Top Med Chem 6(3): 181 -202; Pearce and Jordan, 2004, 
Crit. Rev Oncol Hematol 50(1):3-22). However, simple 
expression of transcription factors like ERu does not neces- 
sarily reflect pathway activation, as transcription factor activ- 
ity is regulatedthroughdiversemechanisms (See, e.g., Levine 
and Tijan, 2003, Nature 424(6945):147-51), including het- 
eromeric complexes, ubiquitination, methylation, acetyla- 
tion, and post-translational modifications such as phosphory- 
lation. However, in some embodiments, compositions and 
methods of the present invention allow for the determination 
of transcription factor activity. For example, the present 
invention provides the ability to characterize the induction of 
activity of ERu by E,. Induction in a transfection cell array of 
the present invention mimicked results obtained through tra- 
ditional luciferase assay methods, with E, inducing luciferase 
expression 10-fold over fulvestrant or vehicle controls (See, 
e.g., Examples 1-5). An array of the present invention is also 
able to characterize activity in response to a range of dosages 
(e.g., the varying ER activity in response to a range of E, 
dosages was detected (See, e.g. Examples 4-5)) demonstrat- 
ing the sensitivity of the compositions andmethods disclosed 
herein. 
[0088] In some embodiments, the present invention pro- 
vides a 3-D array (e.g., transfection cell array). In some 
embodiments, the 3-D array is generated by spotting a sub- 
strate with a biopolymer solution containing cells (e.g., from 
a cell culture line, freshly harvested cells, cloned cells, trans- 
formed cells, etc.) and transfection molecules (e.g., vectors 
containing nucleic acid (e.g., DNA, RNA, cDNA, tRNA, 
siRNA) of interest) (See, e.g., Example 6). Thus, in some 
embodiments, the present invention provides a composition 
comprising a 3-D transfection cell array comprising an array 
of spatially controllable immobilized gels, wherein the gels 
comprise a crosslinkable biopolymer solution comprising 
cells exposed to transfection molecules (e.g., presented by a 
transfectionrea~ent). Thus. in some embodiments. in contrast 
u ,  
to substrate-mediated delivery of a transfection molecule 
(e.g., delivered via a 2-D transfected cell array (e.g., with a 
transfection molecule immobilized to a surface)), the present 
invention provides for polymeric-mediated delivery of trans- 
fection molecules to cells within a 3-dimensional transfection 
cell array (e.g., via distribution (e.g., homogenous distribu- 
tion) of transfection molecules and cells within a polymer 
(e.g., biopolymer (e.g., acrylated poly(ethy1ene glycol) 
(PEG-Acryl)hydrogels, collagen gels, alginate gels, or other 
suitable biomaterial disclosed herein)). 
[0089] In some embodiments, the biopolymer is cross- 
linked (e.g., forming an array of spatially controlled, immo- 
bilized gels). In some embodiments, the transcriptional activ- 
ity of the cells (e.g., within spatially controlled, immobilized 
gels) is determined. The present invention is not limited by 
the method of characterizing the transcriptional activity of the 
cells. Indeed, a variety of methods are contemplated to be 
useful for characterizing such activity including, but not lim- 
ited to those described herein. In some embodiments, a vector 
(e.g., plasmid) encoding a luciferase reporter gene driven by 
a regulated promoter is utilized. In some embodiments, 
expression of nucleic acid expression is determinedcharac- 
terized. In some embodiments, detection of protein expres- 
sion is determinedcharacterized. A vast of amount of infor- 
mation can be accumulated via such characterization. For 
example, the present invention provides a method for gener- 
ating andor characterizing information regarding signaling 
pathways and the production of genes relevant to cancer 
progression. Indeed, many other types of information are 
contemplated to be collected as described herein. 
[0090] In some embodiments, transcriptional activation as 
well as transfection efficiency can be quantified (e.g., by 
analyzing the level of reporter (e.g., luciferase) expression 
(e.g., through automated andor manual visual imaging of 
light production by the reporter (e.g., luciferase) upon the 
addition of its substrate luciferin)). In some embodiments, 
transfection efficiency is determined via normalization with a 
separate vector (e.g., plasmid) containing a minimal promoter 
driving a second reporter gene (e.g., a second luciferase or 
other reporter gene). In some embodiments, a 3-D transfec- 
tion cell array provides an in vivo like cellular environment to 
evaluate cell performance. In some embodiments, the 3-D 
cellular array is utilized to evaluate (e.g., characterize andor 
detect) cancer cell formation into cell structures. It is contem- 
plated that data generated utilizing compositions and meth- 
ods of the present invention will find use to assist in charac- 
terizing tumor stage and pathologic grade (e.g., physician's 
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assessment of grade andor pathology). However, the present 
invention is not so limited. For example, as described herein, 
information generated utilizing compositions and methods of 
the present invention also find use in molecular staging of 
disease, diagnostics and prognostics for disease and treat- 
ment, and as research tools (e.g., to analyze the activity of 
cellular signaling pathways (e.g., in specific cell populations 
andor under specific environmental conditions), to charac- 
terize cellular matrix design (e.g., how matrix design corre- 
lates with cellular response and cellular signaling pathways), 
and for characterizing tissue engineering (e.g., by providing a 
method for screening changes incell activity andmorphology 
(e.g., as function of gel rigidity and composition (e.g., when 
various extracellular matrices are also incorporated)))). In 
some embodiments, 3-D transfection cell arrays and methods 
of using the same described herein provide information 
regarding effects on cell morphology and transcriptional acti- 
vation as a function of gel elasticity, crosslink density, mesh 
size andor composition (e.g., comprising extracellularmatri- 
ces). 
[0091] In some embodiments, the present invention pro- 
vides compositions and methods (e.g., using 2-D andor 3-D 
transfection cell arrays described herein) for high throughput 
analysis of gene function in cells. For example, in some 
embodiments, compositions and methods of the present 
invention provide the ability to screen large sets of nucleic 
acid constructs for those encoding desired products or for 
causing cellular phenotypes of interest. In some embodi- 
hereby incorporated by reference in its entirety)) is deposited 
into a plurality of wells in an array mold (e.g., formed by 
generating holes in a first material (e.g., polydimethylsilox- 
ane (PDMS) or other material described herein) to generate 
an array mold, attaching the array mold to a solid substrate 
(e.g., glass, plastic, or other substrate material disclosed 
herein) to form a complex comprising a plurality of wells)), 
under conditions such that the transfection molecules are 
immobilized on the solid substrate (e.g., in the hole (e.g., spot 
or transfection zone)), wherein the array mold is removed 
from the solid substrate to generate an array (e.g., of one or 
more transfection molecules) on the substrate. In some 
embodiments, a mixture comprising spatially controllable, 
immobilized gels, wherein the gels comprise a crosslinkable 
polymer, cells and transfection molecules are arrayed on a 
substrate to form a plurality of transfection zones or spots. 
[0094] The transfection molecules andor carrier protein(s) 
can be deposited in as many discrete locations (e.g., spots or 
transfection zones created by making holes in a first material 
(e.g., for 2-D arrays), or by controlling the spatial location of 
immobilized gels (e.g., for 3-D arrays)) as desired. Thus, the 
present invention is able to produce a surface bearing a plu- 
rality of transfection molecules in defined, distinct locations 
wherein the identity of the transfection molecule in each of 
the transfection zones/spots is knowddefined. 
[0095] In some embodiments, eukaryotic cells, such as 
mammalian cells (e.g., human, monkey, canine, feline, 
bovine, or murine cells), bacterial, insect, or plant cells, are 
ments, cells transfected using a 2-D or 3-D cell array plated (placed) onto the surface bearing the transfection mol- 
described herein can be screened for the ability of a transfec- ecules (e.g., vector DNA (e.g., for 2-D arrays)) or are mixed 
tion molecule (e.g., nucleic acid) andor other agent (e.g., with transfection molecules and a crosslinkable linker (e.g., 
candidate agent) to confer a particular phenotype on the cells, for 3-D arrays) in sufficient density and under appropriate 
and, by reference to the position of the cell(s) on the array, the conditions for introductiodentry of the transfection mol- 
identity of the transfection molecule (e.g., nucleic acid) or 
other agent can be determined. 
[0092] Accordingly, the present invention is related to a 
method, referred to as a reverse transfection method, in which 
a defined transfection molecule (e.g., nucleic acid (e.g., a 
nucleic acid of known sequence or source)), is introduced into 
cells in defined areas (e.g., within a "lawn" of eukaryotic 
cells) in a 2-D array, or within a 3-D spatially controllable, 
immobilized gel comprising a crosslinkable biolpolymer 
cells and transfection molecules, in which the transfection 
molecules will be expressed or may have an effect on or 
interact with a cellular component or function. The present 
invention is not limited by the type of transfection molecule 
utilized. For example, any suitable nucleic acid such as an 
oligonucleotide, DNA and RNA can be used as a transfection 
molecule in the methods of the present invention. Moreover, 
the nucleic acid may be present in a plasmid or vector for 
expression, or not. It should be understood that any suitable 
nucleic acid can be utilized in the compositions and methods 
of the present invention. 
[0093] In some embodiments, the present invention pro- 
vides a method in which a transfection molecule (e.g., DNA 
(e.g., DNA of known sequence or source)) is introduced into 
cells in defined areas of a "lawn" of cells (e.g., eukaryotic 
cells), in which it will be expressed orwill itselfhave an effect 
ecules into the eukaryotic cells (e.g., host cells) and expres- 
sion of the DNA or its interaction with cellular components 
monitored andor characterized. 
[0096] In some embodiments, the concentration andor 
amount of transfection molecules (e.g., placed in a hole 
formed in a first material (e.g., PDMS) or mixed with a 
crosslinkable volvmer and cells can be determined emviri- 
. ,  
cally for each use. However, it is contemplated that when the 
transfection molecule is nucleic acid, the concentration will 
generally be in the range of from about 0.001 pglpl to about 
0.2 pg/pl and, in some embodiments, is from about 0.005 
pg/pl to about 0.10 pglpl. Alternatively, the concentration of 
DNA present in the mixture can be from about 0.01 pglpl to 
about 0.5 pg/pl, from about 0.007 pg/pl to about 0.021 pg/pl 
and from about 0.01 pglpl to about 0.3 pg/pl. 
[0097] In some embodiments, the amount of nucleic acid 
utilized is determined per surface area. For example, in some 
embodiments, the amount of nucleic acid used will generally 
be in the range of from about 0.001 pg/cm2 to about 5 pg/cm2 
and, in some embodiments, is from about 0.05 pg/cm2 to 
about 0.5 pg/cm2. Alternatively, the amount of DNA present 
can be from about 0.01 pg/cm2 to about 1.0 pg/cm2, from 
about 9.03 pg/cm2to about 0.75 pg/cm2 and from about 0.1 
pg/cm to about 2.5 pg/cm2. 
[0098] In some embodiments, when a carrier molecule is 
on or interact with a cellular component or function. In some utilized with transfectionmolecules for addition to a plurality 
embodiments, a mixture comprising transfection molecules of wells formed by punching holes in a first material (e.g., 
(e.g., nucleic acid (e.g., DNA (e.g., cDNA)) of interest (e.g., PDMS), the concentration of the carrier molecule (e.g., gela- 
incorporated into an expression plasmid or vector)) and a tin or another carrier macromolecule) can be determined 
carrier protein (e.g., a lipid based or gelatin based carrier (See, empirically for each use, but will generally be in the range of 
e.g. U.S. Patent Application Publication No. 20030228601, 0.01% to 0.5% and, in specific embodiments, is from about 
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0.05% to about 0.5%, from about 0.05% to about 0.2% or 
from about 0.1% to about 0.2%. 
[0099] In some embodiments, when cells are mixed with 
transfection molecules and a crosslinkable biopolymer (algi- 
nate andor alginatelcollagen), the concentration of the 
crosslinkable biopolymer can be determined empirically for 
each use, but will generally be in the range of 1% to 5% 
alginate, and, in specific embodiments, is from about 1% to 
about 2% alginate, from about 1.4% to about 1.6% alginate or 
from about 0.1% to about 5% alginate, although higher and 
lower percentages are contemplated. Similarly, the concen- 
tration of collagen will generally be in the range of 0.1% to 
3% alginate, and, in specific embodiments, is from about 
0.1% to about 0.3% alginate, from about 0.1% to about 0.2% 
alginate or from about 0.05% to about 5% alginate, although 
higher and lower percentages are contemplated. 
[0100] In some embodiments, a charge neutralizing reagent 
(e.g., polyethyleimine (PEI)) is added to the solution com- 
prising crosslinkable biopolymer and cells and transfection 
molecules. In some embodiments, the charge neutralizing 
reagent is added such that the nitrogen to phosphate (N:P) 
ratio is achieved to attain an optimal charge balance for trans- 
fection (e.g., optimal transfection). In some embodiments, 
the N:P ration is between around 15-35, from about 20-30, or 
from about 22-27, although higher and lower charge ratios 
may be used (e.g., depending on the type of cell and types of 
transfection molecules utilized). In some embodiments, a 
transfection efficiency of greater than about 50%, greater than 
60%, greater than 70%, greater than SO%, or greater than 90% 
is achieved, although higher and lower transfection efficien- 
cies may be attained. 
[0101] In some embodiments, if the transfection molecule 
(e.g., nucleic acid (e.g., DNA, RNA, cDNA, etc.)) used is 
present in a vector, the vector can be of any type, such as a 
plasmid or viral-based vector, into which a nucleic acid of 
interest (e.g., DNA to be expressed in reverse transfected 
cells) can be introduced and expressed (e.g., after reverse 
transfection) in recipient cells. For example, a CMV-driven 
expression vector can be used. Commercially available plas- 
mid-based vectors, such as pEGFP (CLONTECH) or 
pcDNA3 (INVITROGEN), or viral-based vectors can be used 
(See, e.g., U.S. Patent Application Publication Nos. 
20030228601 and 20060257858, each of which is hereby 
incorporated by reference in its entirety for all purposes). 
[0102] In some embodiments, to generate a transfection 
cell arrav. cells are either vlated over an arrav formed on a 
2 ,  
solid surface (e.g., for a 2-D array) or are mixed with trans- 
fection molecules and a crosslinkable biopolymer prior to 
immobilizing in a spacially definedarea on substrate (e.g., for 
a 3-D array). In some embodiments, actively growing cells 
are4 generally used and are plated, preferably in the range of 
10 -lo7 cells/cm2 (although higher and lower concentrations 
are contemplated (e.g., depending upon the cell type) on top 
of the substrate surface containing the affixed transfection 
molecules (e.g., nucleic acids (e.g., in media such as Dulbec- 
co's Modified Eagles Medium (DMEM) containing 10% 
heat-inactivated fetal serum (IFS) with L-glutamine and peni- 
cillidstreptomycin (pedstrep) or other media)); or for 3-D 
gels, are mixed with transfection molecules and a crosslink- 
able biopolymer in the range of lo4-lo6 cells/mL, although 
more or less cells can also be used (e.g., based upon the type 
of cells to be transfected). 
[0103] The transfection cell arrays (e.g., 2-D andor 3-D 
arrays comprising cells and transfection molecules) are main- 
tained under conditions appropriate for growth of the cells 
and entry of DNA, such as an entry of an expression vector 
containing the DNA, into cells. For example, in some 
embodiments, one to two cell cycles are sufficient for reverse 
transfection to occur, but this can vary depending upon the 
cell type and conditions used and the appropriate length of 
time for a specific combination can be determined empiri- 
cally. After sufficient time has elapsed, cells can be assessed 
for reverse transfection (e.g., entry of transfection molecules 
(e.g., nucleic acid (e.g., DNA)) into cells) and expression of 
the encoded product or effect of the introduced DNA on 
reverse-transfected cells, using known methods. This can be 
done, for example, by detecting immunofluorescence or 
enzyme immunocytochemistry, autoradiography, in situ 
hybridization, or other means of detecting expression of the 
DNA or an effect of the encoded product or of the DNA itself 
on the cells into which it is introduced. 
[0104] In some embodiments, detection of transfection 
(e.g., alteration of transcription within transfected cells) uti- 
lizes detection of a reporter system (e.g., renilla andor firefly 
luciferasereporters (e.g., the substrates ofwhichcan be added 
directly to culture media followed by imaging of the array 
(e.g., of cells present in the array (e.g., cells that have been 
transfected using compositions and methods of the present 
invention))). 
[0105] In some embodiments, immunofluorescence can 
used to detect expression of an encoded protein (e.g., an 
antibody that binds a protein and is fluorescently labeled can 
used (e.g., added to an array under conditions suitable for 
binding of the antibody to the protein) and the location (e.g., 
transfection zone or spot) of the protein identified by detect- 
ing fluorescence). In some embodiments, the presence of 
fluorescence indicates that reverse transfection has occurred 
and the encoded protein has been expressed in the defined 
location(s) which show fluorescence. The presence of a sig- 
nal, detected by the method used, on the slides indicates that 
reverse transfection of the DNA into cells and expression of 
the encodedproduct or an effect of the DNA in recipient cells 
has occurred in the defined location(s) at which the signal is 
detected. As described above, the identity of the DNA present 
at each of the defined locations is known; thus, when expres- 
sion occurs, the identity of the expressed protein is may also 
known. 
[0106] In some embodiments, the present invention pro- 
vides a method for expressing specific, identified nucleic 
acids (e.g., cDNAs or genomic DNAs), in defined locations or 
areas of a surface (e.g., transfection zones or spots) onto 
which the same or different nucleic acids (e.g., variants, 
mutants, etc.) have been attached. Thus, because each area of 
the surface can be coveredspotted with nucleic acid of a 
known composition, this permits identification of the 
expressed protein. In addition, the present method is useful to 
identify DNAs whose expression alters (enhances or inhibits) 
a pathway, such as a signaling pathway in a cell or another 
property of a cell, such as its morphology or pattern of gene 
expression. In some embodiments, compositions and meth- 
ods of the present invention are useful, for example, as a 
high-throughput screening method, such as in a microarray 
format. Thus, compositions and methods described herein 
can be used for identifying nucleic acids whose expression 
change the post-translational status andor subcellular loca- 
tion of a protein of interest or the effect of a test compound or 
agent on the cell (e.g., cellular activity post exposure to a test 
agent or compound (e.g., a small molecule, drug, hormone, 
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siRNAetc.)). Thus, in some embodiments, compositions and 
methods of the present invention can be utilized to character- 
ize cellular activity (e.g., transcriptional activity) post expo- 
sure of cells to a test agent, by measuring transcriptional 
activity (e.g., of a reporter system) within the cell. 
[0107] In some embodiments, the present invention pro- 
vides methods of making arrays of the present invention. The 
methods comprises The method comprises affixing DNAs or 
reverse transfected cells onto a surface by the steps described. 
herein for the gelatin-DNA embodiment or the lipid-DNA 
embodiment. 
[0108] In some embodiments, the present invention relates 
to a method of introducing specific, known transfection mol- 
ecules (e.g., nucleic acids (e.g., DNA)) at specific, discrete, 
defined locations (e.g., transfection zones or spots) on a sub- 
strate surface by lneans of a reverse transfection method. The 
size of the transfection zonesispots, the quantity (density) of 
the transfection zonesispots and the configuration of the 
transfection zoneispots can be adjusted depending upon a 
variety of factors (e.g., the type of cells used, the conditions 
used to transfect, etc.). For example, in some embodiments, 
the transfection zonesispots can be from about 0.1 to about 10 
mm in diameter, from about 0.5 to about 10 mm in diameter, 
from about 1 to about 5 mm in diameter, from about 2 to about 
4 rnm in diameter, or from about 2.3 to about 2.5 mm in 
diameter, although larger and smaller diameters are contem- 
plated. In some embodiments, each transfection zoneispot is 
from about 0.1 to about 0.9 mm away from another transfec- 
tion zoneispot. 
[0109] In some embodiments, the present invention pro- 
vides identification andor detection of cells into which trans- 
fection molecules have been transfected (e.g., reverse trans- 
fected). In one embodiment, transfection molecules (e.g., 
DNA) introduced into cells are expressed in the cells, either 
by an expression vector containing the molecules (e.g., DNA) 
or as a result of integration of molecules (e.g., DNA) into host 
cell DNA, from which it is expressed. In some embodiments, 
nucleic acids (e.g., RNA (e.g., siRNA) or DNA) are intro- 
duced to cells (e.g., are not transfectedly expressed in the 
cells), and are able to alter cellular components and/or func- 
tion (e.g., that can be detected using the compositions and 
methods of the present invention (e.g., reporter constructs 
transfected into cells). For example, small inhibitory RNAs or 
other antisense molecules can be introduced into cells to alter 
cell function. In some embodiments, a nucleic acid can be 
transfected into the cell, wherein the nucleic acid inhibits 
expression of other nucleic acids in the cell. For example, a 
DNA fragment which is anti-sense to an mRNA (e.g., encod- 
ing a receptor for a drug) can be introduced into cells via 
reverse transfection. The anti-sense DNA may decrease the 
expression of mRNA (e.g., of the drug receptor protein (e.g., 
causing a decrease in drug binding to cells containing the 
anti-sense DNA)). 
[0110] In some embodiments, the present invention pro- 
vides detection of effects on recipient cells (cells containing 
transfection molecules introduced using an array of the 
present invention) that can be carried out by a variety of 
known techniques, such as immunofluorescence (e.g., of a 
reporter construct (e.g., a luciferase reporter) or of a protein 
(e.g., in which a fluorescentIy IabeIed antibody that binds a 
protein of interest (e.g., a protein thought to be encoded by a 
reverse transfected DNA or a protein whose expression or 
function is altered through the action of the reverse trans- 
fected DNA)). 
[Olll] In some embodiments, compositions and methods 
of the present invention are utilized to identify nucleic acids 
(e.g., DNAs) of interest (nucleic acids that are expressed in 
recipient cells or act upon or interact with recipient cell con- 
stituents or function (e.g., nucleic acids that encode a protein 
whose function is desired because of characteristics its 
expression gives cells in which it is expressed)). In some 
embodiments, an array of the present invention can be utilized 
as a protein or cell array (e.g., a protein microarray or a cell 
microarray). 
[0112] The present invention is not limited by the type of 
nucleic acid utilized (e.g., as a transfection molecule (e.g., 
introduced into cells for expression)) in a 2-D andor 3-D 
transfection array described herein. The nucleic acid mol- 
ecules used in the transfection arrays of the present invention 
can be, for example, DNA, RNA or modified or hybrid forms 
thereof. The nucleic acids may be from any of a variety of 
sources, such as nucleic acid isolated from cells, or that which 
is recombinantly produced or chemically synthesized. 
[0113] In some embodiments, the nucleic acids include 
coding sequence from cDNAs or genomic DNA. In addition 
to native sequences, the coding sequences can include those 
which have been mutated relative to the native sequence (e.g., 
a coding sequence that differs from a naturally occurring 
sequence by deletion, substitution or addition of at least one 
residue). It can correspond to full length or partial sequences, 
can be antisense in orientation, or can represent a non-coding 
sequence. 
[0114] In some embodiments, all or a portion of the nucleic 
acid sequence can be synthesized chemically. Thus, random 
and semi-random sequence can be introduced into the nucleic 
acid sequences, as well as modified forms of nucleotides and 
nucleotide linkages, such as the use of modified backbones, 
methylated nucleotides and the like. 
[0115] As described herein, the nucleic acid sequences can 
be present as part of a larger vector, such as an expression 
vector (e.g., a plasmid or viral-based vector), but it need not 
be. The nucleic acid of the array can be introduced into cells 
in such a manner that at least the a portion of the nucleic acid 
sequence (e.g., a portion that varies from transfection zone1 
spot to transfection zoneispot) becomes integrated into cel- 
lular genomic DNA and is expressed, or remains extrachro- 
mosomal (e.g., is maintained episomally). 
[0116] The nucleic acid sequences (e.g., utilized in trans- 
fection cell arrays of the present invention) can be linear or 
circular, double stranded or single stranded, and can be of any 
size. In some embodiments (e.g., when expression vectors are 
used) nucleic acid sequences expressed in cells (e.g., result- 
ing from transfection of cells with a vector comprising the 
nucleic acid sequence) is from about 200 nucleotides (nt) to 
about 10 kilobases (kb) in size, in some embodiments, from 
about 200 nt to about 5 kb, and in some embodiments, from 
about 200 nt to 2 kb, although shorter or longer sequences 
may be expressed. In some embodiments, the nucleic acid 
sequence transfected into cells (e.g., including vector 
sequence) is from about 1 kb to about 15 kb, although larger 
and smaller constructs are also contemplated herein. 
[0117] In some embodiments, a transfectioncell array (e.g., 
2-D or 3-D array) of the present invention comprises a varie- 
gated library of expression vectors. 
[0118] The present invention is not limited by the type of 
vector utilized (e.g., to introduce a transfection molecule 
(e.g., into cells for expression)) in a 2-D andor 3-D transfec- 
tion array described herein. In general, it will be desirable that 
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the vector be capable of replication in the host cell. It may be 
a DNA (e.g., plasmid DNA) which is integrated into the host 
genome, and thereafter is replicated as a part of the chromo- 
somal DNA, or it may be DNA which replicates autono- 
mously (e.g., an episomal plasmid). In the latter case, the 
vector will include an origin of replication which is functional 
in the host. In the case of an integrating vector, the vector may 
include sequences that facilitate integration (e.g., sequences 
homologous to host sequences, or encoding integrases). The 
use of retroviral long terminal repeats (LTR) or adenoviral 
inverted terminal repeats (ITR) in the construct of a transfec- 
tion array can, for example, facilitate the chromosomal inte- 
gration of the construct. 
[0119] Cloning and expression vectors for use with bacte- 
rial, fungal, yeast, and mammalian cellular hosts are known in 
the art, and are described in, for example, Powels et al. (Clon- 
ing Vectors: A Laboratory Manual, Elsevier, N.Y., 1985). 
Such vectors may be readily adapted for use in the present 
invention. The expression vectors may comprise non-tran- 
scribed elements such as an origin of replication, a suitable 
promoter and enhancer linked to the gene to be expressed, and 
other 5' or 3' flanking nontranscribed sequences, and 5' or 3' 
nontranslated sequences (e.g., ribosome binding sites, a poly- 
adenylation site, splice donor and acceptor sites, and tran- 
scriptional termination sequences). 
[0120] In some embodiments, expression vectors contain 
bothprokaryotic sequences (e.g., to facilitate the propagation 
of the vector in bacteria (e.g., in an amplification step after 
recovery from the array)), andor one or more eukaryotic 
transcription units for expressing the target sequence in 
eukaryotic host cells. The pcDNAIIamp, pcDNAIIneo, pRc1 
CMV, pSV2gpt, pSV2ne0, pSV2-dhfr, pTk2, pRSVneo, 
pMSG, pSVT7, PKO-neo and pHyg derived vectors are 
examples of mammalian expression vectors that can be 
readily adapted for use in the compositions and methods of 
the present invention. Some of these vectors are modified 
with sequences from bacterial plasmids, such as pBR322, to 
facilitate replication and drug resistance selection in both 
prokaryotic and eukaryotic cells. Alternatively, derivatives of 
viruses, such as the bovine papillomavirus (BPV-I), or 
Epstein-Barr virus (pHEBo, PREP-derived and p205) and the 
like, can also be used. The various methods employed in the 
preparation of the plasmids are well known in the art. For 
other suitable expression systems for both prokaryotic and 
eukaryotic cells, as well as general recombinant procedures, 
see, e.g., Molecular Cloning A Laboratory Manual, 2nd Ed., 
ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor 
Laboratory Press: 1989) Chapters 16 and 17. 
[0121] In some embodiments, vectors contain regulatory 
elements that can be linked to the target sequence for trans- 
fection of mammalian cells. Examples of such vectors 
include, but are not limited to, cytomegalovirus (CMV) pro- 
moter-based vectors such as pcDNAl (INVITROGEN, San 
Diego, Calif.), MMTV promoter-based vectors such as 
pMAMNeo (CLONTECH, Palo Alto, Calif.) and pMSG 
(PHARMACIA, Piscataway, N.J.), and SV40 promoter- 
basedvectors such as pSVO (CLONTECH, Palo Alto, Calif.). 
[0122] A number of vectors exist for the expression of 
recombinant proteins in yeast (e.g., where yeast are used as a 
host cell in an array). Examples include, but are not limited to, 
YEP24,YIP5,YEP51,YEP52, pYES2, andYRP17, andother 
cloning and expression vehicles useful in the introduction of 
genetic constructs into S. cerevisiae (See, e.g., Broach et al. 
(1983) in Experimental Manipulation of Gene Expression, 
ed. M. Inouye Academic Press, p. 83, incorporated by refer- 
ence herein). These vectors can replicate in E. coli due the 
presence of the pBR322 ori, and in S. cerevisiae due to the 
replication determinant of the yeast 2 micron plasmid. More- 
over, if yeast are used as a host cell, it will be understood that 
the expression of a gene in a yeast cell requires a promoter 
which is functional in veast. Suitable vromoters include. but 
are not limited to, the promoters for metallothionein, 3-phos- 
phoglycerate kinase (See, e.g., Hitzeman et al., J. Biol. Chem. 
255,2073 (1980) or other glycolytic enzymes (See, e.g., Hess 
et al., J. Adv. Enzyme Req. 7, 149 (1968); and Holland et al. 
Biochemistry 17, 4900 (1978)), such as enolase, glyceralde- 
hyde-3-phosphate dehydrogenase, hexokinase, pyruvate 
decarboxylase, phospho-fructokinase, glucose-6-phosphate 
isomerase, 3-phosphoglycerate mutase, pyruvate kinase, tri- 
osephosphate isomerase, phospho-glucose isomerase, and 
glucokinase. 
[0123] The present invention is not limited by the source of 
transfection moleclue (e.g., introduced into cells for expres- 
sion)) utilized in a 2-D andor 3-D transfection array 
described herein. For example, in some instances, it may be 
desirable to derive the host cell using insect cells. In such 
embodiments, the transfection array can be derived from, for 
example, a baculovirus expression system. Examples of such 
baculovirus expression systems include, but are not limited 
to, pVL-derived vectors (e.g., pVL1392, pVL1393 and 
pVL941), pAcUW-derived vectors (e.g., pAcUWI), and 
pBlueBac-derived vectors (e.g., beta-galactosidase contain- 
ing pBlueBac 111). 
[0124] In some embodiments, where the source of target 
sequence for the array are naturally occurring, sequences can 
be isolated from any cell or collection of cells. For example, 
the target sequences can be isolated from the cells of either 
adult tissue or organs or embryonic tissue or organs at any 
given developmental stage (e.g., including, but not limited to, 
oocyte, blastocyte, etc.). The cells can be derived from 
healthy tissue or diseased tissue. In the case of a solid organ, 
cells can be obtained by biopsy or other mechanical means. 
For blood, lymph and other bodily fluids, cells can be isolated 
from the fluid component (e.g., by filtration, affinity purifica- 
tion, centrifugation or any other technique known in the art). 
The cells can be isolated to include a specific subset of phe- 
notypes of cells from a given tissue, or can include or can be 
derived to include all or a substantial portion of cells repre- 
sentative of the tissue. For example, cells can be derived from 
an organ where the cells are particularly of epithelial, mes- 
enchymal or endothelial origin. Subsets of cells can be iso- 
lated, for example, by use of cell surface markers or careful 
sectioning of a tissue. 
[0125] In some embodiments, cells can be harvested from 
neoplastic or cancerous tissue. For example, cells may be 
cultured from any type of tumor or cancerous tissue (e.g., 
identified via pathologic means). 
[0126] In some embodiments, nucleic acid sequences (e.g., 
transfected into host cells) are cDNA sequences (e.g., derived 
from mRNA isolated from a cell or cells of interest (e.g., 
cancer cell or normal cell) or that are chemically synthe- 
sized). There are a variety of methods known in the art for 
isolating RNA from a cellular source. For example, isolation 
of total cellular RNA using guanidine isothiocyanate (de- 
scribed, e.g., in U.S. Pat. No. 4,843,155) used in conjunction 
with, for example, oligo-dT strepavidin beads, is an example 
of one means of isolating mRNA. The RNA, as desirable, can 
be converted to cDNA using reverse transcriptase. 
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[0127] A wide range of techniques for isolating genomic 
DNA exist that are amenable for use in a varietv of embodi- 
ments of the present invention. In some embodiments, only a 
portion of the total genomic DNA is isolated (e.g., on the basis 
of the chemical andor physical state in which it is present 
(e.g., in a collection of cells)). For example, transcriptionally 
active andor potentially active genes can be isolated (e.g., 
away from inactive sequences (e.g., using Dnase I digestion). 
[0128] The present invention is not limited by the type of 
nucleic acid utilized (e.g., as a transfection molecule (e.g., 
that is introduced into cells for expression)) in a 2-D andor 
3-D transfection array described herein. In some embodi- 
ments, libraries of nucleic acid molecules are utilized in a 
transfection array. In some embodiments, an array may com- 
prise a library of related, mutated sequences, such as a library 
of mutants of a particular protein, or libraries of potential 
promoter sequences, etc. A variety of forms of mutagenesis 
exist that are well known in the art that can be utilized to 
generate a combinatorial library. For example, homologs of a 
protein of interest can be generated and isolated from a library 
by screening using, for example, alanine scanning mutagen- 
esis and the like (See, e.g., Ruf et al. (1994) Biochemistry 
33:15 65-1572; Wang et al. (1994) J. Biol. Chem. 269:3095- 
3099; Balint et al. (1993) Gene 137:109-118; Grodberg et al. 
(1993) Eur. J. Biochem. 218:597-601; Nagashima et al. 
(1993) J. Biol. Chem. 268:2888-2892; Lowinan et al. (1991) 
Biochemistry 30:10832-10838; and Cunningham et al. 
(1989) Science 244: 1081-1085), by linker scanning 
mutagenesis (See, e.g., Gustinet al. (1993)Virology 193:653- 
660; Brown et al. (1992) Mol. Cell. Biol. 12:2644-2652; 
McKnight et al. (1982) Science 232:316); by saturation 
mutagenesis (See, e.g., Meyers et al. (1986) Science 232: 
613); by PCR mutagenesis (See, e.g., Leung et al. (1989) 
Method Cell Mol Biol 1 : 1 1-1 9); andor by random mutagen- 
esis (See, e.g., Miller et al. (1 992) A Short Course in Bacterial 
Genetics, CSHL Press, Cold Spring Harbor, N.Y.; and 
Greener et al. (1994) Strategies in Mol. Biol. 7:32-34). 
[0129] In some embodiments, a transfection array (e.g., 
2-D andor 3-D array) of the present invention utilizes a 
library of small gene fragments (e.g., sequences that encode 
dominant-acting synthetic genetic elements (SGEs) (e.g., 
molecules that interfere with the function of genes from 
which they are derived (antagonists) or that are dominant 
constitutively active fragments (agonists) of such genes)). 
SGEs that can be identified by the subject method include, but 
are not limited to, polypeptides, inhibitory antisense RNA 
molecules (e.g., siRNAs, shRNAs, snRNAs, etc.), ribozymes, 
nucleic acid decoys, and small peptides. 
[0130] In some embodiments, an SGE is identified using 
the compositions andmethods ofthe present invention. These 
genetic elements mi& function to inhibit the function of an 
u u 
endogenous gene at the level of nucleic acid expression a n d  
or translation (e.g., by an antisense or decoy mechanism. 
Alternatively, the synthetic genetic elements might encode a 
polypeptide that is inhibitory through a mechanism of inter- 
ference at the protein level (e.g., a dominant negative frag- 
ment of the native protein). In some embodiments, a synthetic 
genetic element may function to enhance the function of an 
endogenous gene (e.g., by encoding apolypeptide that retains 
at least a portion of the bioactivity of the corresponding 
endogenous gene, and may in particular instances be consti- 
tutively active). 
[0131] In some embodiments, a synthetic genetic element 
library is generated from total cDNA, that may be further 
fragmented, and provided in the form of an expression library. 
In some embodiments, the inserts in the library range from 
about 100 base pairs (bp) to about 700 bp, In some embodi- 
ments, from about 20 bp to about 100 bp, and in some 
embodiments, from about 30 bp to about 70 bp, although 
shorter and longer sequences are contemplated. 
[0132] For cDNA-derived libraries, the nucleic acid library 
can be a normalized library containing roughly equal num- 
bers of clones corresponding to each gene expressed in the 
cell type from which it was made, without regard for the level 
of expression of any gene. 
[0133] Libraries can be generated to include both sense and 
antisense coding (and non-coding sequences) sequences. In 
some embodiments, expression (e.g., &anscription) of library 
sequences in targethost cells creates antisense nucleic acids 
(e.g., RNAs) that inhibit transcription of the corresponding 
endogenous gene. In some embodiments, compositions and 
methods described in U.S. Pat. No. 5,702,898 (hereby incor- 
porated by reference in its entirety) for normalizing a cDNA 
library constructed in a vector are utilized. In some embodi- 
ments, a sequence library is a subtractive cDNA library. Many 
strategies have been used to create subtractive libraries. and 
u 
can be readily adapted for use in the present method. For 
example, use of directionally cloned cDNA libraries as start- 
ing material may be used (See, e.g., Palazzolo and Meyerow- 
itz, (1987) Gene 52:197; Palazzolo et al. (1989) Neuron 
3:527: Palazzolo et al. (1990) Gene 88:25). In some embodi- 
, , 
ments, a library of sequences is utilized that has been gener- 
ated by providing an endonuclease restriction site at the 5' end 
of an oligo(dT) primer. The restriction enzyme recognition 
sequence does not affect the annealing of the 12-20 base 
oligo(dT) primer to the mRNA, so the cDNA second strand 
synthesized from the first strand template includes the new 
recognition site added to the original 3' end of the coding 
sequence. After second strand cDNA synthesis, a blunt ended 
linker molecule containing a second restriction site (or a 
partially double stranded linker adapter containing a protrud- 
ing end compatible with a second restriction site) is ligated to 
both ends of the cDNA. The site encoded by the linker is now 
on both ends of the cDNA molecule, but only the 3' end of the 
cDNA has the site introduced by the modified primer. Fol- 
lowing the linker ligation step, the product is digested with 
both restriction enzymes (or, if a partially double stranded 
linker adapter was ligated onto the cDNA, with only the 
enzyme that recognizes the modified primer sequence). A 
population of cDNA molecules results which all have one 
defined seauence on their 5' end and a different defined 
sequence on their 3' end. In some embodiments, a sequence 
library is generated according to a directional cloning strat- 
egy developed by Meissner et al. (1987) PNAS 84:4171) that 
requires no sequence-specific modified primer, but rather a 
double stranded palindromic BamHIIHindIII directional 
linker having the sequence d(GCTTGGATCCAAGC), that is 
ligated to a population of oligo(dT)-primed cDNAs, followed 
by digestion of the ligation products with BamHI and HindIII. 
The palindromic linker, when annealed to double stranded 
form, includes an internal BamHI site (GGATCC) flanked by 
4 of the 6 bases that define a HindIII site (AAGCTT). The 
missing bases needed to complete a HindIII site are d(AA) on 
the 5' end or d(TT) on the 3' end. Regardless of the sequence 
to which this directional linker ligates, the internal BamHI 
site will be present. However, HindIII can only cut the linker 
if it ligates next to an d(AA):d(TT) dinucleotide base pair. In 
an oligo(dT)-primed strategy, a HindIII site is always gener- 
May 8,2008 
ated at the 3' end of the cDNA after ligation to this directional 
linker. For cDNAs having the sequence d(TT) at their 5' ends 
(statistically 1 in 16 molecules), linker addition will also yield 
a Hind111 site at the 5' end. However, because the 5' ends of 
cDNA are heterogeneous due to the lack of processivity of 
reverse transcriptases, cDNA products from every gene seg- 
ment will be represented in the library. 
[0134] In some embodiments, a sequence library encodes 
molecules (e.g., nucleic acid sequences) that correspond to 
regulatory elements of a gene and that can inhibit expression 
of the gene by sequestering molecules important for tran- 
scription (e.g., transcriptional factors) thereby competing for 
the necessary components to express the endogenous gene. 
[0135] In some embodiments, a sequence library can be 
generated by randomly fragmenting a single gene to obtain a 
random fragment expression library derived exclusively from 
the gene of interest. As a practical matter, such a library 
contains a much greater variety of sequences from the gene of 
interest than will a random fragment library prepared from 
total cDNA. 
[0136] In some embodiments, a purified DNA correspond- 
ing to a gene or genome to be suppressed (e.g., within cells 
transfected in an array of the present invention) is first ran- 
domly fragmented by enzymatic, chemical, or physical pro- 
cedures. In some embodiments, random fragments of DNA 
are produced by treating the DNA with a nuclease, such as 
DNase I. In some embodiments, the random DNA fragments 
can be incorporated as inserts in a sequence library. DNase I 
partial digestion and library construction are described gen- 
erally in Molecular Cloning, A Laboratory Manual, Sam- 
brook et al., Eds., Cold Spring Harbor Laboratory, Cold 
Spring Harbor, N.Y. (1 989). In some embodiments, sequence 
fragment are expressed as part of a fusion protein. In some 
embodiments, the inserted sequence fragment alone may be 
expressed. In another embodiment, ribozyme-encoding 
sequences may be inserted directly adjacent to the insert to 
allow for selection of most efficient ribozyme-antisense 
clones. In still other embodiments the sequence library (e.g., 
gene suppression element library) may be further modified by 
random muta~enesis vrocedures known in the art. The 
u 
inserted fragments may be expressed from either a constitu- 
tive or an inducible promoter. 
[0137] In some embodiments, compositions and methods 
of the present invention utilize a library encoding a variegated 
population of small peptides (e.g., 4-25 amino acid residues 
in length). The library can be generated from coding 
sequences of total cDNA, or single genes, or can be random or 
semi-random in sequence. 
[0138] In some embodiments, compositions and methods 
of the present invention utilize a transfection array that (e.g., 
when a nucleic acid sequence is transcribed in the host cell) 
gives rise to double stranded RNA (e.g, for use in identifying 
dsRNA constructs that produce a particular phenotype by 
RNA interference). 
[0139] Libraries of coding sequences, whether encoding 
random peptides or full length proteins, may be expressed in 
many ways, including as portions of chimeric (e.g., fusion) 
proteins. In some instances it may be necessary to introduce 
an unstructured polypeptide linker region between portions 
of a chimeric protein derived from different proteins. The 
linker may facilitate enhanced flexibility of the chimeric pro- 
tein allowing each portion to fold correctly and retain appro- 
priate biological activity in the host cell. The linker can be of 
natural origin, such as a sequence determined to exist in 
random coil between two domains of a vrotein. Altemativelv. 
. , 
the linker can be of synthetic origin. In some embodiments, 
naturally occurring unstructured linkers of human origin are 
preferred (e.g., because they reduce the risk of immunoge- 
nicity). In some embodiments, a fusion protein may comprise 
a secretion signal sequence (e.g., where secretion of a protein 
is desired). 
[0140] The present invention is not limited by the number 
of different transfection molecules presented in any particular 
array (e.g., in any particular transfection zoneispot or on any 
give surface of an array). 
[0141] In some embodiments, a transfection cell array pro- 
vides, in a single array, at least 10 different sequences, more 
preferably at least 100,1000 or even 10,000 different, discrete 
types of transfectionmolecules (e.g., nucleic acid sequences). 
In some embodiments, more than 10,000 or less than 10 
different sequences are provided. In some embodiments, 
transfection molecules are arrayed in an addressable fashion, 
suchas rows and columns (e.g., where the substrate is a planar 
surface). 
[0142] The present invention contemplates the formation 
of arrays with a plurality of transfection zonesispots on a 
substrate surface (e.g., for both 2-D and 3-D arrays). In some 
embodiments, a substrate surface has about 10,000 transfec- 
tion zonesispots in a one centimeter square area. In some 
embodiments, a transfection array provides a density of at 
least 1000 different transfection zonesispots per square cen- 
timeter, and more preferably at least 5000, 8000, 10000, 
100000, or more transfection zonesispots. In some embodi- 
ments, lower or higher densities of transfection zonesispots 
are utilized. 
[0143] As described herein, the present invention provides 
the presentation of two or more different transfection mol- 
ecules at any given spotitransfection zone described herein 
(e.g. for co-transfection andor co-expression of the two or 
more molecules in the same cells). Co-transfections can be 
performed with transfected cell microarrays if the solution 
spotted on the surface where reverse transfection occurs (e.g., 
in a 2-D array), or if the crosslinkable biopolymer and cells 
are mixed and (e.g., in a 3-D array) contains more than one 
plasmid or nucleic acid construct. The present invention con- 
templates the transfection of 2 or more, 10 or more, 50 or 
more, 100 or more transfection molecules within any given 
transfection zone. 
[0144] In some embodiments, the ability to transfect two or 
more transfection molecules into cells in a cell arrav of the 
present invention provides a variety of uses. These include, 
but are not limited to, the ability to infer the expression of a 
gene product by detecting the expression of a co-transfected 
plasmid encoding a marker protein (e.g. GFP, luciferase, 
beta-galactosidase, or any protein to which a specific anti- 
body is available), express all the components of a multi- 
subunit complex (e.g. the T-cell receptor) in the same cells, 
express all the components of a signal transduction pathway 
(e.g. MAP kinase pathway) in the same cells, and express all 
the components of a pathway that synthesizes a small mol- 
ecule (e.g. intracellular antibodies, etc). In addition, the 
capacity to co-transfect allows the creation of microarrays 
with combinatorial combinations of co-expressed plasmids. 
This capacity is particularly useful for implementing mam- 
malian two-hybrid assays in which plasmids encoding bait 
and prey proteins are co-transfected into the same cells by 
spotting them in one feature of the microarray. 
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[0145] The capacity to co-transfect is also useful when the 
goal is to promote differentiation of the transfected cells 
along a certain tissue lineage. For example, combination of 
genes can be expressed in a stem cell or early progenitor cell 
that may alter the differentiation of the cells (e.g., into endot- 
helial, liver, heart, pancreatic, lymphoid, islet, brain, lung, 
kidney or other cell types). In this fashion, arrays can be made 
with primary-like cells that can be used to examine interac- 
tions of protein or small molecules that are cell-type specific. 
[0146] Furthermore, transfection molecules may be intro- 
duced in specific locations on or within a 2-D or 3-D array, 
respectively. For example, combinations of cDNAs can be 
printed in different patterns on a substrate surface or be made 
to be included in a plurality of spatially isolated crosslinked 
biopolymers comprising cells and transfection molecules. 
Exemplary patterns include, but are not limited to, bulls-eyes, 
squares, rectangles of varying heights and widths, and lines of 
single cell thickness. By placing (e.g., in particular patterns) 
combinations of cDNAs that cause differentiation of cells 
into different tissue types, this technology can be used to 
obtain arrays with distinct cell types in distinct locations. This 
capacity can be useful when trying to create tissue-like struc- 
tures on the array, such as blood capillaries andor stromal 
structures, or when studying the response of one cell type to 
the protein secretions of another cell type. For example, a 
secreting cell type can be created in the center of a bulls-eye 
pattern and responder cell types of different tissues can be 
created on the edge of bulls-eye. The response of the 
responder cells to the secretions of the center cell can then be 
examined (e.g., utilizing compositions and methods 
described herein). 
[0147] Arrays containing mixtures of plasmids at each 
transfection zone can be constructed by mixing plasmids 
before fixation to the substrate surface (e.g., printing, printing 
in serial, printing with masks, or printing withpatternedprint- 
heads) or before mixing a crosslinking agent to a composition 
comprising a crosslinkable biopolymer, cells and transfection 
molecules. For example, plasmids could be mixed in a con- 
tainer (e.g., before printing and printed as a homogenous 
mixture). 
[0148] A carrier andor biopolymer useful in the composi- 
tions and methods of the present invention can be, for 
example, gelatin or an equivalent thereof. In certain embodi- 
ments, the carrier is a hydrogel, such as polycarboxylic acid, 
cellulosic polymer, polyvinylpyrrolidone, maleic anhydride 
polymer, polyamide, polyvinyl alcohol, or polyethylene 
oxide. 
[0149] The present invention is not limited by the type of 
substrate surface to which transfection molecules are 
attached (e.g., for 2-D transfection arrays) or to which 3-D 
components (e.g., a crosslinkable biopolymer comprising 
transfection molecules and cells) are attached. 
[0150] Any suitable surface that can be used to affix mix- 
tures of the present invention to its surface can be used. For 
example, the surface can be glass, plastics (such as polytet- 
rafluoroethylene, polyvinylidenedifluoride, polystyrene, 
polycarbonate, polypropylene), silicon, metal, (such as gold), 
membranes (such as nitrocellulose, methylcellulose, PTFE or 
cellulose), paper, biomaterials (such as protein, gelatin, agar), 
tissues (suchas skin, endothelial tissue, bone, cartilage), min- 
erals (such as hydroxylapatite, graphite) andor a combina- 
tion of the same. Additional compounds may be added to the 
base material of the surface to provide functionality. For 
example, scintillants can be added to a polystyrene substrate 
to allow Scintillation Proximity Assays to be performed. The 
substrate may be a porous solid support or non-porous solid 
support. The surface can have concave or convex regions, 
patterns of hydrophobic or hydrophilic regions, diffraction 
gratings, channels or other features. The scale of these fea- 
tures can range from the meter to the nanometer scale. For 
example, the scale can be on the micron scale for microflu- 
idics channels or other MEMS features or on the nanometer 
scale for nanotubes or buckyballs. The surface can be planar, 
planar with raised or sunken features, spherical (e.g. optically 
encoded beads), fibers (e.g. fiber optic bundles), tubular (both 
interior or exterior), a 3-dimensional network (such as inter- 
linking rods, tubes, spheres) or other shapes. The surface can 
be part of an integrated system. For example, the surface can 
be the bottom of a microtitre dish, a culture dish, andor a 
culture chamber. Other components, such as lenses, gratings, 
and electrodes, can be integrated with the surface. In general, 
the material of the substrate and geometry of the array will be 
selected based on criteria that it be useful for automation of 
array formation, culturing andor detection of cellular pheno- 
type. 
[0151] In still other embodiments, the solid support is a 
microsphere (bead), especially a FACS sortable bead. In 
some embodiments, each bead is an individual transfection 
zoneispot (e.g., having a homogenous population of target 
seauences and distinct from most other beads in the mixture. 
and one or more tags that can be used to the identify any given 
bead and therefore the sequence it displays). The identity of 
any given sequence that can induce a FACS-detectable 
change in cells that adhere to the beads can be readily deter- 
mined from the tag(s) associate with the bead. For example, 
the tag can be an electrophoric tagging molecules that are 
used as a binary code (See, e.g., Ohlmeyer et al. (1 993) PNAS 
90:10922-10926). Exemplary tags are haloaromatic alkyl 
ethers that are detectable as their trimethylsilyl ethers at less 
than femtomolar levels by electron capture gas chromatogra- 
phy (ECGC). Variations in the length of the alkyl chain, as 
well as the nature and position of the aromatic halide sub- 
stituents, may also be utilized. In some embodiments, a 
sequence is attached to a photocleavable linker and the tag is 
attached through a catechol ether linker via carbene insertion 
into the bead matrix (See, e.g., Nestler et al. (1994) J. Org. 
Chem. 59:4723-4724). This orthogonal attachment strategy 
permits the FACS sorting of the cellhead entities and subse- 
quent decoding by ECGC after oxidative detachment of the 
tag sets from isolated beads. In other embodiments, the beads 
can be tagged with two or more fluorescently active mol- 
ecules, and the identity of the bead is defined by the ratio of 
the various fluorophores. 
[0152] In some embodiments, the transfection array can be 
disposed on the end of a fiber optic system, such as a fiber 
optic bundle. Each fiber optic bundle contains thousands to 
millions of individual fibers depending on the diameter of the 
bundle. Changes in the phenotype of cells applied to the 
transfection array can be detected spectrometrically by con- 
ductance or transmittance of light over the spatially defined 
optic bundle. An optical fiber is a clad plastic or glass tube 
wherein the cladding is of a lower index of refraction than the 
core of the tube. When a plurality of such tubes are combined, 
a fiber optic bundle is produced. The choice of materials for 
the fiber optic will depend at least in part on the wavelengths 
at which the spectrometric analysis of the transfected cells is 
to be accomplished. 
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[0153] In some embodiments, a substrate surface can be 
coated with. for examvle. a cationic moietv. The cationic 
. , 
moiety can be any positively charged species capable of elec- 
trostatically binding to negatively charged polynucleotides. 
Preferred cationic moieties for use in the carrier are polyca- 
tions, such as polylysine (e.g., poly-L-lysine), polyarginine, 
polyomithine, spermine, basic proteins such as histones (See, 
e.g., Chen et al. (1994) FEBS Letters 338:167-169), avidin, 
protamines (see e.g., Wagner et al. (1990) PNAS 87: 3410- 
3414), modified albumin (i.e., N-acylurea albumin) (See e.g., 
Huckett et al. (1990) Chemical Pharmacology 40: 253-263), 
and polyamidoamine cascade polymers (See e.g., Haensler et 
al. (1993) Bioconjugate Chem. 4:372-379). Apreferredpoly- 
cation is polylysine (e.g., ranging from 3,800 to 60,000 dal- 
tons). Alternatively, the surface itself can be positively 
charged (e.g., gamma amino propyl silane or other alkyl 
silanes). 
[0154] The substrate surface can also be coated with mol- 
ecules for additional functions. For example, molecules can 
be capture reagents such as antibodies, biotin, avidin, Ni- 
NTA to bind epitopes, avidin, biotinylted molecules, or 6-His 
tagged molecules. Alternatively, the molecules can be culture 
reagents such as extracellular matrix, fetal calf serum, col- 
lagen, etc. 
[0155] In some embodiments, once a microarrays of trans- 
fected cells have formed (e.g., cDNAs in transfection zones1 
spots have entered cells and the cells have expressed the 
encoded gene products), the microarrays can be transferred 
onto a variety of surfaces. Surfaces can be flexible or non- 
flexible and porous or non-porous. The surfaces can be flat or 
patterned with concave or convex regions, patterns of hydro- 
phobic or hydrophilic regions, diffraction gratings, channels 
or other features. The scale of these features can range from 
the meter to the nanometer scale. Examples of surfaces 
include, but are not limited to, glass, plastics (such as poly- 
tetrafluoroethylene, polyvinylidenedifluoride, polystyrene, 
polycarbonate, polypropylene), silicon, metal, (such as gold), 
membranes (such as nitrocellulose, methylcellulose, PTFE or 
cellulose, polyvinylidene fluoride (PVDF)), paper, biomate- 
rials (such as protein, gelatin, agar), tissues (such as skin, 
endothelial tissue, bone, cartilage), minerals (such as 
hydroxylapatite, graphite). Furthermore, many of these sur- 
faces can be derivatized to provide additional functionalities. 
For example, scintillants can be added to a polystyrene sub- 
strate to allow Scintillation Proximity Assays to be per- 
formed. In another example, nitrocellulose membranes can 
be covalently modified with metal chelators that immobilize 
metals, such as nickel or cobalt, and allow the selective bind- 
ing of proteins carrying a specific amino acid sequence, such 
as a hexa-histidine tag. 
[0156] In some embodiments, transfers are performed such 
that the entire cellular material on the microarray is trans- 
ferred (e.g., both the endogenous and recombinant materials 
made by the cells (e.g., RNA or protein) are transferred); or 
such that only the recombinant material is transferred. In 
some embodiments, the transfer of the microarray to another 
surface is accomplished by directly contacting themicroarray 
to the other surface and allowing the material to move to the 
new surface under the influence of a force, such as capillary 
forces (e.g., commonly referred to as "blotting"), electric or 
magnetic fields, vacuum suction forces, or other forces. The 
material may bind to thelnew surface through an interaction 
mediated by hydrophobic, hydrophillic, Van der Waals, ionic 
or other forces, or through specific receptor-ligand interac- 
tions (e.g. antibody-epitope interactions) or by becoming 
entangled in the molecular structure of the other surface. 
[0157] The ability to transfer cellular material from the 
microarrays to another surface has many potential uses. 
These include, but are not limited to, the capacity to detect 
cellular phenotypes or protein properties using techniques 
normally performed on specific surfaces and the capacity to in 
parallel purify the recombinant gene products expressed in 
the microarray. Examples of techniques normally performed 
on specific surfaces include western blotting, far-western 
blotting, southwestern blotting, surface plasmon resonance 
(SPR), mass spectroscopy, and others. These techniques nor- 
mally require the immobilization of native or denatured pro- 
teins on nitrocellulose, nylon, paper, polyvinylidene fluoride 
(PVDF), or gold or other metal surfaces or membranes. 
Southwestern blotting is used to detect the interaction of a 
nucleic acid (such as DNA or RNA) with a protein. After 
transfer to an appropriate membrane, microarrays of cells 
expressing a collection of DNA binding proteins, such as 
transcription factors, can be used to identify binding proteins 
for genomic DNA sequence elements. 
[0158] The transfer of microarrays to other surfaces is also 
useful for the in parallel purification of the recombinant pro- 
teins expressed on the microarray. The binding of proteins or 
small molecules with the microarray can be detected with 
autoradiography, fluorescence, mass spectroscopy, immunof- 
luorescence, or calorimetry. 
[0159] The present invention is not limited by the type of 
cells utilized in a transfection cell array of the present inven- 
tion. Indeed, a variety of cells may be utilized. 
[0160] Examples of host cells for generating arrays of the 
present invention include prokaryotes, yeast, or higher 
eukaryotic cells, including plant and animal cells, especially 
mammalian cells. Prokaryotes include gram negative or gram 
positive organisms. 
[0161] In some embodiments, compositions and methods 
of the present invention method utilize cells derived from 
higher eukaryotes (e.g., metazoans, mammalian cells, pri- 
mate cells andlor human cells). Other species of mammalian 
cells that may be utilized include canine, feline, bovine, por- 
cine, mouse and rat. For instance, such cells can be hemato- 
poietic cells, neuronal cells, pancreatic cells, hepatic cells, 
chondrocytes, osteocytes, or myocytes. The cells can be fully 
differentiated cells or progenitorlstem cells. The cells can be 
derived from normal or diseased tissue, from differentiated or 
undifferentiated cells, from embryonic or adult tissue. The 
cells maybe dispersed in culture, or can be tissues samples 
containing multiple cells that retain some of the microarchi- 
tecture of the organ. 
[0162] In some embodiments, a transfection array of the 
present invention is used to transfect a cell that can be co- 
cultured with a target cell. A biologically active protein 
secreted by the cells expressing nucleic acids (e.g., genes) 
from the transfection array can diffuse to neighboring target 
cells and induce a particular biological response (e.g., prolif- 
eration or differentiation, or activation of a signal transduc- 
tion pathway (e.g., that can be detected by phenotypic crite- 
ria)). Likewise, antagonists of a given factor can be selected 
by the ability of the cell producing a functional antagonist to 
protect neighboring cells from the effect of exogenous factor 
added to the culture media. The host and target cells can be in 
direct contact, or separated (e.g., by a cell culture insert). 
[0163] If yeast cells are used, the yeast may be of any 
species that are cultivable and in the transfection array can be 
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maintained upon transfection. Suitable species include 
Kluyverei lactis, Schizosaccharomyces pombe, and Ustilaqo 
maydis; Saccharomyces cerevisiae is preferred. Other yeast 
that can be used in practicing the present invention are Neu- 
rospora crassa, Aspergillus niger, Aspergillus nidulans, 
Pichiapastoris, Candida tropicalis, and Hansenulapolymor- 
pha. The term "yeast," as used herein, includes not only yeast 
in a strictly taxonomic sense (i.e., unicellular organisms), but 
also yeast-like multicellular fungi or filamentous fungi. 
[0164] The choice of appropriate host cell can be influ- 
enced by the choice of detection signal. For instance, reporter 
constructs can provide a selectable or screenable trait upon 
gain-of-function or loss-of-function induced by a target 
nucleic acid. The reporter gene may be an unmodified gene 
already in the host cell pathway, or it may be a heterologous 
gene (e.g., a "reporter gene construct" described herein). In 
other embodiments, second messenger generation can be 
measured directly in a detection step, such as mobilization of 
intracellular calcium or phospholipid metabolism, in which 
case the host cell should have an appropriate starting pheno- 
type for activation of such pathways. 
[0165] In some embodiments, host cells can be engineered 
to express other recombinant genes. For instance, the host 
cells can be engineered with a reporter gene construct, and the 
ability of members of the transfection array to alter the level 
of expression of the reporter gene can be characterized. For 
example, a transfection array can be assessed for members 
which encode transcriptional activators or transcriptional 
repressors of the reporter gene, and may include native and 
non-native sequences. For example, a host cell can be trans- 
fected with reporter gene construct including a promoter 
sequence for which a protein which binds that sequence is 
sought. 
[0166] In some embodiments, a host cell can be engineered 
so as to have a loss-of-function or gain-of-function pheno- 
type, and the ability of members of the transfection array to 
alter the phenotype assessed. 
[0167] In some embodiments, a host cell is engineered to 
express a recombinant cell surface receptor, and the transfec- 
tion array might encode a variegated library of gene products 
or peptides, and the ability of one or more members of that 
library to induce or inhibit signal transduction by the receptor 
is assessed. For example, the transfection array can provide a 
library of secreted peptides, and the ability of a given peptide 
to induce signal transduction is detected by the conversion of 
the cell to an autocrine phenotype. 
[0168] The present invention is not limited by the method 
of detecting cellular characteristics (e.g., nucleic acid andor 
protein expression, cellular signaling, division, etc.) in a 2-D 
andor 3-D transfection array described herein. 
[0169] A variety of methods can be used to detect the con- 
sequence of uptake, and in many embodiments, expression 
(e.g., transcription) of sequences within cells (e.g., present in 
a 2-D andor 3-D array of the present invention). In a general 
sense, assays described herein provide means for determining 
if the target sequence is able to confer a change in the pheno- 
type of the cell relative to the same cell but which lacks the 
target sequence. Such changes can be detected on a gross 
cellular level, such as by changes in cell morphology (e.g., 
membrane ruffling, rate of mitosis, rate of cell death, mecha- 
nism of cell death, dye uptake, and the like). In other embodi- 
ments, changes to the cell's phenotype, if any, can be detected 
by more focused means, such as the detection of the level of 
a particular protein (e.g., a selectable or detectable marker), or 
level of mRNA or second messenger). Changes in the cell's 
phenotype can be determined by assaying reporter genes 
(beta-galactosidase, green fluorescent protein, beta-lacta- 
mase, luciferase, chloramphenicol acetyl transferase), assay- 
ing enzymes, using immunoassays, staining with dyes (e.g. 
DAPI, calcofluor), assaying electrical changes, characteriz- 
ing changes in cell shape, examining changes in protein con- 
formation, counting cell number, etc. Other changes of inter- 
est could be detected by methods such as chemical assays, 
light microscopy, scanning electron microscopy, transmis- 
sion electron microscopy, atomic force microscopy, confocal 
microscopy, image reconstruction microscopy, scanners, 
autoradiography, light scattering, light absorbance, NMR, 
PET, patch clamping, calorimetry, mass spectrometry, sur- 
face plasmon resonance, andor time resolved fluorescence. 
Data could be collected at single or multiple time points and 
analyzed by the appropriate software (See, e.g., U.S. Patent 
Application Publication No. 20030228601, hereby incorpo- 
rated by reference in its entirety)). 
[0170] In some embodiments, transcriptional activity 
within a cell is detected andor measured by a transcription 
product (e.g., by detecting transcriptional activation (or 
repression) of an indicator gene(s)). Detection of the tran- 
scription product includes detecting the gene transcript, 
detecting the product directly (e.g., by immunoassay) or 
detecting an activity of the protein (e.g., such as an enzymatic 
activity or chromogenic1fluorogenic activity). The indicator 
gene may be an unmodified endogenous gene of the host cell, 
a modified endogenous gene, or a part of a completely heter- 
ologous construct (e.g., part of a reporter gene construct). 
[0171] In some embodiments, the indicator gene is an 
unmodified endogenous gene. For example, compositions 
and methods of the present invention may detect the tran- 
scriptional level of one or more endogenous genes. 
[0172] In some embodiments, a heterologous reporter gene 
construct can be used to provide the function of an indicator 
gene. Reporter gene constructs are prepared by operatively 
linking a reporter gene with at least one transcriptional regu- 
latory element (See, e.g., Example 1) 
[0173] The present invention is not limited by any particu- 
lar reporter gene construct. Many reporter genes and tran- 
scriptional regulatory elements are known to those of skill in 
the art and others may be identified or synthesized by methods 
known to those of skill in the art. Examples of reporter genes 
include, but are not limited to CAT (chloramphenicol acetyl 
transferase) (See, e.g., Alton andvapnek (1 979), Nature 282: 
864-869) luciferase, and other enzyme detection systems, 
such as beta-galactosidase; firefly luciferase (See, e.g., deWet 
et al. (1987), Mol. Cell. Biol. 7:725-737); bacterial luciferase 
(See, e.g., Engebrecht and Silverman (1984), PNAS 1:4154- 
4158; Baldwin et al. (1984), Biochemistry 23:3-663-3667); 
alkaline phosphatase (See, e.g., Toh et al. (1989) Eur. J. Bio- 
chem. 182:231-238, Hall et al. (1983) J. Mol. Appl. Gen. 
2: 101), human placental secreted alkaline phosphatase (See, 
e.g., Cullen and Malim (1992) Methods in Enzymol. 216: 
362-368); beta-lactamase, and GST. 
[0174] Transcriptional control elements for use in the 
reporter gene constructs, or for modifying the genomic locus 
of an indicator gene include, but are not limited to, promoters, 
enhancers, and repressor and activator binding sites. Suitable 
transcriptional regulatory elements may be derived from the 
transcriptional regulatory regions of genes whose expression 
is linked to the desired phenotype sought from the arrayed 
library. 
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[0175] In some embodiments, the reporter gene is a gene 
whose expression causes a phenotypic change which is 
screenable or selectable. If the change is selectable, the phe- 
notypic change creates a difference in the growth or survival 
rate between cells which express the reporter gene and those 
which do not. If the change is screenable, fhe phenotype 
change creates a difference in some detectable characteristic 
u 
of the cells, by which the cells which express the marker may 
be distinguished from those which do not. Selection is pref- 
erable to screening in that it can provide a means for ampli- 
fying from the cell culture those cells which express a test 
polypeptide which is a receptor effector. 
[0176] Many different types of information are contem- 
plated to be generated using the compositions and methods of 
the present invention. For example, binding partners for mol- 
ecules such as drugs, hormones, interleukins, or secreted 
proteins can be identified by incubating the compounds of 
interest (test agents) with an array that overexpresses poten- 
tial targets within each array feature or combinations of 
potential targets within each cell of an array feature. Binding 
can be detected by methods such as SPR, SPA, TRF, or 
autoradiography. 
[0177] An array can also be used to identify targets of an 
organism's immune response to cancer, an infectious or 
autoimmune disease, exposure to chemicals, or environmen- 
tal changes. In some embodiments, the present invention 
facilitates drug target discovery by permitting the identifica- 
tion of an endogenous gene wherein inhibition or activation 
of the gene may be of therapeutic value. In some embodi- 
ments, loss of function of genes can be characterized. For 
example, transcription arrays that give rise to dsRNA in the 
host cell can be used to assess the loss-of-function of a par- 
ticular gene (e.g., via RNAi or gene silencing (See, e.g., Fire 
A (1999) Trends Genet. 15:358-363; Sharp PA (1999) Genes 
Dev 13:139-141; Hunter C. (1999) Curr. Biol. 9:R440-R442; 
Baulcombe D.C. (1 999) Curr. Biol. 9:R599-R601; Vaucheret 
et al. (1998) Plant J. 16:651-659)). In some embodiments, an 
array of the present invention is utilized to characterize a gene 
of interest. 
[0178] In some embodiments, an array of the present inven- 
tion is utilized to characterize candidate agents (e.g., for 
therapeutics (e.g., proteins, small molecules, oligonucle- 
otides, etc.). In some embodiments, arrays are used to char- 
acterize compound libraries andor potential drug candidates. 
[0179] The ability of certain viruses to infect cells or enter 
cells via receptor-mediated endocytosis, and to integrate into 
host cell genome and express viral genes stably and effi- 
ciently have made them attractive candidates for the transfer 
of nucleic acid sequences (e.g., transfection molecules) into 
mammalian cells. In some embodiments, vectors of the 
present invention are viral vectors (e.g., phage or andenovirus 
vectors). 
[0180] Although some viruses that can accept foreign 
genetic material are limited in the number of nucleotides they 
can accommodate and in the range of cells they infect, these 
viruses have been demonstrated to successfully effect gene 
expression. However, adenoviruses do not integrate their 
genetic material into the host genome and therefore do not 
require host replication for gene expression, making them 
ideally suited for rapid, efficient, heterologous gene expres- 
sion. Techniques for preparing replication-defective infective 
viruses are well known in the art. 
[0181] Of course, in using viral delivery systems, one will 
desire to purify the virion sufficiently to render it essentially 
free of undesirable contaminants, such as defective interfer- 
ing viral particles or endotoxins and other pyrogens such that 
it will not cause any untoward reactions in the cell, animal or 
individual receiving the vector construct. A preferred means 
of purifying the vector involves the use of buoyant density 
gradients, such as cesium chloride gradient centrifugation. 
[0182] A particular method for delivery of the expression 
constructs involves the use of an adenovirus expression vec- 
tor. Although adenovirus vectors are known to have a low 
capacity for integration into genomic DNA, this feature is 
counterbalanced by the high efficiency of gene transfer 
afforded by these vectors. "Adenovirus expression vector" is 
meant to include those constructs containing adenovirus 
sequences sufficient to (a) support packaging of the construct 
and (b) to ultimately express a tissue or cell-specific construct 
that has been cloned therein. 
[0183] The expressionvector comprises a genetically engi- 
neered form of adenovirus. Knowledge of the genetic orga- 
nization or adenovirus, a 36 kb, linear, double-stranded DNA 
virus, allows substitution of large pieces of adenoviral DNA 
with foreign sequences up to 7 kb (See Grunhaus and Hor- 
witz. 1992). In contrast to retrovirus. the adenoviral infection 
of host cells does not result in chromosomal integration 
because adenoviral DNA can replicate in an episomal manner 
without potential genotoxicity. Also, adenoviruses are struc- 
turally stable, and no genome rearrangement has been 
detected after extensive amplification. 
[0184] Adenovirus is particularly suitable for use as a gene 
transfer vector because of its mid-sized genome, ease of 
manipulation, high titer, wide target-cell range and high 
infectivity. Both ends of the viral genome contain 100-200 
base pair inverted repeats (ITRs), which are cis elements 
necessary for viral DNA replication and packaging. The early 
(E) and late (L) regions of the genome contain different 
transcription units that are divided by the onset of viral DNA 
replication. The El  region (ElA and ElB) encodes proteins 
responsible for the regulation of transcription of the viral 
genome and a few cellular genes. The expression of the E2 
region (E2A and E2B) results in the synthesis of the proteins 
for viral DNA replication. These proteins are involved in 
DNA replication, late gene expression and host cell shut-off 
(Renan, 1990). The products of the late genes, including the 
majority of the viral capsid proteins, are expressed only after 
significant processing of a single primary transcript issued by 
the maior late vromoter (MLP). The MLP (located at 16.8 
, , 
map units (m.~.))  is particularly efficient during the late phase 
of infection, and all the mRNA's issued from this promoter 
possess a 5'-tripartite leader (TPL) sequence which makes 
them preferred mRNA's for translation. 
[0185] In a current system, recombinant adenovirus is gen- 
erated from homologous recombination between shuttle vec- 
u 
tor and provirus vector. Due to the possible recombination 
between two proviral vectors, wild-type adenovirus may be 
generated from this process. Therefore, it is critical to isolate 
a single clone of virus from an individual plaque and examine 
its genomic structure. 
[0186] Generation and propagation of the current adenovi- 
rus vectors, which are replication deficient, depend on a 
unique helper cell line, designated 293, which was trans- 
formed from human embryonic kidney cells by Ad5 DNA 
fragments and constitutively expresses El  proteins (EIA and 
EIB; Graham et al., 1977). Since the E3 region is dispensable 
from the adenovirus genome (Jones and Shenk, 1978), the 
current adenovirus vectors, with the help of 293 cells, cany 
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foreign DNA in either the El ,  the D3 or both regions (Graham [0192] Adenovirus growth and manipulation is known to 
and Prevec, 1991). Recently, adenoviral vectors comprising those of skill in the art, and exhibits broad host range in vitro 
deletions in the E4 region have been described (U.S. Pat. No. and in vivo. This goup of viruses can be obtained in high 
- 
5,670,488, incorporated herein by reference). 
[0187] In nature, adenovirus can package approximately 
105% of the wild-type genome (Ghosh-Choudhury et al., 
1987), providing capacity for about 2 extra kb of DNA. Com- 
bined with the approximately 5.5 kb of DNA that is replace- 
able in the El  and E3 regions, the maximum capacity of the 
current adenovirus vector is under 7.5 kb, or about 15% of the 
total length of the vector. More than 80% of the adenovirus 
viral genome remains in the vector backbone. 
[0188] Helper cell lines may be derived from human cells 
such as human embryonic kidney cells, muscle cells, hemato- 
poietic cells or other human embryonic mesenchymal or epi- 
thelial cells. Alternatively, the helper cells may be derived 
from the cells of other mammalian species that are permissive 
for human adenovirus. Such cells include, e.g., Vero cells or 
other monkey embryonic mesenchymal or epithelial cells. As 
stated above, the preferred helper cell line is 293. 
[0189] Racher et al. (1 995) disclosedimprovedmethods for 
culturing 293 cells and propagating adenovirus. In one for- 
mat, natural cell aggregates are grown by inoculating indi- 
vidual cells into 1 liter siliconized spinner flasks (Techne, 
Cambridge, UK) containing 100-200 ml of medium. Follow- 
ing stirring at 40 rpm, the cell viability is estimated with 
trypan blue. In another format, Fibra-Cel microcarriers 
(Bibby Sterlin, Stone, UK) (5 gll) is employed as follows. A 
cell inoculum, resuspended in 5 ml of medium, is added to the 
carrier (50 ml) in a 250 ml Erlenmeyer flask and left station- 
ary, withoccasional agitation, for 1 to 4 h. Themedium is then 
replaced with 50 ml of fresh medium and shaking initiated. 
For virus production, cells are allowed to grow to about 80% 
confluence, after which time the medium is replaced (to 25% 
of the final volume) and adenovirus added at an MOI of 0.05. 
Cultures are left stationary overnight, following which the 
volume is increased to 100% and shaking commenced for 
another 72 h. 
[0190] Other than the requirement that the adenovirus vec- 
tor be replication defective, or at least conditionally defective, 
the nature of the adenovirus vector is not believed to be 
crucial to the successful practice of the invention. The aden- 
ovirus may be of any of the 42 different known serotypes or 
subgroups A-F. Adenovirus type 5 of subgroup C is the pre- 
ferred starting material in order to obtain the conditional 
replication-defective adenovirus vector for use in the present 
invention. This is because Adenovirus type 5 is a human 
adenovirus about which a great deal of biochemical and 
genetic information is known, and it has historically been 
used for most constructions employing adenovirus as a vec- 
tor. 
[0191] As stated above, the typical adenovirus vector 
according to the present invention is replication defective and 
will not have an adenovirus El  region. Thus, it will be most 
convenient to introduce the transforming construct at the 
position from which the El-coding sequences have been 
removed. However, the position of insertion of the construct 
within the adenovirus sequences is not critical to the inven- 
tion. The polynucleotide encoding the gene of interest may 
also be inserted in lieu of the deleted E3 region in E3 replace- 
ment vectors as described by Karlsson et al. (1986) or in the 
E4 region where a helper cell line or helper virus comple- 
ments the E4 defect. 
titers, e.g., 10.sup.9to 10.sup.l 1 plaque-formingunits 
and they are highly infective. The life cycle of adenovirus 
does not require integration into the host cell genome. The 
foreign genes delivered by adenovirus vectors are episomal 
and, therefore, have low genotoxicity to host cells. 
[0193] Adenovirus vectors have been used in eukaryotic 
gene expression (Levrero et al., 1991; Gomez-Foix et al., 
1992) and vaccine development (Grunhaus and Honvitz, 
1992; Graham and Prevec, 1992). Recombinant adenovirus 
and adeno-associated virus (see below) can both infect and 
transduce non-dividing human primary cells 
[0194] Adeno-associated virus (AAV) is an attractive vec- 
tor system for use in the cell transduction of the present 
invention as it has a high frequency of integration and it can 
infect nondividing cells, thus making it useful for delivery of 
genes into mammalian cells, for example, in tissue culture 
(Muzyczka, 1992) or in vivo. AAV has a broad host range for 
infectivity (Tratschin et al., 1984; Laughlin et al., 1986; Leb- 
kowski et al., 1988; McLaughlin et al., 1988). Details con- 
cerning the generation and use of rAAV vectors are described 
inU.S. Pat. No. 5,139,941 andU.S. Pat.No. 4,797,368, each 
incorporated herein by reference. 
[0195] Studies demonstrating the use ofAAV in gene deliv- 
ery include LaFace et al. (1988); Zhou et al. (1993); Flotte et 
al. (1993); and Walshet al. (1 994). Recombinant AAVvectors 
have been used successfully for in vitro and in vivo transduc- 
tion of marker genes (Kaplitt et al., 1994; Lebkowski et al., 
1988; Samulski et al., 1989; Yoder et al., 1994; Zhou et al., 
1994; Hermonat and Muzyczka, 1984; Tratschin et al., 1985; 
McLaughlin et al., 1988) and genes involved in human dis- 
eases (Flotte et al., 1992; Luo et al., 1994; Ohi et al., 1990; 
Walsh et al., 1994; Wei et al., 1994). Recently, anAAVvector 
has been approved for phase I human trials for the treatment 
of cystic fibrosis. 
[0196] AAV is a dependent parvovirus in that it requires 
coinfection with another virus (either adenovirus or a mem- 
ber of the herpes virus family) to undergo a productive infec- 
tion in cultured cells (Muzvczka. 1992). In the absence of 
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coinfection with helper virus, the wild type AAV genome 
integrates through its ends into human chromosome 19 where 
it resides in a latent state as a provirus (Kotin et al., 1990; 
Samulski et al., 1991). rAAV, however, is not restricted to 
chromosome 19 for integration unless the AAV Rep protein is 
also expressed (Shelling and Smith, 1994). When a cell car- 
rying an AAV provirus is superinfected with a helper virus, 
the AAV genome is "rescued" from the chromosome or from 
a recombinant plasmid, and a normal productive infection is 
established (Samulski et al., 1989; McLaughlin et al., 1988; 
Kotin et al., 1990; Muzyczka, 1992). 
[0197] Typically, recombinant AAV (rAAV) virus is made 
by cotransfecting a plasmid containing the gene of interest 
flanked by the two AAV terminal repeats (McLaughlin et al., 
1988; Samulski et al., 1989; each incorporated herein by 
reference) and an expression plasmid containing the wild 
type AAV coding sequences without the terminal repeats, for 
examplepIM45 (McCarty et al., 1991; incorporatedherein by 
reference). The cells are also infected or transfected with 
adenovirus or plasmids carrying the adenovirus genes 
required for AAV helper function. rAAV virus stocks made in 
such fashion are contaminated with adenovirus which must 
be physically separated from the rAAV particles (for 
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example, by cesium chloride density centrifugatiorl). Alter- 
natively, adenovirus vectors containing the AA\' coding 
regions or cell lines containing the AAV coding regions and 
some or all of the adenovirus helper genes could be used 
(Yang et al., 1994; Clark et al., 1995). Cell lines canying the 
rAAV DNA as an integrated provirus can also be used (Flotte 
et al., 1995). 
[0198] Retroviruses have promise as gene delivery vectors 
due to their ability to integrate their genes into the host 
genome, transferring a large amount of foreign genetic mate- 
rial, infecting a broad spectrum of species and cell types and 
of being packaged in special cell-lines (Miller, 1993). 
[0199] The retroviruses are a group of single-stranded RNA 
viruses characterized by an ability to convert their RNA to 
double-stranded DNA in infected cells by a process of 
reverse-transcription (Coffin, 1990). The resulting DNA then 
stably integrates into cellular chromosomes as a provirus and 
directs synthesis of viral proteins. The integration results in 
the retention of the viral gene sequences in the recipient cell 
and its descendants. The retroviral genome contains three 
genes, gag, pol, and env that code for capsid proteins, poly- 
merase enzyme, and envelope components, respectively. A 
sequence found upstream from the gag gene contains a signal 
for packaging of the genome into virions. Two long terminal 
repeat (LTR) sequences are present at the 5' and 3' ends of the 
viral genome. These contain strong promoter and enhancer 
sequences and are also required for integration in the host cell 
genome (Coffin, 1990). 
[0200] In order to construct a retroviral vector, a nucleic 
acid encoding a gene of interest is inserted into the viral 
genome in the place of certain viral sequences to produce a 
virus that is replication-defective. In order to produce virions, 
a packaging cell line containing the gag, pol, and env genes 
but without the LTR and packaging components is con- 
structed (Mann et al., 1983). When a recombinant plasmid 
containing a cDNA, together with the retroviral LTR and 
packaging sequences is introduced into this cell line (by cal- 
cium phosphate precipitation for example), the packaging 
sequence allows the RNA transcript of the recombinant plas- 
mid to be packaged into viral particles, which are then 
secreted into the culture media (Nicolas and Rubenstein, 
1988; Temin, 1986; Mannet al., 1983). Themedia containing 
the recombinant retroviruses is then collected, optionally 
concentrated, and used for gene transfer. Retroviral vectors 
are able to infect a broad variety of cell types. However, 
integration and stable expression require the division of host 
cells (Paskind et al., 1975). 
[0201] Concern with the use of defective retrovirus vectors 
is the potential appearance of wild-type replication-compe- 
tent virus in the packaging cells. This can result from recom- 
bination events in which the intact sequence from the recom- 
binant virus inserts upstream from the gag, pol, env sequence 
integrated in the host cell genome. However, new packaging 
cell lines are now available that should greatly decrease the 
likelihood of recombination (Markowitz et al., 1988; Hers- 
dorffer et al., 1990). 
[0202] Gene delivery using second generation retroviral 
vectors has been reported. Kasahara et al. (1994) prepared an 
engineered variant of the Moloney murine leukemia virus, 
that normally infects only mouse cells, and modified an enve- 
lope protein so that the virus specifically bound to, and 
infected, human cells bearing the erythropoietin (EPO) 
receptor. This was achieved by inserting a portion of the EPO 
sequence into an envelope protein to create a chimeric protein 
with a new binding specificity. 
[0203] Other viral vectors may be employed as expression 
constructs in the present invention. Vectors derived from 
viruses such as vaccinia virus (Ridgeway, 1988; Baichwal 
and Sugden, 1986; Coupar et al., 1988), sindbis virus, 
cytomegalovirus and herpes simplex virus may be employed. 
They offer several attractive features for various mammalian 
cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sug- 
den, 1986; Coupar et al., 1988; Honvich et al., 1990). 
[0204] With the recent recognition of defective hepatitis B 
viruses, new insight was gained into the structure-function 
relationship of different viral sequences. In vitro studies 
showed that the virus could retain the ability for helper- 
dependent packaging and reverse transcription despite the 
deletion of up to 80% of its genome (Honvich et al., 1990). 
This suggested that large portions of the genome could be 
replaced with foreign genetic material. Chang et al. recently 
introduced the chloramphenicol acetyltransferase (CAT) 
gene into duck hepatitis B virus genome in the place of the 
polymerase, surface, and pre-surface coding sequences. It 
was cotransfected with wild-type virus into an avian 
hepatoma cell line. Culture media containing high titers of the 
recombinant virus were used to infect primary duckling hepa- 
tocytes. Stable CAT gene expression was detected for at least 
24 days after transfection (Chang et al., 1991). 
[0205] In certain further embodiments, the vector will be 
HSV. A factor that makes HSV an attractive vector is the size 
and organization of the genome. Because HSV is large, incor- 
poration of multiple genes or expression cassettes is less 
problematic than in other smaller viral systems. In addition, 
the availability of different viral control sequences with vary- 
ing performance (temporal, strength, etc.) makes it possible 
to control expression to a greater extent than in other systems. 
It also is an advantage that the virus has relatively few spliced 
messages, further easing genetic manipulations. HSV also is 
relatively easy to manipulate and can be grown to high titers. 
Thus, delivery is less of a problem, both in terms of volumes 
needed to attain sufficient MOI and in a lessened need for 
repeat dosings. 
[0206] In still further embodiments of the present inven- 
tion, the nucleic acids to be delivered are housed within an 
infective virus that has been engineered to express a specific 
binding ligand. The virus particle will thus bind specifically 
to the cognate receptors of the target cell and deliver the 
contents to the cell. A novel approach designed to allow 
specific targeting of retrovirus vectors was recently devel- 
oped based on the chemical modification of a retrovirus by the 
chemical addition of lactose residues to the viral envelope. 
This modification can permit the specific infection of hepa- 
tocytes via sialoglycoprotein receptors. 
[0207] Another approach to targeting of recombinant ret- 
roviruses was designed in which biotinylated antibodies 
against a retroviral envelope protein and against a specific cell 
receptor were used. The antibodies were coupled via the 
biotin components by using streptavidin (Roux et al., 1989). 
Using antibodies against major histocompatibility complex 
class I and class I1 antigens, they demonstrated the infection 
of a variety of human cells that bore those surface antigens 
with an ecotropic virus in vitro (Roux et al., 1989). 
[0208] In various embodiments of the invention, nucleic 
acid sequence encoding a fusion protein is delivered to a cell 
as an expression construct. In order to effect expression of a 
gene construct, the expression construct must be delivered 
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into a cell. As described herein, one mechanism for delivery is 
via viral infection, where the expression construct is encapsi- 
dated in an infectious viral particle. However, several non- 
viral methods for the transfer of expression constructs into 
cells also are contemplated by the present invention. In one 
embodiment of the present invention, the expression con- 
struct may consist only of naked recombinant DNA or plas- 
mids (e.g., vectors comprising nucleic acid sequences of the 
present invention). Transfer of the construct may be per- 
formed by any of the methods mentioned which physically or 
chemically permeabilize the cell membrane. Some of these 
techniques may be successfully adapted for invivo or ex vivo 
use, as discussed below. 
[0209] In a further embodiment of the invention, the 
expression construct may be entrapped in a liposome. Lipo- 
somes are vesicular structures characterized by a phospho- 
lipid bilayer membrane and an inner aqueous medium. Mul- 
tilamellar liposomes have multiple lipid layers separated by 
aqueous medium. They form spontaneously when phospho- 
lipids are suspended in an excess of aqueous solution. The 
lipid components undergo self-rearrangement before the for- 
mation of closed structures and entrap water and dissolved 
solutes between the lipid bilayers (Ghosh and Bachhawat, 
1991). Also contemplated is an expression construct com- 
plexed with Lipofectamine (Gibco BRL). 
[0210] Liposome-mediated nucleic acid delivery and 
expression of foreign DNA in vitro has been very successful 
(Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et al., 
1987). Wong et al. (1980) demonstrated the feasibility of 
liposome-mediated delivery and expression of foreign DNA 
in cultured chick embryo, HeLa and hepatoma cells. 
[0211] In certain embodiments of the invention, the lipo- 
some may be complexed with a hemagglutinating virus 
(HVJ). This has been shown to facilitate fusion with the cell 
membrane and promote cell entry of liposome-encapsulated 
DNA (Kaneda et al., 1989). In other embodiments, the lipo- 
some may be complexed or employed in conjunction with 
nuclear non-histone chromosomal proteins (HMG-1) (Kato 
et al., 1991). In yet further embodiments, the liposomemay be 
complexed or employed in conjunction with both HVJ and 
HMG-1. In other embodiments, the delivery vehicle may 
comprise a ligand and a liposome. Where a bacterial promoter 
is employed in the DNA construct, it also will be desirable to 
include within the liposome an appropriate bacterial poly- 
merase. 
[0212] Certain receptor-mediated gene targeting vehicles 
comprise a cell receptor-specific ligand and a DNA-binding 
agent. Others comprise a cell receptor-specific ligand to 
which the DNA construct to be delivered has been operatively 
attached. Several ligands have been used for receptor-medi- 
ated gene transfer (Wu and Wu, 1987; Wagner et al., 1990; 
Perales et al., 1994; Myers, EPO 0273085), which establishes 
the operability of the technique. In certain aspects of the 
present invention, the ligand will be chosen to correspond to 
a receptor specifically expressed on the EOE target cell popu- 
lation. 
[0213] In other embodiments, the DNA delivery vehicle 
component of a cell-specific gene targeting vehicle may com- 
prise a specific binding ligand in combination with a lipo- 
some. The nucleic acids to be delivered are housed within the 
liposome and the specific binding ligand is functionally 
incorporated into the liposome membrane. The liposome will 
thus specifically bind to the receptors of the target cell and 
deliver the contents to the cell. Such systems have been shown 
to be functional using systems in which, for example, epider- 
mal growth factor (EGF) is used in the receptor-mediated 
delivery of a nucleic acid to cells that exhibit upregulation of 
the EGF receptor. 
[0214] In still further embodiments, the DNA delivery 
vehicle component of the targeted delivery vehicles may be a 
liposome itself, which will preferably comprise one or more 
lipids or glycoproteins that direct cell-specific binding. For 
example, Nicolau et al. (1987) employedlactosyl-ceramide, a 
galactose-terminal asialganglioside, incorporated into lipo- 
somes and observed an increase in the uptake of the insulin 
gene by hepatocytes. It is contemplated that the tissue-spe- 
cific transforming constructs of the present invention can be 
specifically delivered into the target cells in a similar manner. 
[0215] Homologous recombination (Koller and Smithies, 
1992) allows the precise modification of existing genes, over- 
comes the vroblems of vositional effects and insertional inac- 
tivation, and allows the inactivation of specific genes, as well 
as the replacement of one gene for another. Methods for 
homologous recombination are described in U.S. Pat. No. 
5,6 14,396, incorporated herein in its entirety by reference. 
Thus. in some embodiments. host cells utilized in an arrav of 
the present invention are generated via homologous recom- 
bination. Homologous recombination relies, like antisense, 
on the tendency of nucleic acids to base pair with comple- 
mentary sequences. In this instance, the base pairing serves to 
facilitate the interaction of two separate nucleic acid mol- 
ecules so that strand breakage and repair can take place. In 
other words, the "homologous" aspect of the method relies on 
sequence homology to bring two complementary sequences 
into close proximity, while the "recombination" aspect pro- 
vides for one complementary sequence to replace the other by 
virtue of the breaking of certain bonds and the formation of 
others. 
[0216] In some embodiments, a candidate agent can be 
added to one or more transfection zones (e.g., to alter expres- 
sion andor activity). As used herein, a "candidate agent" may 
be any agent that potentially inhibits or enhances transcrip- 
tion, translation or the like within a cell, including, but not 
limited to, a drug, a pharmaceutical, a small molecule, and an 
compound. For example, the candidate agent may be a protein 
or fragment thereof, a small molecule, a chemical, or even a 
nucleic acid molecule. Using lead compounds to help develop 
improved compounds is know as "rational drug design" and 
includes not onlv comvarisons with know inhibitors and 
enhancers of protein folding/solubility, but predictions relat- 
ing to the structure of target molecules. Thus, using compo- 
sitions and methods of the present invention, it is possible to 
identify candidate agents that have the ability to alter cellular 
activities (e.g., growth, transcription, cellular signaling, etc.). 
[0217] The goal of rational drug design is to produce struc- 
tural analogs of biologically active polypeptides or target 
compounds. By creating such analogs, it is possible to fashion 
drugs, which are more active or stable than the natural mol- 
ecules, which have different susceptibility to alteration or 
which may affect the function of various other molecules. In 
one approach, it is possible to generate a three-dimensional 
structure for a target molecule, or a fragment thereof. This 
could be accomplished by x-ray crystallography, computer 
modeling or by a combination of both approaches. 
[0218] It also is possible to use antibodies to ascertain the 
structure of a candidate enhancer or inhibitor. In principle, 
this approach yields a pharmacore upon which subsequent 
drug design can be based. It is possible to bypass protein 
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crystallography altogether by generating anti-idiotypic anti- 
bodies to a functional, pharmacologically active antibody. As 
a mirror image of a mirror image, the binding site of anti- 
idiotype would be expected to be an analog of the original 
antigen. The anti-idiotype could then be used to identify and 
isolate peptides from banks of chemically- or biologically- 
produced peptides. Selected peptides would then serve as the 
pharmacore. Anti-idiotypes may be generated using the 
methods described herein for producing antibodies, using an 
antibody as the antigen. 
[0219] On the other hand, one may simply acquire, from 
various commercial sources, small molecule libraries that are 
believed to meet the basic criteria for useful drugs in an effort 
to "brute force" the identification of useful candidate agents. 
Screening of such libraries, including combinatorially gener- 
ated libraries (e.g., peptide libraries), is a rapid and efficient 
way to screen large number of related (and unrelated) agents 
for activity. Combinatorial approaches also lend themselves 
to rapid evolution of potential drugs by the creation of second, 
third and fourth generation compounds modeled of active, but 
otherwise undesirable compounds. 
[0220] Candidate agents may include fragments or parts of 
naturally-occurring compounds, or may be found as active 
combinations of known compounds, which are otherwise 
inactive. It is proposed that compounds isolated from natural 
sources, such as animals, bacteria, fungi, plant sources, 
including leaves and bark, and marine samples may be 
assayed as candidates for the presence of potentially useful 
pharmaceutical agents. It will be understood that the agents 
(e.g., pharmaceuticals) to be screenedcouldalso be derivedor 
synthesized from chemical compositions or man-made com- 
pounds. Thus, it is understood that the candidate agent iden- 
tified by the present invention may be any peptide, polypep- 
tide, polynucleotide, small molecule inhibitors or any other 
chemicals or compounds (e.g., that may be designed through 
rational drug design starting from known inhibitors or 
enhancers). 
[0221] Other potential agents include antisense molecules, 
ribozymes, and antibodies (including single chain antibod- 
ies), each of which would be specific for the target molecule. 
Such compounds are described in greater detail elsewhere in 
this document. For example, an antisense molecule that 
bound to a translational or transcriptional start site, or splice 
junctions, would be ideal candidate inhibitors. 
[0222] In addition to the modulating agents (e.g., com- 
pounds) initially identified, other sterically similar com- 
pounds may be formulated to mimic the key portions of the 
structure of the modulators. Such agents (e.g., compounds), 
which may include peptidomimetics of peptide modulators, 
may be used in the same manner as the initial modulators. 
[0223] The invention also provides a method for screening 
for mutations in a host cell, or in a target protein sequence 
(e.g., that alters transcription in a cell). For example, cells 
comprising a transcription molecule of the present invention 
can be treated with a mutagen. and those host cells that 
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display an increase in growth (e.g., rate or abundance) iden- 
tified. A "mutagen" is intended to include, but not be limited 
to chemical mutagens such as ethyl methane sulphonate, 
N-methyl-N'-nitroso-guanidine and nitrous acid as well as 
physical agents such as ionizing radiation. 
[0224] In an alternative embodiment, mutations can be 
introduced into a polynucleotide sequence encoding a target 
protein. The altered polynucleotide is then tested to determine 
whether the solubility of the target protein is changed (e.g., as 
monitored by growth in a selective environment, e.g., in the 
presence of ampicillin). Such mutations include, but are not 
limited to, mutations induced by a mutagen; site directed 
mutations that alter specific amino acid residues such as 
mutation of cysteine residues to eliminate disulfide bonds; 
deletions that remove sets of specific amino acids such as 
deletion of a continuous stretch of hydrophobic amino acids; 
and fusions of the target protein to a second, particularly 
soluble protein. In each case, the solubility of the target pro- 
tein is assessed by determining growth of the host cells in a 
selective environment. 
[0225] Where employed, mutagenesis can be accom- 
plished by a variety of standard, mutagenic procedures. Muta- 
tion can involve modification of the nucleotide sequence of a 
single gene, blocks of genes or whole chromosome. Changes 
in single genes may be the consequence of point mutations 
which involve the removal, addition or substitution of a single 
nucleotide base within a DNA sequence, or they may be the 
consequence of changes involving the insertion or deletion of 
large numbers of nucleotides. 
[0226] Mutations can arise spontaneously as a result of 
events such as errors in the fidelity of DNA replication or the 
movement of transposable genetic elements (transposons) 
within the genome. They also are induced following exposure 
to chemical or physical mutagens. Such mutation-inducing 
agents include ionizing radiations, ultraviolet light and a 
diverse array of chemical such as alkylating agents and poly- 
cyclic aromatic hydrocarbons all of which are capable of 
interacting either directly or indirectly (generally following 
some metabolic biotransformations) with nucleic acids. The 
DNA lesions induced by such environmental agents may lead 
to modifications of base sequence when the affected DNA is 
replicated or repaired and thus to a mutation. Mutation also 
can be site-directed through the use of particular targeting 
methods. 
Random Mutagenesis. 
[0227] i) Insertional Mutagenesis 
[0228] Insertional mutagenesis is based on the inactivation 
of a gene via insertion of a known DNA fragment. Because it 
involves the insertion of some type of nucleic acid (e.g., 
DNA) fragment, the mutations generated are generally loss- 
of-function, rather than gain-of-function mutations. How- 
ever, there are several examples of insertions generating gain- 
of-function mutations. Insertion mutagenesis has been very 
successful in bacteria and Drosophila. 
[0229] Transposable genetic elements are DNA sequences 
that can move (transpose) from one place to another in the 
genome of a cell. The first transposable elements to be rec- 
ognized were the Activator1Dissociation elements of Zea 
mays. Since then, they have been identified in a wide range of 
organisms, both prokaryotic and eukaryotic. 
[0230] Transposable elements in the genome are character- 
ized by being flanked by direct repeats of a short sequence of 
DNA that has been duplicated during transposition and is 
called a target site duplication. Virtually all transposable ele- 
ments whatever their type, and mechanism of transposition, 
make such duplications at the site of their insertion. In some 
cases the number of bases duplicated is constant, in other 
cases it may vary with each transposition event. Most trans- 
posable elements have inverted repeat sequences at their ter- 
mini. These terminal inverted repeats may be anything from a 
few bases to a few hundred bases long and in many cases they 
are known to be necessary for transposition. 
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(02311 Prokaryotic transposable elements have been most 
studied in E. coli and Gram negative bacteria, but also are 
present in Gram positive bacteria. They are generally termed 
insertion sequences if they are less than about 2 kB long, or 
transposons if they are longer. Bacteriophages such as mu and 
D108, which replicate by transposition, make up a third type 
of transposable element. elements of each type encode at least 
one polypeptide a transposase, required for their own trans- 
position. Transposons often further include genes coding for 
function unrelated to transposition, for example, antibiotic 
resistance genes. 
(02321 Transposons can be divided into two classes accord- 
ing to their structure. First, compound or composite trans- 
posons have copies of an insertion sequence element at each 
end, usually in an inverted orientation. These transposons 
require transposases encoded by one of their terminal IS 
elements. The second class of transposon have terminal 
repeats of about 30 base pairs and do not contain sequences 
from IS elements. 
[0233] Transposition usually is either conservative or rep- 
licative, although in some cases it can be both. In replicative 
transposition, one copy of the transposing element remains at 
the donor site, and another is inserted at the target site. In 
conservative transposition, the transposing element is excised 
from one site and inserted at another. 
[0234] Eukaryotic elements also can be classified accord- 
ing to their structure and mechanism of transportation. The 
distinction is between elements that transpose via an 
RNA intermediate, and elements that transpose directly from 
DNA to DNA. 
[0235] Elements that transpose via an RNA intermediate 
often are referred to as retrotransposons, and their most char- 
acteristic feature is that they encode polypeptides that are 
believed to have reverse transcriptionase activity. There are 
two types of retrotransposon. Some resemble the integrated 
proviral DNA of a retrovirus in that they have long direct 
repeat sequences, long terminal repeats (LTRs), at each end. 
The similarity between these retrotransposons and proviruses 
extends to their coding capacity. They contain sequences 
related to the gag and pol genes of aretrovirus, suggesting that 
they transpose by a mechanism related to a retroviral life 
cycle. Retrotransposons of the second type have no terminal 
repeats. They also code for gag- and 
transpose by reverse transcription of RNA intermediates, but 
do so by a mechanism that differs from that or retrovirus-like 
elements. Transposition by reverse transcription is a replica- 
tive process and does not require excision of an element from 
a donor site. 
[0236] Transposable elements are an important source of 
spontaneous mutations, and have influenced the ways in 
which genes and genomes have evolved. They can inactivate 
genes by inserting within them, and can cause gross chromo- 
somal rearrangements either directly, through the activity of 
their transposases, or indirectly, as a result of recombination 
between copies of an element scattered around the genome. 
Transposable elements that excise often do so imprecisely 
and may produce alleles coding for altered gene products if 
the number of bases added or deleted is a multiple of three. 
[0237] Transposable elements themselves may evolve in 
unusual ways. If they were inherited like other DNA 
sequences, then copies of an element in one species would be 
more like copies in closely related species than copies inmore 
distant species. This is not always the case, suggesting that 
transposable elements are occasionally transmitted horizon- 
tally from one species to another. 
[0238] ii) Chemical Mutagenesis. 
[0239] Chemical mntagenesis offers certain advantages, 
such as the ability to find a full range of mutant alleles with 
degrees of phenotypic severity, and is facile and inexpensive 
to perform. The majority of chemical carcinogens produce 
mutations in DNA. Benzo(a)pyrene, N-acetoxy-2-acetyl 
aminofluorene and aflotoxin B1 cause GC to TA transver- 
sions in bacteria and mammalian cells. Benzo(a)pyrene also 
can produce base substitutions such as AT to TA. N-nitroso 
compounds produce GC to AT transitions. Alkylation of the 
0 4  position of thymine induced by exposure to n-ni- 
trosoureas results in T.4 to CG transitions. 
[0240] A high correlation between mutagenicity and carci- 
nogenity is the underlying assumption behind the Ames test 
(McCann et al., 1975) which speedily assays for mutants in a 
bacterial system, together with an added rat liver homoge- 
nate, which contains the microsomal cytochrome P450, to 
provide the metabolic activation of the mutagens where 
needed. 
[0241] In vertebrates, several carcinogens have been found 
to produce mutation in the ras proto-oncogene. N-nitroso-N- 
methyl urea induces mammary, prostate and other carcino- 
mas in rats with the majority of the tumors showing a G to A 
transition at the second position in codon 12 of the Ha-ras 
oncogene. Benzo(a)pyrene-induced skin tumors containA to 
T transformation in the second codon of the Ha-ras gene. 
[0242] iii) Radiation Mutagenesis. 
[0243] The integrity of biological molecules is degraded by 
the ionizing radiation. L4dsorption of the incident energy leads 
to the formation of ions and free radicals, and breakage of 
some covalent bonds. Susceptibility to radiation damage 
appears quite variable between molecules, and between dif- 
ferent crystalline forms of the same molecule. It depends on 
the total accumulated dose, and also on the dose rate (as once 
free radicals are present, the molecular damage they cause 
depends on their natural diffusion rate and thus upon real 
time). Damage is reduced and controlled by making the 
sample as cold as possible. 
[0244] Ionizing radiation causes DNA damage and cell 
killing, generally proportional to the dose rate. Ionizing radia- 
tion has been postulated to induce multiple biological effects 
by direct interaction with DNA, or through the formation of 
free radical species leading to DNA damage. These effects 
include gene mutations, malignant transformation, and cell 
killing. Although ionizing radiation has been demonstrated to 
induce expression of certain DNA repair genes in some 
prokaryotic and lower eukaryotic cells, little is known about 
the effects of ionizing radiation on the regulation of mamma- 
lian gene expression (Borek, 1985). Several studies have 
described changes in the pattern of protein synthesis observed 
after irradiation of mammalian cells. For example, ionizing 
radiation treatment of human malignant melanoma cells is 
associated with induction of several unidentified proteins 
(Boothanet  al., 1989). Synthesis of cyclinand co-regulated 
polypeptides is suppressed by ionizing radiation in rat REF52 
cells, but not in oncogene-transformed REF52 cell lines 
(Lambert and Borek, 1988). Other studies have demonstrated 
that certain growth factors or cytokines may be involved in 
x-ray-induced DNA damage. In this regard, platelet-derived 
growth factor is released from endothelial cells after irradia- 
tion (Witte, et al., 1989). 
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[0245] In the present invention, the term "ionizing radia- 
tion" means radiation comprising particles or photons that 
have sufficient energy or can produce sufficient energy via 
nuclear interactions to produce ionization (gain or loss of 
electrons). An exemplary and preferred ionizing radiation is 
an y-radiation. The amount of ionizing radiation needed in a 
given cell generally depends upon the nature of that cell. 
Typically, an effective expression-inducing dose is less than a 
dose of ionizing radiation that causes cell damage or death 
directly. Means for determining an effective amount of radia- 
tion are well known in the art. 
[0246] In a certain embodiments, an effective expression 
inducing amount is from about 2 to about 30 Gray (Gy) 
administered at a rate of from about 0.5 to about 2 Gylminute. 
Even more preferably, an effective expression inducing 
amount of ionizing radiation is from about 5 to about 15 Gy. 
In other embodiments, doses of 2-9 Gy are used in single 
doses. An effective dose of ionizing radiation may be from 10 
to 100 Gy, with 15 to 75 Gy being preferred, and 20 to 50 Gy 
being more preferred. 
[0247] Any suitable means for delivering radiation to a 
tissue may be employed in the present invention in addition to 
external means. For example, radiation may be delivered by 
first providing a radiolabeled antibody that immunoreacts 
with an antigen of the tumor, followed by delivering an effec- 
tive amount of the radiolabeled antibody to the tumor. In 
addition, radioisotopes may be used to deliver ionizing radia- 
tion to a tissue or cell. 
[0248] iv) In Vitro Scanning Mutagenesis. 
[0249] Random mutagenesis also may be introduced (e.g., 
using error prone PCR, See Cadwell and Joyce, 1992). The 
rate of mutagenesis may be increased by performing PCR in 
multiple tubes with dilutions of templates. 
[0250] One particularly useful mutagenesis technique is 
alanine scanning mutagenesis in which a number of residues 
are substituted individually with the amino acid alanine so 
that the effects of losing side-chain interactions can be deter- 
mined, while minimizing the risk of large-scale perturbations 
in protein conformation. 
[0251] In recent years, techniques for estimating the equi- 
librium constant for ligand binding using minuscule amounts 
of protein have been developed (See, e.g., U.S. Pat. Nos. 
5,221,605 and 5,238,808, hereinincorporatedby reference in 
their entireties). The ability to perform functional assays with 
small amounts of material can be exploited to develop highly 
efficient, in vitro methodologies for the saturation mutagen- 
esis of antibodies. The inventors bypassed cloning steps by 
combining PCR mutagenesis with coupled in vitro transcrip- 
tionitranslation for the high throughput generation of protein 
mutants. Here. the PCR nroducts are used directlv as the 
template for the in vitro transcriptionitranslation of the 
mutant single chain antibodies. Because of the high efficiency 
with which all 19 amino acid substitutions can be generated 
and analyzed in this way, it is now possible to perform satu- 
ration mutagenesis on numerous residues of interest, a pro- 
cess that can be described as in vitro scanning saturation 
mutagenesis (Burks et al., 1997). 
[0252] In vitro scanning saturation mutagenesis provides a 
rapid method for obtaining a large amount of structure-func- 
tion information including: (i) identification of residues that 
modulate ligand binding specificity, (ii) a better understand- 
ing of ligand binding based on the identification of those 
amino acids that retain activity and those that abolish activity 
at a given location, (iii) an evaluation of the overall plasticity 
of an active site or protein subdomain, (iv) identification of 
amino acid substitutions that result in increased binding. 
[0253] v) Random Mutagenesis by Fragmentation and 
Reassmbly. 
[0254] A method for generating libraries of displayed 
polypeptides is described in U.S. Pat. No. 5,380,721, herein 
incorporated by reference in its entirety. The method com- 
prises obtaining polynucleotide library members, pooling 
and fragmenting the polynucleotides, and reforming frag- 
ments therefrom, performing PCR amplification, thereby 
homologously recombining the fragments to form a shuffled 
pool of recombined polynucleotides. 
b. Site-Directed Mutagenesis 
[0255] Structure-guided site-specific mutagenesis repre- 
sents a powerful tool for the dissection and engineering of 
protein-ligand interactions. The technique provides for the 
preparation and testing of sequence variants by introducing 
one or more nucleotide sequence changes into a selected 
DNA. 
[0256] Site-specific mutagenesis uses specific oligonucle- 
otide sequences which encode the DNA sequence of the 
desired mutation, as well as a sufficient number of adjacent, 
unmodified nucleotides. In this way, a primer sequence is 
provided with sufficient size and complexity to form a stable 
duplex on both sides of the deletion junction being traversed. 
For example, a primer of about 17 to 25 nucleotides in length 
is preferred, with about 5 to 10 residues on both sides of the 
junction of the sequence being altered. 
[0257] The technique typically employs a bacteriophage 
vector that exists in both a single-stranded and double- 
stranded form. Vectors useful in site-directed mutagenesis 
include vectors such as the MI3 phage. These phage vectors 
are commercially available and their use is generally well 
known to those skilled in the art. Double-stranded plasmids 
are also routinely employed in site-directed mutagenesis, 
which eliminates the step of transferring the gene of interest 
from a phage to a plasmid. 
[0258] In general, one first obtains a single-strandedvector, 
or melts two strands of a double-stranded vector, which 
includes within its sequence a DNA sequence encoding the 
desired protein or genetic element. An oligonucleotide primer 
bearing the desired mutated sequence, synthetically prepared, 
is then annealed with the single-stranded DNA preparation, 
taking into account the degree of mismatch when selecting 
hybridizationconditions. The hybridizedproduct is subjected 
to DNA polymerizing enzymes such as E. coli polymerase I 
(Klenow fragment) in order to complete the synthesis of the 
mutation-bearing strand. Thus, a heteroduplex is formed, 
wherein one strand encodes the original non-mutated 
sequence, and the second strand bears the desired mutation. 
This heteroduplex vector is then used to transform appropri- 
ate host cells, such asE. coli cells, and clones are selected that 
include recombinant vectors bearing the mutated sequence 
arrangement. 
[0259] Comprehensive information on the functional sig- 
nificance and information content of a given residue of pro- 
tein can best be obtained by saturation mutagenesis in which 
all 19 amino acid substitutions are examined. The shortcom- 
ing of this approach is that the logistics of multiresidue satu- 
ration mutagenesis are daunting (Warren et al., 1996, Zeng et 
al., 1996; Yelton et al., 1995; Hilton et al., 1996). Hundreds, 
and possibly even thousands, of site specific mutants must be 
studied. However, improved techniques make production and 
rapid screening of mutants much more straightforward. See, 
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U.S. Pat. Nos. 5,798,208 and 5,830,650, herein incorporated 
by reference in their entireties, for a description of "walk- 
through" mutagenesis. 
[0260] Other methods of site-directed mutagenesis are dis- 
closed in U.S. Pat. Nos. 5,220,007; 5,284,760; 5,354,670; 
5,366,878; 5,389,514; 5,635,377; and 5,789,166, herein 
incorporated by reference in their entireties. 
[0261] In some embodiments, a variant (e.g., a mutant) 
includes "nonconservative" changes (e.g., replacement of a 
glycine with a tryptophan). Analogous minor variations can 
also include amino aciddeletions or insertions, or both. Guid- 
ance in determining which amino acid residues can be sub- 
stituted, inserted, or deleted without abolishing biological 
activity can be found using computer programs (e.g., 
LASERGENE software, DNASTAR Inc., Madison, Wis.). 
[0262] vi. Directed Evolution. 
[0263] In some embodiments, variants or other nucleic acid 
molecules of interest, may be produced by methods such as 
directed evolution or other techniques for producing combi- 
natorial libraries of variants. The synthesis of degenerate 
oligonucleotides is well known in the art (See e.g., Narang, 
Tetrahedron Lett., 39:39 (1983); Itakura et al., Recombinant 
DNA, in Walton (ed.), Proceedings of the 3rd Cleveland Sym- 
posium on Macromolecules, Elsevier, Amsterdam, pp 273- 
289 (1981); Itakura et al., Annu. Rev. Biochem., 53:323 
(1984); Itakura et al., Science 198:1056 (1984); Ike et al., 
Nucl. Acid Res., 11:477 (1983), herein incorporated by ref- 
erence in their entireties). Such techniques have been 
employed in the directed evolution of proteins (See e.g., Scott 
et al., Science 249:386 (1980); Roberts et al., Proc. Natl. 
Acad. Sci. USA 89:2429 (1992); Devlin et al., Science 249: 
404 (1990); Cwirla et al., Proc. Natl.Acad. Sci. USA 87: 6378 
(1990); each of which is herein incorporated by reference; as 
well as U.S. Pat. Nos. 5,223,409, 5,198,346, and 5,096,815; 
each of which is incorporated herein by reference). 
EXPERIMENTAL 
[0264] The following examples are provided in order to 
demonstrate and further illustrate certain preferred embodi- 
ments and aspects of the present invention and are not to be 
construed as limiting the scope thereof. 
Example 1 
Lithographic Methods and Materials for Generating 
Transfection Cell Arrays 
[0265] Cells. Estrogen receptor (ER)-positive MCF-71 
WS8 mammary carcinoma cells, clonally derived from 
MCF-7 cells by selection for sensitivity to growth simulation 
by 17-P-estradiol (E,) (See, e.g., Jiang et al., 1992. Mol Cell 
Endocrinol90(1):77-86' Levenson and Jordan, 1997. Cancer 
Res 57(15):3071-a), were utilized. Cells were cultured in 
fully estrogenized, phenol red-containing RPMI-1640 media 
supplemented with 10% fetal bovine serum (FBS), 100 pM 
non-essential amino acids, 100units antibioticlantimycotic, 2 
mM L-glutamine, and 6 nglml insulin and maintained at 37' 
C. in a humidified 5% CO, atmosphere. Prior to transfecting 
cells for an experiment, cells were cultured under estrogen- 
free conditions by substituting phenol red-free RPMI-1640 
and dextran-coated charcoal-treated fetal bovine serum in the 
medium. For experiments in which transfected cells were 
assayed in 24-well plates using a luminometer, or imaged in 
arrays using a CCD camera, cells were cultured under estro- 
gen-free condition for 4 days or 18 h, respectively, prior to 
seeding. Culture in estrogen-free media for either time period 
allowed adequate time for upregulation of ER protein levels 
due to E, withdrawal, while the shorter culture period 
enhanced cell viability in the array. All media and media 
components were purchased from GIBCOIINVITROGEN 
(Carlsbad, Calif.). 
[0266] Plasmids. Plasmids were purified from bacteria cul- 
ture using QIAGEN (Valencia, Calif.) reagents and stored in 
Tris-EDTA buffer solution (10 mM Tris, 1 mM EDTA, pH 
7.4)) or water at -20' C. Plasmid pEGFP-LUC encodes both 
the enhanced green fluorescent protein (EGFP) and firefly 
luciferase protein, under the direction of a CMV promoter 
(CLONTECH, Mountain View, Calif.). Plasmid pLUC 
encodes the firefly luciferase gene in the pNGVLl (National 
Gene Vector Labs, University of Michigan) vector backbone 
with a CMV promoter. Estrogen-responsive plasmid pERE 
(3 X)TK-ffLUC (See, e.g., Catherino and Jordan, 1995. Can- 
cer Lett 92(1):39-47) contains three tandem copies of the 
palindromic estrogen response element (ERE) sequence, 
placed upstream of a minimal herpes simplex thymidine 
kinase (TK) promoter, directing expression of the firefly 
luciferase coding sequence in response to transcriptional acti- 
vation by estradiol (E,)-bound ERu, followed by recruitment 
of cofactor complexes and basal transcriptional machinery. 
PlasmidpTK-rLUC (phRL-TK, PROMEGA, Madison, Wis.) 
contains the minimal TK promoter driving expression of a 
humanized renilla luciferase and was used for normalization 
of the firefly luciferase plasmids. Plasmid pPGAL encodes 
for nuclear-targeted P-galactosidase in the pNGVLl (Na- 
tional Gene Vector Labs, University of Michigan) vector 
backbone with a CMV promoter and was used for control 
spots on the array. 
[0267] DNA complex formation. DNA complexes were 
formed with LIPOFECTAMINE 2000 (INVITROGEN, 
Carlsbad, Calif.), LIPOFECTAMINE LTX (INVITROGEN, 
Carlsbad, Calif.) or EFFECTENE (QIAGEN, Valencia, 
Calif.), following manufacturer's instructions. Briefly, for 
both LIPOFECTAMINE 2000 and LIPOFECTAMINE LTX, 
DNA complexes were formed at a DNA:lipid ratio of 1:2 in 
serum-free, OPTI-MEM media (INVITROGEN, Carlsbad, 
Calif.), by adding transfection reagent diluted in media drop- 
wise to DNA in media, mixing by gentle pipeting, and then 
incubating for 20 minutes. EFFECTENE complexes were 
formed by diluting DNA into EC buffer, to which the 
Enhancer buffer was added at a DNA to Enhancer ratio of 1 :8. 
After 2-5 minutes of incubation at room temperature, the 
EFFECTENE transfection reagent was then added to the 
DNMEnhancer mixture at a DNA to Transfection reagent 
ratio of 1:4. After incubation at room temperature for 10 
minutes, complexes were diluted with serum-free media 
before addition to surfaces or cells. DNA in complexes con- 
taining multiple plasmids was extensively mixed prior to 
complex formation. For induction studies in estrogen-free 
media, phenol red-free OPTI-MEM media was used for com- 
plex formation. 
[0268] Multiwell dish format reporter gene assays. Multi- 
well dish format reporter gene assays were performed (e.g., to 
compare the ability of surface delivery of complexes to moni- 
tor ERu response with traditional bolus delivery). For surface 
delivery, the surface of wells of a 24-well plate (BECTON 
DICKINSON, Franklin Lakes, N.J.) were serum-coated by 
incubation with dextran-coated charcoal-stripped FBS (10% 
in 1 XPBS, pH 7.4,380 pL) for 18 hours at 4" C., followed by 
two wash steps with PBS (See, e.g., Bengali et al., 2005 
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Biotechnol Bioeng 90(3):290-302). Complexes were then 
immobilized following complex formation, as described 
above, by incubation of DNA complexes (475 pL) with the 
serum-coated wells for 2 hours. After complex incubation, 
the wells were washed twice with OPTI-MEM (for LIPO- 
FECTAMINE 2000 complexes) or EC buffer (for EFFECT- 
ENE comvlexes~ and 250.000 MCF-7 cells (cultured in estro- 
gen-free media for 4 days) were seeded onto the immobilized 
DNA-lipid complexes in each well. 
[0269] For bolus delivery, MCF-7 cells cultured in estro- 
gen-free media for 4 days were seeded in estrogen-free 
medium into 24-well plates at densities of 125,000 cells per 
well. Eighteen hours later, complexes formed as described 
above were diluted in antibiotic-free, estrogen-free media and 
then added to the cells. 
[0270] For both surface and bolus delivery, complexes con- 
tained both the pERE(3 X)TK-ffLUC plasmid and the nor- 
malization plasmid, pTK-rLUC, at a ratio of 4: 1. Total DNA 
amourfts added for surface delivery ranged from 0.13-1.32 
pglcm (0.25-2.5 pg per well) and 0.05-0.26 pg/cm2 (0.025- 
0.5 pg per well) for bolus delivery. Given binding profiles, 
these ranges result in approximately the same amount of 
DNA bound to the surface as delivered as a bolus (See, e.g., 
2005, Biotechnol Bioeng 90(3):290-302). 
[0271] Immediately after complex addition for bolus deliv- 
ery and 4 hours after cell seeding for surface delivery, cells 
were treated with combinations of E, (SIGMA-ALDRICH, 
St. Louis, Mo.), the complete anti-estrogen fulvestrant 
(FUL), also termed ICI 182,780, TOCRIS Bioscience, Ellis- 
ville, Mo.) or vehicle controls. E, and FUL were both dis- 
solved in ethanol and diluted in estrogen-free media to obtain 
the indicated concentrations (10- to 1OP9M for E,; 1OP6M 
for FUL) prior to addition to cells. Ethanol diluted in estro- 
gen-free media served as the vehicle control. Cells were har- 
vested and assayed for firefly and renilla luciferase reporter 
gene activities 48 hours after transfection using the Dual- 
Luciferase Reporter assay system (PROMEGA, Madison, 
Wis.). In this dual-luciferase system, firefly and renilla 
luciferases are measured sequentially, in a single well. These 
measurements are accomplished by adding the firefly 
luciferase substrate first. measuring luminescence. and then 
u 
adding reagents that quench the firefly luciferase reaction and 
simultaneously provide the renilla luciferase substrate, fol- 
lowed by measuring renilla luciferase activity. The dual-lu- 
ciferase assays were carried out using an automated micro- 
plate luminometer equipped with dual-injection ports 
(MITHRAS LB 940, Berthold Technologies, Oak Ridge, 
Tenn.). Relative dual-luciferase activity was calculated by 
dividing the luminescent signal from the firefly reporter gene 
by the renilla luminescent signal. 
[0272] Array fabrication. Soft lithography techniques were 
used to pattern DNA complex deposition. A polydimethylsi- 
loxane (PDMS) mold was fabricated by curing PDMS into 
thin, flat disks. Briefly, PDMS was prepared in a 10: 1 (v:v) 
ratio of Silicone Elastomer-184 and Silicone Elastomer Cur- 
ing Agent-1 84 (SYLGARD 184, DOW CORNING, Midland, 
Mich.) by mixing the base and curing agent at least 50 times 
using a syringe mixing system. After allowing all air bubbles 
to escape, the PDMS was poured directly into a polystyrene 
tissue culture dish (100 mm, Corning, Corning, N.Y.) and 
cured at 60' C. for approximately 2 hours. The cured PDMS 
was removed from the dish and rods of precise diameters 
were thenused to punch holes into the PDMS, with diameters 
of 2.4 mm. The PDMS mold was rinsed in 70% ethanol, 
oxidized using oxygen plasma and then reversibly sealed to 
sterile polystyrene microscope slides (NUNC, Rochester, 
N.Y.), which were fitted into custom-fabricated TEFLON 
slide holders that are rinsed in 70% ethanol before use. The 
holes in the PDMS mold, termed microwells, served as res- 
ervoirs for deposition of DNA complexes onto the polysty- 
rene slide. After 2 hours of complex deposition in humid 
conditions, the PDMS mold was peeled away from the poly- 
styrene, and the slide was rinsed thoroughly with OPTI- 
MEM. For all array studies, DNA concentrations ranged from 
0.007 pg/pL to 0.021 pg/pL, with 2.2 pL to 4 pL of complex 
volume added to the microwells of the PDMS mold. 
[0273] To visualize DNA complex immobilization on the 
array and verify deposition replicated the pattern of the 
microwells in the PDMS mold, plasmid (pEGFP-LUC) was 
labeled with tetramethyl rhodamine (LABEL IT Nucleic 
Acid Labeling Kit, MIRUS, Madison, Wis.), complexed as 
describedabove, and depositedin the microwells. After depo- 
sition, PDMS removal and rinsing, the resulting spots were 
visualized with fluorescence microscopy. 
[0274] Transfection of cells on the array was verified by 
depositing complexes formed with plasmid pEGFP-LUC in 
the microwells, and imaging with fluorescence microscopy. 
After complex deposition, PDMS removal and rinsing, 
MCF-7 cells were seeded onto the slide at a density of lo6 
cells per slide (18.75 cm2). Transfection was analyzed after 
24 and 48 hours and characterized through GFP expression. 
Transfected cells were visualized using an epifluorescence 
microscope (LEICA; Bannockbum, Ill.) with a FITC filter 
and equipped with a digital camera. Transfection, as assayed 
through bioluminescence imaging, was verified by deposit- 
ing complexes containing both pLUC and pTK-rLUC plas- 
mids at a 1:l ratio. After deposition, PDMS removal and 
rinsing, cells were seeded as described above. Transfection 
was analvzed after 24 hours and characterized bv dual-lu- 
ciferase expression through light emission. 
[0275] For induction studies in the array, complexes 
formed with different plasmids were immobilized in different 
spots of the array, in triplicate. Briefly, complexes were 
formed with pLUC, pERE(3 X)TK-ffLUC, pERE(3 X)TK- 
ffLUC and pTK-rLUC (2:l ratio), or pPGAL. After deposi- 
tion, PDMS removal and rinsing, MCF-7 cells that had been 
cultured in estrogen-free media for 18 hours were seeded in 
estrogen-free medium on arrays at a density of lo6 cells per 
slide. Immediately after cell seeding, cells were treated with 
combinations E,, FUL, or vehicle control, as described 
above. Dual-luciferase levels were analyzed 24 hours later by 
bioluminescence imaging. 
[0276] Bioluminescence imaging. Expression of both 
luciferase reporter genes was assessed through imaging of 
light production upon sequential addition of the luciferase 
substrates to the bulk media. Bioluminescence imaging of the 
array was performed using an IVIS imaging system (XENO- 
GEN Corp., Alameda, Calif.), which utilizes a cooled CCD 
camera. For imaging, a modified renilla luciferase substrate, 
VIVIREN (Promega, Madison, Wis.), was diluted to 0.66 
mM in serum-containing media and then added to the arrays 
at a final concentration of 10 pM. After 2 minutes, the arrays 
were placed into a light-tight chamber and bioluminescence 
images were acquired for a total exposure time of 1 minute. 
Immediately following imaging with VIVIREN, 1 mM of 
luciferase substrate D-luciferin (Molecular Therapeutics Inc., 
MI, 20 mg1mL in PBS), was added into the media above the 
cells cultured on the array and bioluminescence images 
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acquired 3 minutes later, with 1 minute exposure. Gray scale 
and bioluminescence images were superimposed using the 
LIVING IMAGE software (XENOGEN Corp., Alameda, 
Calif.). A constant size region of interest (ROI) was drawn 
overthe spots ofthe array to calculate light signals. The signal 
intensity was reported as an integrated light flux (photonsis), 
determined by IGOR software (WAVEMETRICS, Lake 
Oswego, Oreg.). The signal due to firefly luciferase was deter- 
mined by subtracting VIVIREN signal from the luciferin 
signal. Normalization was accomplished by dividing the fire- 
fly luciferase signal (luciferin signal minus VIVIREN signal) 
by the renilla luciferase signal (VIVIREN signal). A renilla 
signal threshold was set at 3.5E4 photods (2X background) 
to distinguish spots of unreliable signals indicating insuffi- 
cient transfection. 
[0277] Statistics. Statistical analysis was performed using 
JMP software (SAS Institute, Inc., Cary, N.C.). Comparative 
analyses were completed using one-way ANOVA with Tukey 
post-tests, at a 95% confidence level. Mean values with stan- 
dard deviation are reported. 
Example 2 
Multiwell Dish Format Estrogen Responsive Ele- 
ment (ERE)-Reporter Gene Induction Studies 
[0278] Multiwell dish format reporter gene assays were 
performed to compare estrogen receptor-alpha (Era)-rep- 
lated, estrogen response element (ERE)-dependent transcrip- 
tional activity in MCF-7 cells transfected via surface-medi- 
ated delivery of DNA complexes in comparison to traditional 
bolus delivery (See FIG. 1). DNA complexes formedusing an 
E,-responsive firefly luciferase reporter plasmid pERE(3 X) 
TK-ffLUC and a normalization plasmidpTK-rLUC encoding 
renilla luciferase were delivered to cells via bolus or surface 
delivery. Transfected cells were treated with various combi- 
nations of the agonist E,, the complete antiestrogen FUL, or 
ethanol. Surface delivery of the plasmids (See FIG. 1B) 
resulted in E,-stimulated responses similar to bolus delivery 
(See FIG. lA), with E, statistically inducing firefly luciferase 
expression 6-7 fold (p<0.001) over vehicle control or the 
addition of FUL. Thus, the present invention provides that the 
physiologic state of the cells during surface-mediated deliv- 
ery allowed the cells to transcriptionally respond to E,. Fur- 
ther, the maximal induction of reporter gene activity was 
similar whether the DNA complexes were delivered via bolus 
or surface-mediated techniques. 
[0279] The amount of transfected plasmid was subse- 
quently investigated, which indicated a similar DNA mass- 
dependent effect in reporter gene activity for both surface and 
bolus-mediated transfection methods (See FIG. 2). For bolus 
delivery (See FIG. 2A), all DNA amounts resulted in signifi- 
cantly different responses (p<0.01), except for 0.1 1 and 0.2 
pg/cm2, which were not statistically different from each 
other. Maximal induction was achieved at 0.13 pg/cm2 (0.25 
pg per well). For surface delivery (See FIG. 2B), all DNA 
amounts resulted in significantly different responses (p<O. 
05), with 1.05 pg/cm2 (2 pg per well) corresponding to the 
highest induction by E,. These results indicate that sufficient 
amounts of DNA must be transfected for optimal reporter 
gene activitv and excess amounts of DNA lead to less efficient 
u 
reporter gene activity, possibly due to toxicity, for both deliv- 
ery methods. 
[0280] Assuming that approximately 20% of DNA added 
to the cell culture dish surface is immobilized (See, e.g., 
Bengali et al., Biotechnol Bioeng 90(3):290-302) 2005), the 
condition with the highest induction (1.05 pg/cm2) would 
have presented approximately 0.21 pg/cm2 of DNA to the 
cells, which is higher than the bolus condition with the high- 
est induction (0.13 pg/cm2), but still in the range of robust 
activity. Therefore, surface delivery required more DNA 
added to the surface than what would have been expected 
given binding profiles (See, e.g., Bengali et al., Biotechnol 
Bioeng 90(3):290-302) 2005). Although an understanding of 
the mechanism is not necessary to practice the present inven- 
tion and the present invention is not limited to any particular 
mechanism of action, in some embodiments, the requirement 
for more DNA may be due to lower than anticipated binding 
efficiencies (-lo%, but still within the range of profiles 
reported). 
[0281] The specific transfection reagent used to form DNA 
complexes and E, concentration responses were subse- 
quently investigated to determine the applicability and sensi- 
tivity of the reporter system (See FIG. 3). For LIPO- 
FECTAMINE 2000-DNA complexes (See FIG. 3A), 
E,-induction profiles were not significantly different using 
bolus versus surface delivery (See FIG. 3A), with E, eliciting 
a concentration response from lop1' M to lop9  M (p<0.05), 
and maximal responsiveness observed from lop1' M to 
10p9M E, (p>0.05) for bothdelivery methods. For EFFECT- 
ENE complexes (See FIG. 3B), bolus delivery resulted in 
statistically higher levels of ERE induction (p<0.05) than 
surface delivery for all concentrations of E,, except control. 
However, the level of ERE induction for surface-mediated 
delivery was similar whether complexing DNA with 
EFFECTENE (See FIG. 3B) or with LIPOFECTAMINE 
2000 (See FIG. 2A). Therefore, the particular transfection 
reagent used affected transcriptional activity via the conven- 
tional bolus delivery, but not via surface delivery. Thus, the 
present invention provides that either EFFECTENE or LIPO- 
FECTAMINE 2000 can be used to delivery plasmid via sur- 
face-mediated transfection. Additionally, other transfection 
reagents could easily be adapted by one of ordinary skill in the 
art for use in surface-mediated delivery. 
Example 3 
Array Fabrication and Verification 
[0282] An array was created using soft lithography tech- 
niques to pattern DNA-lipid complex deposition and subse- 
quent transfection upon cell seeding (See FIG. 4). Briefly, a 
polydimethylsiloxane (PDMS) mold with microwells (e.g., 
generated as described in Example 1) (See FIG. 4A) was 
reversibly sealed to polystyrene microscope slides (See FIG. 
4B) with the microwells serving as reservoirs for deposition 
of DNA complexes onto the polystyrene slide (See FIG. 4C). 
Rhodamine-labeled DNA complexes deposited within 
microwells were immobilized to the slide in distinct regions, 
replicating the pattern of microwells in the PDMS mold (See 
FIG. 4D-F). Transfection of MCF-7 cells seeded onto arrays 
of complexes was determined by GFP expression, and was 
also confined to the patterns (See FIG. 4G-I). 
Example 4 
Bioluminescence Imaging of the Array 
[0283] Arrays formed with complexes containing plasmids 
encoding firefly and renilla luciferase reporter genes (pLUC 
and pTK-rLUC) were used to verify the ability of biolumi- 
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nescence imaging to detect dual-luciferase expression (See 
FIG. 5). Transfectionof MCF-7 cells seededonto these arravs 
was assayed after 24 hours by sequentially adding the renilla 
and firefly luciferase substrates. Following VIVIREN addi- 
tion, spot intensities averaged 1 .lOX lo5 ?2.56X lo4 pho- 
tods (See FIG. 5A), which are similar to signals obtained 
with arrays of only pTK-rLUC plasmid. D-Luciferin was 
subsequently added to the same array, which was then imaged 
to acquire a dual signal (See FIG. 5B), with average spot 
intensities of 3.66X 106?4.34x lo5 photods. Firefly 
luciferase expression was determined by subtracting the ini- 
tial VIVIREN signal from the signal obtained through imag- 
ing wit) D-luciferin. Firefly expression averaged 
3.55 X 10 ? 4 . 3 0 ~  lo5 photods, also similar to intensities 
obtained with arrays formed with only rLUC plasmid. After 
normalization, the firefly luciferase signal was 34?8 fold 
greater than the respective renilla expression. Timecourse 
studies revealed that the VIVIREN signal remained constant 
for 10 minutes after substrate addition. Therefore, the present 
invention provides that the firefly luciferase signal can be 
obtained using a dual imaging strategy (e.g., as described 
herein) followed by subtraction techniques (e.g., since imag- 
ing can be accomplished within 10 minutes of VIVIREN 
umn 4) resulted in higher signal intensities in the presence of 
luciferin than cells transfected with only the pERE(3 X)TK- 
ffLUC (See FIG. 6B, column 3), as there was no carryover of 
VIVIREN signal in the latter spots of transfected cells with- 
out pTK-rLUC. For E, addition to the array, signal intensities 
with luciferin increased as compared to the control condition 
for all cells transfected with pERE(3 X)TK-ffLUC plasmids 
(See FIG. 6D, columns 3 and 4), indicating ERu-dependent 
transcriptional activation of the ERE-regulated plasmid. 
Expression of the pLUC plasmid was largely unaffected by 
E2 (See FIG. 6D, column 1). Additionof the antiestrogenFUL 
to the arrays completely eliminated the signal in cells trans- 
fected withpERE(3 X)TK-ffLUC alone (See FIG. 6F, c o l u  
3), or substantially reduced signal intensities in cells trans- 
fected with both pERE(3 X)TK-ffLUC and pTK-rLUC (See 
FIG. 6F, c o l u  4), in which the luminescence that was 
detected was again due to carryover of the VIVIREN signal. 
Therefore, addition of lop6 M FUL led to a complete block- 
ade of ERu-stimulated activity by lop9 M E,. pLUC expres- 
sion was also lowered in the presence of FUL (See FIG. 6F, 
c o l u  1) indicating that some transcriptional elements in the 
CMV may be indirectly regulated by ERu, possibly by ERu 
tethering to AP1 and SP1 proteins bound directly to DNA in 
addition. The present invention also provides that biolumi- this promoter. 
nescence imaging is able to sensitively capture both [0286] Average renilla luminescence intensities in cells 
luciferase signals, thereby enabling the same cell population transfected with pERE(3 X)TK-ffLUC and pTK-rLUC plas- 
to be analyzed for the expression of multiple reporter genes. mids (See FIG. 6A, C, E, c o l u  4) were similar in control 
and E, +FUL treated cells, but lower in E, alone treated cells. 
Example 5 Although an understanding of the mechanism is not neces- 
sary to practice the present invention and the present inven- 
Array Format ERE-Reporter Gene Induction Studies tion is not limited to any varticular mechanism of action, in 
[0284] In order to assess the ability of the arrays to monitor 
induction of ERu transcriptional activity (See FIG. 6), com- 
plexes formed with different plasmids were immobilized as 
an array as follows: 1. pLUC; 2. no DNA (mock); 3. pERE 
(3 X)TK-ffLUC; 4. pERE(3 X)TK-ffLUC and pTK-rLUC 
(2:l ratio); and 5. pPGAL. Cells seeded on the arrays were 
treated with combinations of ethanol control (See FIG. 
6A-B), lop9  ME, (See FIG. 6C-D), or lop9  M E,+ lop6  M 
FUL (See FIG. 6E-F). Dual-luciferase levels were analyzed 
24 hours later using bioluminescence imaging, by first imag- 
ing with VIVIREN (See FIG. 6A, C, E), and then imaging 
each array with D-luciferin (See FIG. 6B, E, F). Renilla 
luciferase activity was only detected in cells transfected with 
pTK-rLUC plasmid (See FIG. 6A, C, E, column 4), andnot in 
cells transfected with only firefly luciferase-encoding plas- 
mids (See FIG. 6A, C, E, c o l u s  1 and 3), a control PGAL- 
encoding plasmid (See FIG. 6A, C, E, column 5) or no DNA 
(See FIG. 6A, C, E, column 2). Accordingly, firefly luciferase 
activity was only detected in cells transfected with pLUC 
(See FIG. 6B, D, F, column 1) or pERE(3 X)TK-ffLUC (See 
FIG. 6B, D, F, columns 3 and 4), but not in mock or PGAL 
control transfectedcells (See FIG. 6B, D, F, columns 2 and 5). 
These results verify the specificity of renilla and firefly 
luciferase detection in this system. 
[0285] Firefly luciferase activity was detected at substan- 
tially higher levels in cells transfected with pERE(3 X)TK- 
ffLUC and treated with E, (See FIG. 6D, columns 3 and 4) 
compared to those treated with ethanol (See FIG. 6B, col- 
. A 
some embodiments, lower renilla luciferase activity is due to 
competition for transcriptional cofactors between the ERE 
(3 X)TK and TK-only regulated promoters. For example, 
under E, stimulation conditions, ERu transcriptional coregu- 
lators and basal transcriptional machinery may be preferen- 
tially recruited to ERE-containing promoters rather than pro- 
moters lacking EREs. Hence, in cells treated with E,, may 
occur at the TK-renilla luciferase promoter due to titrating out 
of limiting transcription factors. 
[0287] Induction of the ER-regulated plasmid system in the 
array mimicked results obtained through traditional assay 
methods. Firefly luciferase expression was determined by 
subtracting the VIVIREN signal from the signal obtained 
through imaging with D-luciferin, which was then normal- 
ized by the VIVIREN signal (See FIG. 6G). For cells trans- 
fected with both the pERE(3 X)TK-ffLUC and pTK-rLUC 
plasmids (See FIG. 6, column 4), E, statistically induced 
dual-luciferase activity 10-fold (p<0.001) over control or 
FUL conditions (See FIG. 6G). Thus, the present invention 
provides that the arrays described herein can accurately 
report activity of the ERu transcription factor. The concen- 
tration response of E, was examined to determine the sensi- 
tivity of the reporter system in an array format (See FIG. 7). 
For arrays with spots containing both the pERE(3X)TK- 
ffLUC and pTK-rLUC plasmids, increasing the concentra- 
tion of E, statistically increased the induction of firefly 
luciferase expression (p<0.05), capturing the concentration- 
response of E, in the induction of this plasmid system. 
umni 3 and 4) or E,+FUL (See FIG. 6 F, columns 3 and 4). Example 6 
In control-treated arrays, spots of highest intensity were visu- 
alized for pLUC (See FIG. 6B, column I), given its highly Three Dimensional Transfected Cell Arrays 
active CMV promoter. Cells transfected with both the pERE [0288] Experiments conducted during development of 
(3 X)TK-ffLUC and pTK-rLUC plasmids (See FIG. 6B, col- some embodiments of the present invention were performed 
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to determine cell viability after encapsulation within a three- 
dimensional matrix, alginate. Alginate is a naturally occur- 
ring polymer produced by brown algae and has the ability to 
ionically crosslink in the presence of divalent cations (See, 
e.g., Gombotz and Wee 1998 Advanced Drug Delivery 
Reviews 31(3): 267-285). Cell encapsulation begins by mix- 
ing cells into a solution containing a concentration of algi- 
nate. Using a syringe, the solution is added dropwise to a 40 
mM CaCl, and 150 mMNaCl solution. After a short period of 
time (e.g., 2-3 minutes) the alginate gels to form small beads, 
which can then be removed and placed into cell media. The 
present invention provides that this process is relatively mild, 
providing a gentle environment for cell growth and prolifera- 
tion. FIG. 8 shows a phase image of MCF-7 cells encapsu- 
lated within alginate beads. The cells were stained with MTT, 
testing for cell viability (Live cells appear darkly stained). 
The present invention provides that almost all cells remain 
viable after 2 days of encapsulation. 
[0289] A suspended solution of complexes composed of 
DNA plasmids and a cationic polymer was added to the 
alginatelcell solution prior to gelation. The cationic polymer, 
polyethyleimine (PEI), contains positively charged imine 
groups that neutralize the DNA's negatively charged phos- 
phate backbone. Thus, in some embodiments, the neutraliza- 
tion allows the polymer to act as a delivery agent, facilitating 
transport of the DNA across the cell membrane and to the 
nucleus, thereby enhancing gene transfer. The present inven- 
tion provides that by varying the PEI and DNA concentrations 
it is possible to control the nitrogen to phosphate (N:P) ratio 
to obtain a charge balance for optimal DNA transfection. 
[0290] Complex suspension involved the addition of PEI to 
a solution containing a plasmid encoding a beta-galactosidase 
reporter gene. MCF-7 cells were added to the complex solu- 
tion, mixed thoroughly and then this solution was added to an 
alginate solution. Beads were formed, placed in media and 
stained for beta-galactosidase transfection 1, 2, 3 and 4 days 
after initial incubation. This procedure was performed for 
1.5% alginate beads with complexes varying in N:P ratios 
from 5-100, as shown in FIG. 9a.  An N:P ratio of around 25 
consistently gave the highest percent transfection efficiency. 
Using an N:P ratio of 25, transfection efficiency as a function 
of DNA concentration was characterized in which a maxi- 
mum appeared to be reached at 12 pglml given a cell concen- 
tration of 250,000 cellslml (See FIG. 2b).  FIG. 10 shows 
phase imaging for alginate beads containing 12 pglml DNA in 
comvlexes with an N:P ratio of 25 and cell concentration of 
250,000 cellslml (See FIG. 10c at a lower magnification). The 
present invention provides, as determined by beta-galactosi- 
dase staining, a transfection efficiency of 70-90% was 
obtained counting only stained cells. 
[0291] Using these optimized conditions an array of algi- 
nate and alginatelcollagen beads was formed, encapsulating a 
mixture of MCF-7 cells and P-Luc-DNMPEI complexes, P- 
Luc-DNA being plasmid containing the luciferase reporter 
gene. Briefly, MCF-7 cells were added to a solution of sus- 
pended complexes composed of PEI and plasmids encoding a 
luciferase reporter gene. The solution was mixed thoroughly 
and added to alginate and alginatelcollagen solutions, creat- 
ing mixtures with final concentrations of 1.5% alginate or 
1.5% alginate with 0.2% collagen. Each mixture was then 
placed into a separate syringe. With a needle attached, the 
alginatelcomplexicel1 mixture was added dropwise to glass 
coverslips and immediately submerged into a 150 mM NaCl 
and 40 mM CaCl, solution. Forming beads on a glass cover- 
slip secured the beads to a surface while allowing them to 
maintain a 3D hemispherical shape. Gels were analyzed 48 
hours later using real-time luciferase imaging. A 1 mM 
luciferin solution was added to the media above the array. 
Light emission was imaged 3 minutes later with an exposure 
time set for 1 min. FIG. 11 shows the expression for both 
alginate (top) and alginatelcollagen (bottom) beads. Expres- 
sion was confined solely to the area containing the gels 
[0292] All publications and patents mentioned in the above 
specification are herein incorporated by reference. Various 
modifications and variations of the described compositions 
and methods of the invention will be apparent to those skilled 
in the art without departing from the scope and spirit of the 
invention. Although the invention has been described in con- 
nection with specific preferred embodiments, it should be 
understood that the invention as claimed should not be unduly 
limited to such specific embodiments. Indeed, various modi- 
fications of the describedmodes for carrying out the invention 
that are obvious to those skilled in the relevant fields are 
intended to be within the scope of the present invention. 
1.  A composition comprising a three-dimensional transfec- 
tion cell array comprising an array of spatially controllable 
immobilized gels, wherein said gels comprise a crosslinkable 
biopolymer solution comprising cells exposed to transfection 
molecules. 
2 .  The composition of claim 1, wherein the gels are formed 
by adding a solution comprising transfection molecules and 
cells to an alginate solution, allowing beads to form, and 
placing the same within cell growth media. 
3 .  The composition of claim 2,  wherein said alginate solu- 
tion comprises alginate and collagen. 
4. The composition of claim 3,  wherein said composition 
further comprises polyethyleimine (PEI). 
5. The composition of claim 3,  wherein the alginate is 
present at a final concentration of about 1.5%. 
6. The composition of claim 3,  wherein the collagen is 
present at a final concentration of about 0.2%. 
7. The composition of claim 4, wherein PEI is present in an 
amount such that the nitrogen to phosphate ratio is 25. 
8 .  The composition of claim 1, wherein the transfection 
molecules are nucleic acid sequences. 
9 .  The composition of claim 8 ,  wherein the nucleic acid 
sequences are located within expression vectors. 
10. The composition of claim 1, wherein said transfection 
molecules comprise a normalization plasmid and a functional 
plasmid, wherein the normalization plasmid, comprising a 
promoter region and a reporter molecule, allows cellular 
transfection efficiency to be normalized over said array. 
11. The composition of claim 10, wherein the functional 
plasmid comprises a reporter molecule that is different from 
the reporter molecule of said normalization plasmid. 
12. A method of transfecting cells comprising 
a) providing: 
i) a composition comprising a biopolymer comprising 
alginate and collagen, 
ii) transfection molecules, and 
ii) cells; and 
b) mixing the composition comprising biopolymer, trans- 
fection molecules and cells, in the presence of PEI, 
under conditions such that beads form; and 
c) placing said beads in cell growth media. 
13. A method of generating an array, comprising: 
a) forming holes in a first material to generate an array 
mold, 
b) attaching said array mold to a solid substrate to form a 
complex comprising a plurality of wells; 
c) depositing first nucleic acidvectors into saidplurality of 
wells under conditions such that said first nucleic acid 
vectors are generally immobilized on said solid sub- 
strate, wherein said first nucleic acid vectors comprise 
nucleic acid, and wherein said nucleic acid comprises: 1) 
a reporter gene; and 2) a promoter region configured to 
bind transcription factors; and 
d) removing said array mold from said solid substrate to 
generate an array on said solid substrate. 
14. The method of claim 13, wherein said first material 
comprises PDMS. 
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15. The method of claim 13, wherein said solid substrate 
comprises polystyrene. 
16. The method of claim 13, prior to step d) depositing 
second nucleic acid vectors into said plurality of wells, 
wherein said second nucleic acid vectors comprise nucleic 
acid comprising: 1) a second reporter gene; and 2) a promoter 
region that allows transfection efficiency to be normalized 
over said array. 
17. The method of claim 13, wherein said first nucleic acid 
vectors are immobilized on said solid substrate such that they 
can deliver said nucleic acid to a cell. 
